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MRI Evaluation of Injectable Hyaluronic Acid Hydrogel Therapy to Attenuate
Myocardial Infarct Remodeling
Abstract
Left ventricular (LV) remodeling following myocardial infarction (MI) leads to maladaptive processes that
often progress to heart failure. Injectable biomaterials can alter the mechanical signaling post-MI to limit
this progression. To design optimal therapies, noninvasive techniques are needed to elucidate the
reciprocal interaction between the injected material and the surrounding myocardial tissue. Towards this
goal, the general hypothesis of this dissertation was that magnetic resonance imaging (MRI) can be used
to characterize the properties of injectable materials once delivered to the myocardium and evaluate the
temporal effects of injectable materials on myocardial tissue properties post-MI. To test this hypothesis,
injectable hyaluronic acid (HA) hydrogels were developed with a range of gelation, degradation and
mechanical properties by altering the initiator concentration, macromer modification, and macromer
concentration, respectively. Non-contrast MRI was then used to characterize the properties (e.g.,
distribution, chemical composition) of injectable HA hydrogels in myocardial explants. Altering hydrogel
gelation led to differences in distribution in myocardial tissue, as quantified by T2-weighted MRI. As an
alternative to conventional (i.e.T2-weighted) MRI where contrast depends on differences in MR properties
and thus, is non-specific for the material, chemical exchange saturation transfer (CEST) MRI was used to
specifically image hydrogels based on their functional (i.e. exchangeable proton) groups. CEST contrast
correlated with changes in material properties, specifically macromer concentration. Furthermore, CEST
MRI was shown to simultaneously visualize and discriminate between different injectable materials
based on their unique chemistry. Finally, the effect of injectable HA hydrogels on myocardial tissue
properties was temporally evaluated in a porcine infarct model up to 12 weeks post-MI. Outcome
assessment using MRI (e.g. cine, late-gadolinium enhancement, and spatial modulation of magnetization
MRI) and finite element (FE) modeling demonstrated that hydrogel therapy led to improved global LV
structure and function, increased wall thickness, preserved borderzone contractility, and increased infarct
stiffness, respectively. This work demonstrates that MRI can be used to simultaneously study hydrogel
properties after injection into the myocardium and evaluate the ability of injectable hydrogels to alter
myocardial tissue properties to ultimately improve cardiac outcomes and enable future optimization of
biomaterial therapies to attenuate adverse remodeling post-MI.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Bioengineering

First Advisor
Jason A. Burdick

Keywords
Hyaluronic Acid, Hydrogel, Left Ventricular Remodeling, Magnetic Resonance Imaging

Subject Categories
Biomedical | Radiology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1046

MRI EVALUATION OF INJECTABLE HYALURONIC ACID HYDROGEL THERAPY TO
ATTENUATE MYOCARDIAL INFARCT REMODELING
Shauna M. Dorsey

A DISSERTATION
In Bioengineering
Presented to the Faculties of the University of Pennsylvania
In Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2015

__________________________
Supervisor of Dissertation
Jason A. Burdick, Ph.D.
Professor of Bioengineering

__________________________
Graduate Group Chairperson
Jason A. Burdick, Ph.D.
Professor of Bioengineering

Dissertation Committee
Hee Kwon Song, Ph.D. (Chair), Associate Professor of Radiology
Robert C. Gorman, M.D., Professor of Surgery
Andrew Tsourkas, Ph.D., Associate Professor of Bioengineering

DEDICATION
I would like to dedicate my dissertation to my grandfather, Joseph H. Gainer, D.V.M, who
first inspired my interests in science and encouraged me to pursue a career in scientific research.

ii

ACKNOWLEDGEMENTS
I would first like to sincerely thank my thesis advisor, Jason A. Burdick, Ph.D., for giving
me the amazing opportunity to work in his lab for the past several years and for his support and
guidance throughout my dissertation research. I am truly grateful for the counsel, patience, and
help from such an incredible mentor that has both encouraged me to grow as a scientific
researcher as well as to pursue my interests in a career in engineering education throughout my
time at the University of Pennsylvania. In addition to the mentorship I have received from my
thesis advisor, I would also like to thank my dissertation committee, Hee Kwon Song, Ph.D.
(Chair), Robert C. Gorman, M.D., and Andrew Tsourkas, Ph.D., who have provided valuable
insight into the direction of my project at critical stages throughout my dissertation.
I would also like to acknowledge that this work could not have been possible without
several collaborations, both at the University of Pennsylvania and at other universities. I would
like to thank Robert C. Gorman, M.D., and members of his lab, especially Jeremy McGarvey,
M.D., for their work in our large animal studies. I would also like to thank Ravinder Reddy, Ph.D.,
and members of his lab, especially Mohammad Haris, Ph.D., Anup Singh, Ph.D., and Feliks
Kogan, Ph.D., for their help in our chemical exchange saturation transfer (CEST) MRI studies. In
addition, I would like to thanks Jonathan Wenk, Ph.D. at the University of Kentucky for his work
on our finite element (FE) modeling. Especially, I would like to thank Walter Witschey, Ph.D. for
his assistance on both the large animal imaging as well as the CEST MRI work.
In addition to the research collaborations that made this work possible, I would also like
to acknowledge the support of the past and current members of the Polymer Biomaterials
Laboratory (under the direction of Jason A. Burdick, Ph.D.). The students and postdocs in my lab
have been integral in every stage of my research. In particular, I would like to thank Elena Tous
Kichula, Ph.D. for her mentorship during the initial stages of my dissertation research and
Christopher B. Rodell for his assistance in the later stages of my research as he continues on our
cardiac biomaterial collaboration with the Gorman laboratory. I would also like to thank Vanessa

iii

Chou and Leron Arama, both of whom were students I had the pleasure of mentoring during their
masters and undergraduate levels of study, respectively.
Finally, I would like to thank my family for their encouragement throughout my
dissertation, especially my parents, Arthur J. Dorsey, Ph.D. and Lisa G. Dorsey. They have given
me the drive and focus to face any challenge with determination and enthusiasm. My academic
success throughout both my undergraduate and graduate careers would not be possible without
their continuous love and support and I could not be the person I am today without them.

iv

ABSTRACT

MRI EVALUATION OF INJECTABLE HYALURONIC ACID HYDROGEL THERAPY TO
ATTENUATE MYOCARDIAL INFARCT REMODELING

Shauna M. Dorsey
Jason A. Burdick, Ph.D.

Left ventricular (LV) remodeling following myocardial infarction (MI) leads to maladaptive
processes that often progress to heart failure. Injectable biomaterials can alter the mechanical
signaling post-MI to limit this progression. To design optimal therapies, noninvasive techniques
are needed to elucidate the reciprocal interaction between the injected material and the
surrounding myocardial tissue. Towards this goal, the general hypothesis of this dissertation was
that magnetic resonance imaging (MRI) can be used to characterize the properties of injectable
materials once delivered to the myocardium and evaluate the temporal effects of injectable
materials on myocardial tissue properties post-MI.
To test this hypothesis, injectable hyaluronic acid (HA) hydrogels were developed with a
range of gelation, degradation and mechanical properties by altering the initiator concentration,
macromer modification, and macromer concentration, respectively. Non-contrast MRI was then
used to characterize the properties (e.g., distribution, chemical composition) of injectable HA
hydrogels in myocardial explants. Altering hydrogel gelation led to differences in distribution in
myocardial tissue, as quantified by T 2-weighted MRI. As an alternative to conventional (i.e.T 2weighted) MRI where contrast depends on differences in MR properties and thus, is non-specific
for the material, chemical exchange saturation transfer (CEST) MRI was used to specifically
image hydrogels based on their functional (i.e. exchangeable proton) groups. CEST contrast
v

correlated with changes in material properties, specifically macromer concentration. Furthermore,
CEST MRI was shown to simultaneously visualize and discriminate between different injectable
materials based on their unique chemistry. Finally, the effect of injectable HA hydrogels on
myocardial tissue properties was temporally evaluated in a porcine infarct model up to 12 weeks
post-MI. Outcome assessment using MRI (e.g. cine, late-gadolinium enhancement, and spatial
modulation of magnetization MRI) and finite element (FE) modeling demonstrated that hydrogel
therapy led to improved global LV structure and function, increased wall thickness, preserved
borderzone contractility, and increased infarct stiffness, respectively.
This work demonstrates that MRI can be used to simultaneously study hydrogel
properties after injection into the myocardium and evaluate the ability of injectable hydrogels to
alter myocardial tissue properties to ultimately improve cardiac outcomes and enable future
optimization of biomaterial therapies to attenuate adverse remodeling post-MI.
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CHAPTER 1

Introduction

1.1. Significance
Cardiovascular disease (CVD) remains to be the leading cause of death in the United
States. Although there has been a dramatic reduction in the death rate due to CVD over the past
1

four decades, CVD still accounts for nearly 1 of every 3 deaths in the U.S. Of these deaths,
about half are due to coronary heart disease (CHD), which causes myocardial infarction (MI).
Each year, approximately 600,000 Americans suffer their first MI and another 300,000 have a
1

recurrent attack, with an additional 150,000 silent MIs estimated. Advances in the treatment of
1

acute MI have reduced hospital mortality to about 6%. However, in spite of this success, or
perhaps because of it, MI has become a major cause of heart failure with approximately 20% of
1

patients developing heart failure within 5 years of their first MI. MI initiates a dynamic process of
left ventricular (LV) remodeling, which includes both maladaptive biological and mechanical
changes that may lead to altered contractile properties and ultimately, heart failure. Despite
current standard of treatment, LV remodeling caused by a MI is responsible for 70% of the 5.1
million cases of heart failure present in the U.S.

2

1.2. LV Remodeling Post-MI
MI occurs following coronary artery occlusion, resulting in depletion of nutrients and
oxygen to the myocardium and subsequent cardiomyocyte death. This cardiomyocyte necrosis
leads to an influx of inflammatory cells (i.e., macrophages, monocytes, and neutrophils) into the
3

infarcted area to remove the necrotic debris. Fibroblasts also infiltrating the infarct region secrete
4,5

bioactive molecules, such matrix metalloproteinases (MMPs).

Although initially essential to

provide the necessary substructure for subsequent scar formation, MMP upregulation is not met
1

by a concomitant upregulation of their endogenous inhibitors (TIMPs), leading to a substantial
increase in the breakdown of cardiomyocyte extracellular matrix (ECM) and collagen.

6

To

counteract the ECM breakdown, fibroblasts and myofibroblasts secrete collagen which leads to
the formation of a fibrotic scar that is non-contractile and maladaptive.

3,5,7,8

Furthermore, since

cardiomyocytes are tethered together with collagen, this leads to continuous stretch and slippage
of cardiomyocytes from one another, which weakens the myocardial wall and makes it
susceptible to global geometric changes, including thinning and dilatation.

9,10

Figure 1.1. Schematic of LV remodeling following MI, highlighting the infarct expansion and
global geometric changes that occur over time. Figure adapted from [11].
The mechanical phenomenon that both initiates and sustains the entire adverse LV
12-15

remodeling process is the initial infarct expansion (Figure 1.1).

From a structural perspective,

early infarct expansion results from thinning of the ventricular wall and increased compliance.
However, it is a progressive pathologic process that eventually causes abnormal stress
distributions in the borderzone (BZ) regions surrounding the infarct. As part of this selfperpetuating process, increased regional BZ stresses lead to maladaptive cellular and enzymatic
processes, such as additional cardiomyocyte apoptosis and MMP activation.

2

13-15

Once initiated,

these biological processes are difficult to reverse by medical or surgical means and ultimately
lead to altered contractile properties and heart failure.

4

1.3. Strategies for the Treatment of MI
Clinical approaches to MI focus on the acute setting, yet few therapies have been
developed to prevent the progression from MI to eventual heart failure, at which point heart
transplantation remains the only definitive treatment. Current treatments focus on two main
approaches: 1) restoring blood flow to the occluded vessel to reperfuse the ischemic tissue
through the use of bypass surgery, balloon angioplasty, or coronary stents or 2) replacing the
damaged heart tissue using ventricular assist devices, artificial hearts, or ideally, heart
transplants. Pharmacological therapies, such as angiotensin-converting enzyme (ACE) inhibitors
and beta-blockers, help by either reducing the blood volume to decrease demands on the heart or
minimizing arrhythmias to limit recurrent MI attacks, respectively.

11,16

Whereas reperfusion and

pharmacologics have been shown to delay the onset of heart failure post infarction, they do little
to address the changes in the myocardial tissue properties that occur during remodeling.
As suggested above, limiting initial infarct expansion has been identified as a potential
therapy to alter myocardial properties post-MI and reduce the morbidity associated with LV
remodeling that leads to heart failure.

17

Previous strategies to limit infarct expansion include

surgical reconstruction of the dilated LV and physical restraint of the ventricle or infarct region
using polymeric meshed materials to prevent dilation.

18-21

Injectable biomaterials have been

explored to circumvent the surgical placement of LV restraining devices or cardiac patches.
Injectable biomaterials offer the potential for minimally invasive delivery, which decreases
damage to the target and surrounding tissues and enables more rapid clinical translation.
Recently, injectable hydrogels have been used to mechanically stabilize the myocardial wall and
modulate maladaptive biological processes post-MI through delivery of therapies, such as cells
22,23

and growth factors (Figure 1.2),

as will be discussed more in depth in Chapter 3. Hydrogels

are water-swollen networks of polymer chains with a high degree of flexibility, similar to natural
3

24

tissue

and can be formed through numerous mechanisms, including in situ formation.

25

Due to

their high tissue-like water content, structural similarity to native macromolecular components,
and mechanical properties resembling those of soft tissues, they have been used for numerous
applications in tissue engineering and drug delivery.

26

Figure 1.2. Delivery of injectable hydrogels as bulking therapy to stabilize the LV wall and alter
the local myocardial wall stresses post-MI. Figure adapted from [27].
1.4. Principles of MRI
In addition to developing therapies to attenuate LV remodeling, noninvasive techniques
are also needed to assess the effects of these therapies once delivered to the myocardium.
Imaging can noninvasively provide mechanistic information over time regarding the presence and
distribution of hydrogels throughout the tissue and simultaneously investigate the impact of
injectable materials on myocardial properties post-MI, which may lead to better design principles
for future material optimization. Magnetic resonance imaging (MRI) offers advantages over other
imaging modalities, such as optical

28-31

or x-ray imaging,
4

32-35

due to its high spatial and temporal

resolution at any tissue depth without the use of ionizing radiation,

36,37

and thus, has been widely

used in the clinic and applied to evaluate cardiac outcomes following MI.

38-40

To understand the

ability of MRI to assess injectable hydrogel properties, as will be discussed in Chapters 5 and 6,
and evaluate the alterations in myocardial tissue properties with hydrogel therapy, as will be
discussed in Chapter 7, an exploration of the basic principles of MRI is needed.
A MRI signal is generated from manipulating the water protons in materials or tissues
using oscillating magnetic fields. Any nucleus with an odd number of protons or neutrons can be
exploited for MRI but the protons in water are primarily targeted since biological tissues have a
high water content. Due to their charge and intrinsic spin property, water protons have a magnetic
dipole moment causing them to act like a bar magnet.

41

In the absence of a magnetic field, water

protons are randomly oriented and precessing (i.e., spinning) at their natural frequency. To image
a material or tissue, the dipole moment property of water protons is manipulated using magnetic
fields.

36

When placed in an external, static magnetic field of strength B (referred to as B0), the

protons align themselves with and begin precessing around the magnetic field. Approximately half
of the protons point in the direction of the field and half point in the opposite direction. Over time,
slightly more protons align with the B0 field (about one in a million), creating a macroscopic
magnetic moment referred to as the net magnetization (M) vector.

41

As a reference, the

conventional MRI coordinate system specifies that both the B0 field and the magnetization vector
M are aligned along the z-axis at equilibrium. The maximum signal is obtained when the net
magnetization is perpendicular to the B0 field (i.e., in the x-y plane).
Therefore, to acquire a signal and subsequently generate an image, the protons must be
further manipulated. To do so, the MR scanner contains a radiofrequency (RF) coil situated within
the larger main (B0) magnet. The RF coil is selectively tuned to the resonance frequency of water
protons and creates a secondary magnetic field (B1) which rotates the net magnetization of the
o

o

protons away from their alignment with B0. The degree of rotation (e.g. 90 , 180 ) is specified in
the pulse sequence, which describes the series of RF pulses.
5

37,41

For instance, application of a

o

90 RF pulse causes the protons to become perpendicular to the B 0 field. Whereas the B0 field is
always present, the B1 field can be turned on and off. When the B1 magnetic field is removed, the
protons relax back to their equilibrium state and realign so that their net magnetization M is again
parallel with B0. During this relaxation process, protons emit energy in the form of an freeinduction decay (FID) that can then be detected by the RF coil and processed (by Fourier
transformation) to generate an image.

36,41

Gradient coils also embedded within the main magnet

are applied during the RF pulse train to produce gradients in the B0 magnetic field and encode
slice, phase and frequency information.

41

This encoding process enables extraction of three-

dimensional information and, once reconstructed, results in images with high spatial resolution.
Image contrast between tissues or materials is generated based on differences in
composition, specifically proton density and relaxation properties. The relaxation properties
describe the manner by which protons respond to RF pulse manipulation. During a RF pulse,
interactions between protons cause them to precess at slightly different rates, leading them to
dephase (or spread out) from one another, which results in signal decay. Transverse (T 2)
relaxation describes this rate of proton dephasing and magnetization decay in the transverse
plane.

37

When the RF pulse is turned off, the protons first rephrase rapidly and then recover back

to equilibrium along the longitudinal axis (i.e., z-axis) by the process of longitudinal (T 1)
relaxation.

41

In terms of the magnetization, the Mxy component of the magnetization vector

decays rapidly and the Mz component slowly recovers along the z-axis; these are independent
but simultaneous processes.

36,37,41

These MR properties (i.e., T1/T2 relaxation times, proton

density) are intrinsic to the material or tissue of interest but can be manipulated to enhance
differences in endogenous image contrast, as will be discussed further in Chapters 5 and 6 in
references to visualizing injectable hydrogels in the myocardium.
1.5. Cardiac MRI
Noninvasive imaging techniques are needed not only to visualize the injected material
once delivered to the myocardium but also to assess cardiac outcomes to determine the impact
6

of injectable hydrogel therapies on the heart. The evaluation of cardiac disease and therapeutic
interventions with noninvasive imaging techniques has assumed increasing importance over the
past few decades, with the goal of defining anatomic abnormalities in the heart and coronary
arteries to provide insight to the pathophysiology of cardiac diseases. Advances in rapid MRI
acquisition techniques and its application to cardiac imaging have shown its tremendous potential
for evaluation of cardiac diseases and the efficacy therapeutic interventions.

42-49

When compared

with other well-established cardiac imaging modalities, such as echocardiography, single-photon
emission computed tomography (SPECT), or positron-emission tomography (PET), cardiac MRI
offers an excellent depiction of myocardial wall motion, high image contrast, and high spatial
resolution without using ionizing radiation. Its efficacy, together with its excellent safety profile and
increasing availability, makes cardiac MRI an important and sophisticated tool for noninvasive 3D
evaluation of cardiovascular structure, function and viability.
The most accurate method for evaluating the morphology and function of the heart has
become cine MRI. Cine MRI enables noninvasive assessment of global morphology and altered
50,51

regional wall motion in all segments of the LV, with high spatial and temporal resolution.

Direct imaging of non-viable myocardial regions can be performed using myocardial lategadolinium enhancement (LGE) MRI. LGE is exclusively related to irreversible injury, irrespective
of contractile function or age of injury and hence, can be used to detect regions of infarction.

52

Using gadolinium-based contrast agents, this technique visualizes MI as regions of bright signal
compared to normal myocardium. Finally, myocardial tagging with MRI can be used to directly
visualize the contractility of the ventricles. Using pre-saturation pulses, a grid of dark lines or
“tags” is produced immediately following the R-wave trigger and then, as the tissue moves and
deforms through the cardiac cycle, the tagging pattern moves correspondingly.

50,53-55

By acquiring

images perpendicular to the tagging planes, the tags can be used to track the motion of the heart.
The power of myocardial tagging lies in the ability to perform quantitative myocardial strain
analysis with great accuracy and precision.

36,43

Using MRI tagging data, theoretical finite element
56-59

(FE) models can compute myocardial stress and strain distributions in the LV post-MI.
7

Recently, FE models have been developed to investigate the effects of injectable biomaterials on
56,60-62

attenuating adverse LV remodeling post-MI.

In one study, simulations indicated that

injection of a noncontractile material to an infarcted LV has the potential to reduce elevated
myofiber stresses.

60,61

However, the use of in vivo-derived MRI data as an input to a FE model

has yet to be explored prior to this dissertation (as will be addressed in Chapter 7).
1.6. Summary
Motivated by the clinical burden of heart failure, injectable biomaterials are a promising
therapy to target the tissue remodeling process that is known to cause progression from MI to
heart failure. Despite experimental successes in animal models, only one injectable material has
progressed to clinical trials.

63,64

Therefore, to more efficiently develop injectable systems with

optimal materials properties to attenuate cardiac remodeling post-MI, noninvasive tools are
needed to simultaneously investigate materials properties and cardiac outcomes. To address this
need, this dissertation will focus on the use of MRI to both examine material properties once
delivered to the myocardium as well as assess the impact of injectable materials on myocardial
remodeling post-MI. The imaging techniques explored can be applied to a wide range of
injectable materials to better understand the material-myocardial interactions and facilitate
selection of injectable systems with higher translational potential for MI repair.
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CHAPTER 2

Research Overview

2.1. Objectives
Cardiovascular disease is the leading cause of death in the U.S. Each year, over one
million of U.S. residents have myocardial infarctions (MI) and roughly one-third of them progress
to heart failure and death. MI leads to abnormal stress distributions in the myocardium, which
results in maladaptive biologic processes that may lead to altered contractile properties and heart
failure. Although numerous surgical and pharmacological have been shown to delay the onset of
heart failure post-MI, they do little to address the myocardial tissue remodeling that occurs
following infarction. Hence, there is a need for new therapeutic interventions that target the postMI left ventricular (LV) remodeling process to further limit progression to heart failure.
Injectable biomaterials, specifically hydrogels, have become an attractive therapy to
provide mechanical stabilization to attenuate adverse remodeling after MI. Despite the wide range
of injectable hydrogels investigated for MI-induced remodeling, there is a lack of techniques to
evaluate the properties of injected hydrogels and their impact on myocardial tissue in vivo.
Imaging modalities, such as magnetic resonance imaging (MRI), can noninvasively characterize
biomaterial and myocardial properties, which may lead to better design principles for future
biomaterial optimization. Therefore, the purpose of this dissertation is to use injectable hyaluronic
acid (HA) hydrogels and MRI as a platform to investigate the presence and composition of
hydrogels once injected into the myocardium and the effect of injectable hydrogels on myocardial
tissue properties for the attenuation of LV remodeling post-MI.
Towards this goal, an HA hydrogel system will be developed and examined for the range
of properties that are attainable. After understanding how hydrogel properties can be tuned for an
17

intended application, non-contrast MRI techniques will be used to visualize and quantify
differences in hydrogel distribution based on gelation in myocardial explants and differences with
macromer concentration and chemistry using chemical exchange saturation transfer (CEST).
Finally, a single degradable hydrogel formulation will be applied to an in vivo infarct model and
MRI will be used to evaluate differences in myocardial tissue properties after hydrogel delivery
throughout the remodeling process.
2.2. Specific Aims and Hypotheses
The global hypothesis of this dissertation is that MRI can be used to evaluate the
properties of injectable materials once delivered to the myocardium and systematically investigate
the therapeutic effects of injectable materials on tissue properties of the remodeling myocardium
post-MI. This advance would provide technology and insight into design criteria for targeted
biomaterial therapies for MI repair. This hypothesis will be systematically investigated using the
following three Specific Aims.
Specific Hypothesis 1: Hydrogel degradation, mechanics, and rate of gelation can be controlled
by altering macromer chemistry, macromer concentration, and initiation conditions.
Specific Aim 1: Synthesize and characterize degradable HA hydrogels with a range of properties,
particularly gelation, degradation, and mechanics.
HA will be modified with a hydrolytically degradable functional group, hydroxyethyl
methacrylate (HeMA), to generate the gel precursor, HeMA-HA. HeMA-HA can be crosslinked
through a radical polymerization reaction to form HA hydrogels and will be further optimized to
obtain formulations with a range of gelation times, degradation profiles, and mechanical
properties. These properties will be assessed in vitro using rheological characterization, an uronic
acid assay to measure HA release, and compressive mechanical testing, respectively.
Characterization will be performed for both pure HeMA-HA homopolymer hydrogels and
copolymer hydrogels with a hydrolytically stable macromer, methacrylated HA (MeHA). Hydrogels
18

will be formed with a range of initiator concentrations, macromer modifications, and macromer
concentrations to explore the parameter space of tunable properties. The ability to tune hydrogel
properties will then be utilized in subsequent imaging (Aim 2) and in vivo (Aim 3) studies.
Specific Hypothesis 2: Non-contrast MRI can be used to visualize and quantify differences in
hydrogel distribution volume and macromer chemistry within myocardial tissue.
Specific Aim 2: Visualize HA hydrogels using MRI as a means to examine hydrogel dispersion
and detect differences in hydrogel chemical composition ex vivo.
The gelation of HA hydrogels will be altered to form hydrogels with varied distribution in
myocardial tissue, through changes in initiator concentration and macromer modification. Threedimensional hydrogel dispersion volumes will be visualized and quantified using conventional (T 2weighted) MRI. As an alternative to the radically polymerized MeHA and HeMA-HA hydrogels,
guest-host chemistry will also be introduced into HA hydrogels to form materials through
supramolecular self-assembly. Thus, the effect of both the timing of gelation and the mechanism
of hydrogel formation on hydrogel distribution in myocardial tissue will be assessed.
To expand upon traditional MRI approaches, a new MRI acquisition technique will be
explored that is based on chemical exchange saturation transfer (CEST), where the signal relies
on the exchange of protons in specific molecules (either endogenous to or engineered into the
material) with bulk water protons. CEST MRI will be used to identify the exchangeable proton
groups in HA hydrogels and manipulate those protons to visualize HeMA-HA hydrogels either
alone or after injection into tissue. Changes in the CEST contrast with changes in hydrogel bulk
properties (i.e. macromer concentration) will be investigated. To detect differences in hydrogel
chemistry using CEST MRI, an arginine-based peptide will be coupled to HeMA-HA hydrogels to
introduce an additional exchangeable proton group known to generate a CEST effect.
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Specific Hypothesis 3: The delivery of HA hydrogels to the myocardium post-MI alters LV
volumes, cardiac function, and myocardial wall thicknesses, strains and stiffnesses to attenuate
remodeling.
Specific Aim 3: Assess the temporal effects of degradable HA hydrogel therapy on long-term
myocardial tissue remodeling post-MI using cardiac MRI and finite element (FE) modeling in an in
vivo porcine infarct model.
A previously characterized HeMA-HA hydrogel formulation (selected based on Aim 1) will
be applied to an in vivo porcine infarct model and cardiac MRI will be used to evaluate myocardial
tissue properties over time, up to 12 weeks post-MI. More specifically, cine MRI will assess global
LV structure and function, late-gadolinium enhancement (LGE) MRI will visualize changes (i.e.
thinning, expansion) in the infarct region, and spatial modulation of magnetization (SPAMM)
tagging will measure myocardial strains as an assessment of wall motion and contractility. Finite
element (FE) modeling with MRI-derived strain inputs will be used to simulate the impact of
injectable hydrogels on regional myocardial stiffness over time.
2.3. Chapter Outline
Chapter 1 presented the translational motivation for designing injectable hydrogels as
bulking agents to attenuate LV remodeling and the use of imaging, specifically MRI, as a tool to
noninvasively assess the effects of these therapies. An extensive review of natural and synthetic
injectable hydrogels as acellular, cellular, and therapeutic delivery vehicle therapies for MI
treatment will be presented in Chapter 3. Chapter 4 will then focus on the in vitro characterization
of hydrolytically degradation HA hydrogels. The effect of altering material parameters (e.g.
initiator concentration, macromer modification, and macromer concentration) on the resulting
hydrogel properties (e.g. gelation, degradation, and mechanics) will be investigated in both pure
HeMA-HA and HeMA-HA/MeHA copolymer hydrogels.
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Based on an understanding of the tunability of injectable HA hydrogels, the next portion
of the dissertation (Chapters 5 and 6) will focus on the noninvasive characterization of hydrogel
properties in myocardial explants using non-contrast agent based-MRI techniques. Chapter 5 will
explore the use of conventional MRI to qualitatively and quantitatively assess three-dimensional
HA hydrogel dispersion. Differences in hydrogel volume distribution in tissue will be induced by
alterations in gelation conditions. Chapter 6 will utilize MRI with endogenous CEST contrast to
detect differences in material properties (i.e. macromer concentration) and visualize HA hydrogels
in tissues by manipulating the exchangeable protons. In contrast to traditional MRI, CEST MRI
will be applied to discriminate between injectable materials based on their distinctive chemistries.
After exploring the ability to examine differences in hydrogel properties after injection into
the myocardium, the following portion of the dissertation (Chapter 7) will focus on understanding
the impact of hydrogels on the surrounding myocardial tissue properties in an in vivo porcine
infarct model. Cardiac MRI will be used to temporally evaluate the effect of injectable HA
hydrogels on remodeling post-MI by measuring global LV volumes and functional outputs as well
as regional thicknesses, wall strains, and myocardial stiffnesses with the use of FE modeling.
Finally, Chapter 8 will summarize the main conclusions and discuss the limitations and future
directions of each Specific Aim.
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CHAPTER 3

A Review of Hydrogels in Cardiac Tissue Engineering

(Adapted from: Dorsey SM, Burdick JA. In: Khademhosseini A, Demirci U, editors. Applications of
Hydrogels in Regenerative Medicine, in press.)
3.1. Introduction
Heart failure is a major public health issue that affects almost 23 million individuals
1

worldwide and 5 million individuals in the US alone. As discussed in Chapter 1, survival after the
diagnosis of heart failure has improved but the death rates remain high, with half of patients dying
2

within 5 years. In fact, one in every nine U.S. death certificates in 2010 mentioned heart failure
2

as a contributing factor. Moreover, the majority of heart failure cases have been attributed to the
process of left ventricular (LV) remodeling following myocardial infarction (MI).

2,3

As described in

Chapter 1, injectable hydrogels are a promising therapy to attenuate this adverse remodeling by
limiting infarct expansion to prevent progression to heart failure. In contrast to LV restraints and
surgical reconstruction of the LV as means to alter geometry post-MI, injectable hydrogels offers
the potential of minimally-invasively, percutaneous delivery to facilitate clinical translation.
Both natural and synthetic materials have been explored as acellular bulking agents to
mechanically stabilize the myocardium and as delivery vehicles for cells and/or therapeutic
molecules to modulate the maladaptive biological processes after infarction (Figure 3.1). Various
materials, cells, and therapeutic molecules have shown positive outcomes in animal models and,
in doing so, provide insight for future material development and optimization. However, many
questions remain before injectable hydrogel systems can be safely translated to patients. Future
work should focus on elucidating the mechanism behind the positive outcomes of hydrogel
delivery in vivo and the application of these systems to clinically relevant scenarios, including
22

minimally-invasive, percutaneous delivery. Further development of injectable hydrogel systems
for cardiac repair will have considerable clinical impact with respect to broadening our
understanding of the mechanisms of remodeling post-MI and improving therapies to prevent
progression to heart failure. Towards this goal, this chapter will focus the in vivo applications of
biomaterials for 1) tissue bulking, 2) cell delivery, 3) small molecule delivery, and 4) combined cell
and molecule delivery (Figure 3.1) approaches, with an emphasis on injectable hydrogels.

Figure 3.1. Schematic of injectable hydrogel strategies for MI repair. Hydrogels can be used as
acellular bulking agents (A) or as a delivery vehicle for cells (B), therapeutic molecules (C), or a
combination of cells and molecules (D).
3.2. Acellular Approaches
3.2.1. LV Restraints
Over the past decade, it has become evident that the regional mechanical changes in the
myocardial tissue properties following MI must be considered when designing biomaterial-based
approaches for cardiac repair.

4,5

After MI, the myocardial wall thins in the infarct region and the
23

LV dilates as the heart shifts to a more spherical shape; this leads to an increase in stress in the
borderzone (BZ) regions surrounding the infarct. As described by the Law of Laplace (Equation
3.1), stress (T) is directly proportional to pressure (P) and the radius of curvature (R) and
inversely proportional to the myocardial thickness (h). Therefore, an increase in the ventricular
radius (R) and decrease in wall thickness (h) leads to an increase in myocardial stress.

(3.1)

Previous strategies to attenuate LV expansion include the use of polymeric meshes wrapped
around the heart or sutured to the infarct surface, referred to as LV restraints. The theory behind
the use of ventricular restraints is that by forcing the heart to maintain its elliptical shape and
preventing an increase in the ventricular radius (R) of the LV, this will, in turn, lead to decreased
myocardial wall stress (T) to ultimately attenuate LV remodeling.

6-9

Several studies examined the use of biomaterial supports to restrain the LV to prevent
dilatation and adverse remodeling.

10

Kelley et al. demonstrated preserved LV geometry and

cardiac function in a sheep MI model with suturing of a poly(propylene) (Marlex) mesh to the
7

infarct. Subsequently, Bowen et al. demonstrated that the poly(propylene) restraint has biological
significance, leading to increased collagen and decreased protease (MMP-1, MMP-2) activity in
the BZ myocardium.

11

Since these initial studies, the use of heart-wrapping techniques has

shown that infarct expansion limitation has a pronounced effect in ameliorating post-MI
6-9,12

remodeling

, motivating translation to clinical trials. Acorn Cardiovascular, Inc. (St. Paul,

Minnesota) developed the first commercially available restraint, consisting of a knitted polyester
mesh to be fitted around both ventricles. In both canine

13,14

and ovine

12,15

infarct models, the

Acorn CorCap restraint decreased LV volumes and improved function. This led to a clinical trial
encompassing 300 patients where the use of CorCap decreased LV volumes, improved quality of
life, and decreased the likelihood of additional cardiac procedures.

16

More recently, Paracor

Medical (Sunnyvale, California) developed a HeartNet LV support system made from a nitinol
24

mesh that is placed around the ventricles. Similarly, both canine

17

and ovine

18

MI models showed

decreased LV end diastolic volume (EDV) and end systolic volume (ESV). An initial safety and
feasibility clinical study suggested a functional and clinical benefit from the Paracore HeartNet
19

device,

leading to a phase II clinical trial (PEERLESS-HF).

20

However, the clinical trial was
21

stopped prematurely due to limited effects on certain functional end points.

Ultimately, despite

promising results in both large animal models and clinical trials, a major limitation of polymeric LV
restraints is the highly invasive surgical procedure necessary for implantation. Thus, minimally
invasive approaches are needed to limit infarct expansion and preserve LV geometry post-MI.
3.2.2. Injectable Hydrogels as Bulking Agents
Similar to infarct restraints, acellular injectable biomaterials can also limit infarct
expansion by bulking the damaged myocardial wall to provide mechanical stabilization.

23

Infarcts

naturally stiffen over time as wound healing progresses and collagen is deposited. Therefore, the
goal of injectable hydrogels is to modify the material properties of the infarct region before the
body compensates for the remodeling process; in doing so, infarct expansion and remodeling
post-MI can be limited.

23

Referring back to the Law of Laplace (Equation 3.1), the theory behind

the use of injectable hydrogels as bulking agents is that they increase the wall thickness (h) to
decrease LV dilatation (R) and in turn, decrease wall stress (T). Theoretical finite element (FE)
models have been used to evaluate the ability of injectable biomaterials to attenuate remodeling
22,24,25

(Figure 3.2).

Simulated injections of a non-contractile material into an infarcted LV were

shown to decrease LV dilatation and reduce elevated myofiber stresses.

24

In a subsequent study,

injection of a tissue filler into the infarct reduced stress in the LV and improved ejection fraction
(EF) in an ovine infarct model.

25

For the first time, the use of injectable biomaterials presents the

real possibility of limiting adverse LV remodeling using minimally invasive delivery.

25

Figure 3.2. Finite element (FE) model of simulated polymer injections, demonstrating injected
materials and the importance of injection pattern (A) and volume of material dispersion (B) in
decreasing myocardial stress. Figure adapted from [22].
3.2.2.1. Natural Acellular Hydrogels
Hydrogels can be grouped into either natural or synthetic materials. Natural materials
offer several advantages due to their inherent biological properties, including presentation of
receptor-binding ligands and susceptibility to cell-triggered proteolytic degradation

26,27

For cardiac

applications where the goal is to replace or repair the damaged ECM, natural biomaterials more
closely mimic features of the native ECM, enabling them to increase cell adhesion, activate cell
proliferation, and maintain cell differentiation.

28

Commonly used natural, injectable materials for

cardiac repair include fibrin, alginate, collagen, Matrigel, chitosan, hyaluronic acid, keratin, and
decellularized matrices (Table 3.1).
Fibrin: Fibrin, a fibrillar protein consisting of fibrinogen and thrombin, is natively a blood
component critical to the clotting cascade. A two component system is required to form fibrin
26

hydrogels: 1) fibrinogen and aprotinin, a fibrinolysis inhibitor, and 2) thrombin, factor XIIIa, and
calcium chloride (CaCl2). When combined, fibrinogen converts to fibrin and self-assembles to
form a mesh crosslinked by factor XIIIa. Fibrin naturally has binding domains for soluble growth
factors and cellular integrin receptors, making it an ideal candidate for wound healing
applications.

29

Fibrin hydrogels have been used for MI therapy

30-33

due to favorable properties

such as biodegradability, mechanical strength, and angiogenic activity.

34

Christman et al. first injected fibrin and showed positive outcomes on cardiac function.
32

30-

Specifically, MI was induced in rats (temporary coronary occlusion) followed by injection of

fibrin glue ten days later. Assessment five weeks after delivery revealed preserved infarct wall
thickness and fractional shortening (FS) as compared to bovine serum albumin (BSA) controls.

30

In a subsequent study, Christman et al. showed that injectable fibrin alone significantly decreased
infarct area and increased arteriole density in the infarct region as compared to control BSA
injections.

31

The ability of injectable fibrin to induce neovascularization in the infarct region was

later confirmed by Huang et al.

33

Alginate: Alginate is a naturally occurring, linear polysaccharide derived from seaweed.
Its tailorability and non-thrombogenicity make it attractive for cardiac repair.

35-37

It consists of

linked ß-D-mannuronate and α-L-guluronate residues that crosslink into hydrogels in the
presence of calcium.

38

Alginate’s unique gelation enables delivery using minimally invasive,

catheter-based intracoronary infusion, which relies on the infarct myocardium’s leaky vasculature.
Due to inadequate levels of calcium in the vasculature, alginate does not crosslink until it reaches
the infarct, where high levels of calcium induce gelation.

36

Landa et al. delivered alginate to rats at seven and 60 days post-MI (permanent coronary
occlusion) for acute and chronic remodeling, respectively.

37

Eight weeks after injection, delivery

into recent or old infarcts increased scar thickness and attenuated LV systolic and diastolic
37

dilatation and dysfunction. However, FS was not improved in either group.

These results

provide insight into the timing for hydrogel delivery post-MI. In contrast, Leor et al. delivered
27

alginate hydrogels to a clinically relevant, porcine MI model using a coronary catheter.

36

To

investigate the effects of delivering different hydrogel volumes, alginate solutions at incremental
volumes (1, 2, or 4 mL) were delivered four days post-MI (temporary occlusion). At 60 days after
delivery, intracoronary injection of alginate (2 and 4 mL) prevented and even reversed LV systolic
and diastolic dilatation. In addition, the 2 mL alginate injection led to myofibroblast infiltration and
36

increased scar thickness as compared to saline controls.

Similar to the study by Landa et al.,

there were no significant FS improvements.
37

Due to the positive results of alginate in both small

and large

36

animal models, it has

become the first injectable acellular biomaterial used in clinical trials. An injectable system of
sodium alginate and calcium gluconate was first developed and tested by BioLineRx, Ltd. as BL1040. In a phase I/II pilot clinical trial, the safety and feasibility of BL-1040 was demonstrated in
27 patients, including improved survival, preserved LV EDV and ESV, prevention of FS
deterioration,

improved

(NCT00557531).

39

mitral

regurgitation,

and

limitation

of

systolic

wall

thinning

Since then, BioLine, Ltd. out-licensed BL-1040 to Ikaria Holdings, Inc., which

is currently performing a placebo-controlled, double-blind phase II clinical trial with 300 patients
(NCT01226563).

40

More recently, LoneStar Heart, Inc. developed an injectable alginate hydrogel

(Algisyl-LVR) that demonstrated improved LV function and decreased myofiber stress

41

in a

safety and feasibility phase II clinical trial of 11 patients with dilated cardiomyopathy undergoing
open-heart surgery (NCT00847964).

42,43

Subsequently, in an ongoing randomized, controlled

phase II/III clinical trial, Algisyl-LVR was delivered to 35 heart failure patients and compared to
38 patients who received standard medical care. Primary 6-month results showed significantly
improved clinical outcomes in terms of peak maximum oxygen uptake VO2 and a 6-minute walk
test with hydrogel therapy (NCT01311791),

44

leading to an open-label rollover trial for those

enrolled in the control portion of the study (NCT02226679).

45

Several studies have studied the effect of modifying normally non-adhesive alginate with
adhesive peptides such as Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR).
28

46,47

Yu et al.

delivered modified and unmodified alginate to rats five weeks post-MI (temporary occlusion).

46

Five weeks after injection, delivery of either RGD modified or unmodified alginate led to
decreased EDV and ESV, improved FS, significantly increased myocardial wall thickness, and
significantly increased arteriogenesis as compared to BSA controls. Although both groups led to
increased arterioles in the infarct, the RGD modified alginate group had the highest number of
arterioles,

46

demonstrating that surface modification can influence the infarct microenvironment.

Further, Tsur-Gang et al. delivered unmodified alginate, alginate modified with adhesion peptides
RGD and YIGSR, and alginate modified with a non-specific peptide, RGE, to rats seven days
post-MI (permanent occlusion).

47

In this case, unmodified alginate led to the best improvements

in infarct thickness, LV geometry, and FS 60 days after injection. However, no significant
differences were seen in relative infarct thickness, cell infiltration, or blood vessel density between
47

the groups.

Differences in material viscosity may explain some of these findings.

Due to the positive benefits of fibrin and alginate alone, Mukherjee et al. delivered a
fibrin-alginate composite to pigs one week post-MI (permanent occlusion).

48

Injections were

performed using a double-barrel syringe; one component was composed of fibrinogen,
fibronectin, factor XIII, plasminogen, and gelatin-grafted alginate dissolved in an aprotinin solution
while the other consisted of thrombin and CaCl2. Assessment performed at one, two, and three
weeks after delivery demonstrated significantly increased wall thickness at one week and limited
LV expansion at two and three weeks post-injection. However, no functional improvements were
observed. In addition, the composite led to significantly reduced soluble collagen vulnerable to
protease degradation and decreased protease levels (e.g., MMP-2) in the infarct as compared to
saline controls, providing a potential mechanism for attenuated infarct expansion.

48

Collagen: Collagen is the most abundant protein in the human body and the predominant
ECM protein. Due to extensive ECM damage post-MI, delivery of injectable collagen is well-suited
for cardiac repair.

49

Collagen can be prepared in an injectable form which self-assembles at

physiological pH and temperature into a fibrous hydrogel.
29

50

In addition, collagen has been shown

33

to promote angiogenesis and myoblast infiltration in the ischemic myocardium.

Dai et al.

delivered commercially available Zyderm (INAMED Corp., Santa Barbara, California), a bovine
dermal collagen (95% collagen type I, 5% collagen type III) to rats one week post-MI (permanent
occlusion).

51

Six weeks after delivery, collagen treated animals had higher stroke volume (SV),

increased EF, increased wall thickness, and absence of paradoxical LV systolic bulging as
compared to controls.

51

Unlike other natural hydrogels for cardiac repair, this study did not show

increased angiogenesis or cell infiltration, potentially due to differences in collagen types or
concentration injected, limiting cell migration into the infarct.
Matrigel: As an alternative to pure collagen, Matrigel (BD Biosciences) is a commercially
available, purified matrix isolated from a mouse sarcoma line that encompasses collagen as well
as basement membrane proteins, including laminin and entactin, and growth factors.

52,53

Similar

to collagen, it undergoes a phase transition at physiological temperature to generate hydrogels.
Ou et al. delivered Matrigel to rats immediately post-MI (permanent occlusion) and demonstrated
significantly increased vessel density, enhanced recruitment of cardiac progenitor cells (CPCs),
improved LV peak rate of pressure rise, increased wall thickness, and enhanced EF four weeks
54

post-MI.

In contrast, Kofidis et al. delivered growth-factor free Matrigel to mice immediately post-

MI (permanent occlusion) but did not demonstrate significantly increased FS at two weeks postMI as compared to controls but did show trends towards increased scar thickening and improved
function.

55

In another study, Kofidis et al. delivered Matrigel to a rat MI model and saw trends

towards increased wall thickness and decreased end diastolic diameter (EDD) compared to
56

controls two weeks post-MI.

Chitosan: Chitosan is a non-mammalian, linear polysaccharide derived by deacetylating
chitin, the main component of crustacean exoskeletons. Chitosan undergoes a temperatureinduced phase transition to form hydrogels at physiological temperature when mixed with glycerol
phosphate and a glyoxal salt solution.

57,58

Gelation temperature can be altered by changing the

glyoxal concentration and degradation kinetics can be controlled by the degree of
30

deacetylation.

59-61

Lu et al. delivered a previously developed chitosan hydrogel

59

to rats one week

post-MI (permanent occlusion). Four weeks after injection, the myocardial wall thickness was
significantly increased, LV EDD and end systolic diameter (ESD) significantly decreased, EF and
FS enhanced, infarct size decreased, and microvessels within the infarct increased for animals
57

treated with chitosan as compared to saline controls.
Wang et al.

62

and Liu et al.

58

These results were further confirmed by

where chitosan alone resulted in significant improvements in EF, FS,

infarct size, wall thickness, and vessel density.
Hyaluronic acid: Hyaluronic acid (HA) is a linear polysaccharide abundant in the body
that serves a role in processes such as scar reduction, cell migration, and angiogenesis.

63

Even

though HA is naturally derived, it is often chemically modified to tune its material properties and
enable hydrogel formation.

64-66

Yoon et al. developed HA hydrogels consisting of acrylated HA

with thiol-terminated PEG crosslinkers (PEG-SH4). Injection into rats two weeks post-MI
(permanent occlusion) led to increased vessel formation, decreased apoptosis, reduced infarct
area, and significantly enhanced EF and SV as compared to infarct controls at four weeks after
delivery. Interestingly, results showed increased wall thickness while histology revealed complete
64

hydrogel degradation at four weeks.

Figure 3.3. Natural, injectable hydrogel for acellular cardiac repair. Chemical structure of
methacrylated HA (A) and representative H&E stain of the hydrogel at 8 weeks post-MI (B). G =
Gel, Scale bar = 50 mm. Figure adapted from [65].
31

Ifkovits et al. developed methacrylated HA (MeHA) hydrogels crosslinked with redox
radical initiators, ammonium

persulfate (APS)

and N,N,N′,N′-tetramethylethylenediamine

65

(TEMED). Two formulations with different initial mechanics but similar degradation were injected
into sheep thirty minutes post-MI (permanent occlusion). Both hydrogels significantly increased
wall thickness relative to infarct controls eight weeks post-MI (Figure 3.3). However, only the
higher modulus gels significantly reduced infarct expansion with trends toward decreased EDV
65

and ESV and increased EF.

In a subsequent study, Tous et al. compared stable MeHA

hydrogels with hydrolytically degradable HA hydrogels and demonstrated that stable hydrogels
improved wall thickness and LV volumes more efficiently than degradable hydrogels.

66

These

studies highlight the importance of material properties (e.g., mechanics, degradation) in MI repair.
Keratin: Keratin is another injectable, natural hydrogel being explored for cardiac
applications. It can be extracted from human hair or animal wool and processed into an injectable
material that self-assembles into a fibrous hydrogel.

67

Shen et al. delivered keratin-based

hydrogels to rats immediately post-MI (permanent occlusion) and revealed increased
angiogenesis, increased wall thickness, decreased infarct size, and enhanced EF and FS as
68

compared to saline controls at four and eight weeks post-MI.

Based on these results, keratin-

based hydrogels are a promising acellular therapy for cardiac repair.
Decellularized ECM: Decellularization of tissues is appealing for tissue engineering
because tissue-specific materials can be generated from the same tissue being treated.

69

Decellularized ECM more closely mimics the unique ECM composition of each tissue, which
includes

specific

fibrous

proteins

(collagen,

fibrin,

elastin,

etc.),

proteoglycans

and

glycosaminoglycans. In addition, its natural thermoresponsive behavior enables it to be a liquid
hydrogel precursor at 25°C and then self-assemble to form nanofibrous hydrogels at 37°C.

70-73

Singelyn et al. utilized a decellularized porcine ECM that self-assembles to form a
70-72

myocardial matrix at physiological temperature.

When injected into the LV of healthy rats, it
70

induced significant increases in arteriole formation 11 days after injection.
32

Injection into infarcted

rats two weeks post-MI (temporary occlusion) led to preserved cardiac function and structure at
one and four weeks after delivery, as evidenced by maintained EF, EDV, and ESV. Histology
revealed increased proliferating cells and recruitment of endogenous CPCs to the infarct. A
feasibility study was then performed to assess the efficacy of catheter delivery in a porcine model;
histology confirmed hydrogel retention and distribution. This was the first study to successfully
demonstrate transendocardial injections of an in situ gelling material in a clinically relevant, large
71

animal model.

In a subsequent study, Seif-Naraghi et al. delivered this porcine ECM hydrogel to

pigs two weeks post-MI (permanent occlusion) using a NOGA-guided MyoStar catheter (Biologics
Delivery Systems, Irwindale, California). Three months after delivery, echocardiography revealed
increased cardiac function, decreased LV volumes, and improved global wall motion scores.

72

Okada et al. developed injectable hydrogels from decellularized small intestinal
submucosa (SIS) and injected them into mice immediately post-MI (permanent occlusion).

73

Two

hydrogel forms, SIS-B and SIS-C, were evaluated for their therapeutic potential post-MI. SIS-B
was characterized to have increased mechanical properties and significantly more basic fibroblast
growth factor (bFGF) as compared to SIS-C. Assessment at two and six weeks post-MI revealed
SIS-B delivery led to reduced infarct size, increased capillary density, preserved LV end systolic
geometry, and improved cardiac contractility whereas SIS-C had minimal to no benefits as
compared to saline controls.

73

Since no further information was provided on the two SDS forms, it

can be hypothesized that the outcomes were due to differences in bFGF concentration.
3.2.2.2. Synthetic Acellular Hydrogels
Despite several advantageous properties, natural materials are generally limited in the
ability to tailor their properties. In contrast, synthetic materials have defined material properties,
including molecular weight, gelation, hydrophilic/hydrophobic properties, degradation, and
mechanics, without batch-to-batch variations.

27

Despite their inherent lack of bioactivity, synthetic

materials can be modified with cell binding sites or adhesive ligands to encourage cell
interaction.

74

For cardiac applications, synthetic materials can be designed to trigger cellular
33

events, minimize the immune response, and degrade at a controlled rate, thus enabling cell
integration and potentially, improvements in cardiac function long-term.

26

Various synthetic

materials have been explored for cardiac repair therapy, including poly(N-isopropylacrylamide)
(PNIPAAm) and poly(ethylene glycol) (PEG) based hydrogels (Table 3.1).
Poly(N-isopropylacrylamide) (PNIPAAm): Several studies have focused on the use of
75-78

PNIPAAm-based hydrogels due to their thermoresponsive properties.

Fujimoto et al.

developed a hydrogel from the copolymerization of NIPAAm, acrylic acid (AAc) and hydroxylethyl
methacrylate-poly(trimethylene carbonate) (HEMAPTMC) to generate poly(NIPAAm-co-AAc-coHEMAPTMC), which gels at 37°C and degrades over five months.

75

Injection into rats two weeks

post-MI (permanent occlusion) led to significantly increased wall thickness, maintained LV end
diastolic area, and preserved percent LV fractional area change compared to saline controls at
four and eight weeks post-MI. There was also enhanced capillary density and positive staining for
75

α-smooth muscle actin in the infarct, providing insight to the mechanism of functional repair.

Similarly, Wang et al. developed a thermosensitive hydrogel consisting of biodegradable
dextran grafted to hydrophobic poly(ϵ-caprolactone)-2-hydroxylethyl methacrylate (PCL-HEMA)
and copolymerized with thermoresponsive PNIPAAm to form Dex-PCL-HEMA/PNIPAAm.

76

Injection into rabbits four days post-MI (permanent occlusion) led to significantly increased EF,
reduced EDD and ESD, increased end systolic pressure (ESP), decreased end diastolic pressure
(EDP), increased cardiac contractility, and reduced infarct size as compared to saline controls at
one month after delivery. Hydrogel treatment led to significantly increased infarct thickness
76

despite no histological evidence of the material remaining at 30 days.

Wall et al. developed semi-interpenetrating polymer network (sIPN) hydrogels with RGD
adhesion

sites

and

MMP

isopropylacrylamide-co-acrylic

degradable

acid)

77

crosslinkers.

[p(NIPAAm-co-AAc)] was

Thermoresponsive

poly(N-

gelled

radical

using

free

polymerization induced by APS and TEMED. Injection into mice immediately post-MI (permanent
ligation) led to significantly increased wall thickness and increased FS as compared to saline
34

controls with a trend towards improved EF at six weeks post-MI. In addition, there were no
statistical differences in FS or EF between animals treated with sIPN injection as compared to
77

sham-operated, noninfarcted mice by six weeks.

Polyethylene glycol (PEG): PEG and its derivatives have been widely studied as
injectable hydrogels for MI repair.

79-84

Jiang et al. developed a novel hydrogel consisting of α-

cyclodextrin (α-CD) and linear triblock copolymer, poly(ethylene glycol)-b-polycaprolactone(dodecanedioic

acid)-polycaprolactone-poly(ethylene

degradation is controlled by the triblock copolymer.

79

glycol)

(MPEG-PCL-MPEG),

where

Injection into rabbits one week post-MI

(permanent occlusion) resulted in significantly improved LV EF, decreased EDD and ESD,
reduced scar thickness, and decreased infarct size at four weeks after delivery. In a subsequent
study, Wang et al. applied the same α-CD/MPEG-PCL-MPEG hydrogel to rats five minutes postMI (permanent occlusion) and demonstrated significantly improved FS, decreased LV EDD and
ESD, increased ESP, and decreased infarct size as compared to saline controls one month after
delivery.

82

In both studies, no significant improvements were seen in infarct neovascularization.

Wu et al. developed a thermoresponsive PEG-based hydrogel consisting of an aliphatic,
triblock

copolymer,

poly

(δ-valerolactone)-block-poly

valerolactone) (PVL-b-PEG-b-PVL).

83

(ethylene

glycol)-block-poly

(δ-

This polymer dissolves in water at room temperature, but

gels at 37°C. Injection into rats one week post-MI (permanent occlusion) led to significantly
increased EF, improved end systolic elastance, improved preload recruitable strong work,
reduced ESV and EDV, decreased infarct area, increased wall thickness, and increased blood
vessel density five weeks after injection.

83

Similarly, Kraehenbuehl et al. delivered a MMP-

responsive, PEG-vinylsulfone (PEG-VS) hydrogel to rats one hour post-MI (permanent occlusion)
and showed significantly increased EF and decreased ESV with trends toward decreased EDV
84

and reduced infarct size as compared to saline controls at six weeks post-MI.

35

Table 3.1. Summary of acellular hydrogel systems and their assessment in animal MI models.
Material

Animal/
MI Model

Alginate

Rat;
Proximal
LCA ligation
Swine; Transient
LAD occlusion
Rat;
Proximal
LCA ligation

Injection
Time
(post-MI)
1 week and
2 months

Injection
Volume

Evaluation
Time (postdelivery)

Ref.

100-150 μL

2 months

37

4 days

1, 2, and 4
mL

2 months

36

1 week

130 μL

2 months

47

Collagen

Rat;
Proximal
LCA ligation

1 week

100 μL

6 weeks

51

Matrigel

Rat;
ligation

LAD

Immediate

50 μL x 5
sites

4 weeks

54

Rat;
ligation

LCX

2 weeks

50 μL

4 weeks

64

Sheep; LAD and
D2 ligation

30 minutes

200 μL x 20
sites

2 and
weeks

8

65

Sheep; LAD and
D2 ligation

30 minutes

200 μL x 20
sites

2 and
weeks

8

66

Keratin

Rat;
ligation

Immediate

100 μL

4 and
weeks

8

68

Decellularized
ventricular
ECM

Rat;
LAD
ligation/
reperfusion
Swine;
LAD
embolization

2 weeks

75 μL

1 and
weeks

4

71

2 weeks

250 μL x 1415 sites

3 months

Decellularized
SIS ECM

Mouse;
ligation

LAD

Immediate

20 μL

2 and
weeks

6

73

Rat;
ligation

LAD

2 weeks

100 μL x 5
sites

4 and
weeks

8

75

Rabbit; Proximal
LCA ligation

4 days

50 µL x 4
sites

1 month

76

Rabbit;
ligation

LAD

1 week

50 μL x 4
sites

4 weeks

79

Rat;
ligation

LAD

2 minutes

100 μL (via
2-3 sites)

4 and
weeks

Hyaluronic acid

Poly(NIPAAmco-AAc-coHEMAPTMC)
Dex-PCLHEMA/
PNIPAAm
αCD/MPEGPCL-MPEG

PEG-VS

LAD

72

13

80

Rat;
LCA
7 and 50 81
9 days
100 μL
ligation
days
*SIS = small intestinal submucosa, LAD = left anterior descending coronary artery; LCX = left
circumflex coronary artery, LCA = left coronary artery, OM1 = obtuse marginal I branch, OM2 =
obtuse marginal II branch, D2 = second diagonal branch
36

In contrast to degradable PEG hydrogels, Dobner et al. delivered a non-degradable PEGVS hydrogel polymerized with dithiothreitol (DTT) to rats two minutes post-MI (permanent
80

occlusion).

At four weeks post-MI, the PEG-VS hydrogel significantly increased wall thickness

and decreased LV EDD. However, at 13 weeks, the pathological progression of the treatment
animals was similar to that of saline controls. FS was not improved in hydrogel animals at either
time point.

80

Rane et al. applied the same bioinert, non-degradable PEG-VS hydrogel to rats nine

days post-MI (permanent occlusion) and demonstrated significant increases in wall thickness as
compared to saline controls at 50 days post-MI.

81

Despite this, there was a steady decline in

cardiac function and expansion of LV volumes in both the hydrogel and control animals. In
addition, there were no significant differences in neovascularization or cell infiltration between
hydrogel and control groups.

81

Similar to Dobner et al., Rane et al. found that increased wall

thickness alone was insufficient to cause positive structural and functional outcomes. These
studies suggest that the bioactivity and ability for cells to infiltrate degradable biomaterials are
important to preserving cardiac function post-MI. In addition, prolonged material presence alone
may be insufficient to attenuate adverse LV remodeling.
3.3. Cellular Approaches
3.3.1. Cell Delivery
MI results in the loss of over one billion cardiomyocytes in the infarct region.

85

It was

previously believed that after such massive cardiomyocyte loss, the adult myocardium lacked an
intrinsic regenerative capacity for repair.

86

Recently, studies have confirmed the activation of

resident cardiac stem/progenitor cells and/or recruitment of endogenous stem cells post-MI.

87

However, this innate regenerative capacity is not sufficient to compensate for the large-scale
tissue loss post-MI.
repair.

89

88

Thus, the delivery of exogenous cells has emerged as a therapy for MI

A variety of cell types have been shown to be effective for cardiac repair, including fetal

or neonatal cardiomyocytes, embryonic stem cells (ESCs), skeletal myoblasts, bone marrowderived stem cells (BSCs), adipose-derived stem cells, and cardiac stem cells (CSCs).
37

90,91

ESCs offer the advantage of differentiating into both cardiomyocyte and vascular
lineages but are limited due to their immunogenicity, risk of tumor development, and ethical
concerns.

92

Skeletal myoblasts have fewer ethical concerns and offer the advantages of being

autologous, easy to obtain and expand, and resistant to ischemia.
differentiate into cardiomyocytes

94

93

However, they cannot

and, even though they are naturally contractile, they have a

limited ability to contract synchronously with host cardiomyocytes.

95

BSCs are another autologous

option that can be readily isolated, rapidly expanded in culture, and can maintain or modify their
phenotype to complement the host tissue.

96

The bone marrow is a common source of adult

stem/progenitor cells, including mesenchymal stem cells (MSCs), endothelial progenitor cells
(EPCs), and hematopoietic stem cells (HSCs).
94

differentiate into cardiomyocytes in vivo.
differentiate into cardiomyocytes in vivo,
isolation from patients with recent MI.

87

98

97

However, it remains unclear if BSCs can truly

In contrast, resident CSCs are multipotent and can

but there are concerns with scalability and autologous

Thus, each cell type offers a unique set of advantages

and limitations, making it challenging to select an ideal cell source for cardiac repair.
Cell delivery, or cellular cardiomyoplasty, involves directly delivering cells to the infarcted
myocardium using intramyocardial injection, intracoronary infusion, or interstitial retrograde
coronary venous delivery. The feasibility of delivering cells alone to the heart has been confirmed
for nearly two decades.

99

While both animal models

91

and clinical studies

90

demonstrate

significant improvements in cardiac function, this improvement is often not clinically relevant and,
for the most part, transient.
engraftment.

89

100

This transiency is due to unsatisfactory cell retention, survival, and

Regardless of the delivery method, there is lack of cell retention at the injection

site due to the low viscosity of a cell-saline suspension, causing the cells to leak out during
injection.

101

Of the small percentage of cells that do engraft, they often lack appropriate

functionality to have a therapeutic effect.

102

Hofmann et al. and Hou et al. showed that less than

10% of BMCs delivered are detected two hours after injection.

103,104

Of the retained cells,

approximately 90% die within the first week due to the myriad of stresses encountered upon
injection into the infarct, including physical stress, ischemia due to microvasculature obstruction,
38

myocardial hypoxia, inflammation, and release of cytokines and reactive oxygen species.

105

In

addition, due to ECM breakdown post-MI, the retained cells lack an anchoring matrix which may
result in anoikis, a form of programmed cell death due to loss of normal cell-matrix interactions.

106

Ultimately, in spite of enthusiasm for cell delivery, regeneration of functional, integrated
myocardium in the infarct has yet to be demonstrated in large animal models or patients.
Due to these challenges, biomaterials have been explored to enhance cell retention and
engraftment for cardiac repair by improving cell attachment, migration, and survival upon
delivery.

33

In addition, biomaterials can enhance tissue angiogenesis,

produce cytokines,

33

enhance cell retention,

31

31,33

and influence cell differentiation.

activate cells to
107

Polymers can

be designed to influence integrin binding sites with a range of matrix pore sizes, substrate
topography, and substrate rigidity.

108

Biomaterial approaches for cell delivery include in vitro

engineered cardiac muscle patches and injectable biomaterials.
3.3.2. Cardiac Patches
Cardiac patches may provide structural support to limit LV dilation post-MI, similar to LV
restraints, but with the added benefit of cell delivery. They are constructed by seeding cells onto a
biomaterial scaffold in vitro for subsequent in vivo implantation onto the infarcted
myocardium.

109,110

Theoretically, cardiac function improves through the combination of cell-

mediated remodeling
dilatation.

112

111

and material-based mechanical stabilization which attenuates myocardial

Because the cells are anchored to the scaffold, cardiac patches lead to better

engraftment when compared to cell delivery alone.

112

Li et al. demonstrated the use of a cardiac patch to deliver cells for cardiac repair.

113

Fetal cardiomyocytes were seeded on a gelatin mesh in vitro and subsequently implanted onto
the infarct of a rat MI model, leading to prolonged cell survival over five weeks and a trend
towards improved LV function.

113

Since this early study, a variety of natural and synthetic cardiac

patches have led to positive functional outcomes in vivo as compared to injection of cells
39

alone.

109,110

Hamdi et al. compared delivery of skeletal myoblasts through intramyocardial

injection, formation as a cell sheet, or using a collagen-based cardiac patch at four weeks post114

MI.

Animals that received the cell sheet or cell seeded scaffold had significantly improved EF

and increased vessel density one month after delivery as compared to culture medium
controls.

114

The promising results in animal models have led to clinical trials involving cardiac

patches for MI repair. In the MAGNUM phase I clinical trial, BMCs were seeded on type I collagen
cardiac patches and delivered to ten patients with coronary artery bypass grafts and intrainfarct
implantation of autologous bone marrow cells. The combined cell injection and cardiac patch
approach led to improved LV EDV and increased scar thickness as compared to cell injection
alone.

115

Additional studies using 3D fibrin cardiac patches have shown similar results.

116-118

Despite success with cardiac patches, major drawbacks still remain. Although the
purpose is to improve cell engraftment, the reality is there is low engraftment within patches when
implanted in vivo due to inadequate angiogenesis.

112,116,117

Low vascularization limits graft

thickness due to an inability to support the high oxygen and nutrient demands of cells at depths
greater than ~100 μm.

119

In addition, the patches must be sutured to the infarct,

35

a technique

which may be useful to prevent LV dilatation but is unlikely to directly contribute to myocardial
contractility and function. The location of the patch on the epicardial surface of the heart also
limits the region of therapeutic benefit. Most importantly, the invasive surgical procedure
necessary for implantation limits clinical translation.
3.3.3. Injectable Hydrogels for Cell Delivery
Injectable hydrogels for cell delivery offer the advantage of enhancing cell retention,
survival, and engraftment with the potential for minimally-invasive, percutaneous catheter-based
delivery,

36,71,72

which may enhance clinical translation.

37,53,57,120

As compared to rigid cardiac

patches with limited radial engraftment, injectable hydrogels can form in situ, integrate into the
host tissue, and adapt to the surrounding contracting myocardium.

121

One of their major benefits

is that hydrogel crosslinking typically occurs after the addition of cells, enabling complete cell
40

encapsulation into a viscous but flowable delivery matrix that solidifies upon injection into the
myocardium. Hydrogel shape, stiffness, and thickness can be controlled to ensure formation into
the geometry of the injection site.

122

Hydrogels not only provide three-dimensional support to

enhance cell retention, but also permit control over the biophysical and biochemical
microenvironment of the transplanted cells to prolong survival and engraftment.

123

In turn,

encapsulated cells are allowed to produce their own ECM and remodel the construct into a more
suitable environment.
Delivery of cells using injectable biomaterials may provide additional benefit over
acellular materials. However, many studies show similar functional benefits with delivery of
hydrogels alone. As previously discussed in Section 3.2.2, injection of hydrogels into the infarct
region results in improved passive myocardial properties, mechanical stabilization due to LV
geometry alterations, and ultimately, reduced myocardial wall stress.

24

However, to improve

cardiac function long-term, the therapy should also contribute to active myocardial regeneration,
including the introduction of viable, contractile tissue.

124

This can potentially be achieved by

combining cell approaches with injectable hydrogels. Ultimately, hydrogels provide a platform for
cell delivery, a structural matrix to direct tissue formation, and an improved microenvironment for
myocardial repair.

30,74

Similar to acellular approaches both natural and synthetic hydrogels have

been utilized to deliver cells for myocardial repair (Table 3.2).
3.3.3.1. Natural Hydrogels for Cell Delivery
Natural materials are popular choice for cell delivery due to their inherent ability to be
recognized by cell-surface receptors and potential for cell-mediated remodeling, thus facilitating
cell-biomaterial interactions. Similar to acellular approaches, commonly used naturally derived
hydrogels for cell delivery include fibrin, alginate, collagen, Matrigel, chitosan, and selfassembling peptides.

41

Table 3.2. Summary of cellular hydrogel systems and their assessment in animal MI models.
Material

Fibrin

Collagen

Matrigel

Chitosan

Animal/
MI Model
Rat;
LAD
ligation/
reperfusion
Rat;
cryoinjury
Sheep; LCX
constriction
Rat;
LAD
ligation
Rat;
LAD
ligation
Mouse;
LAD ligation
Rat;
LAD
ligation/
heterotopic
transplant
Rat;
LAD
ligation
Rat;
LAD
ligation

Injection
Time
(post-MI)
43
10 days
or
1
44
week

Cells Delivered
Skeletal
myoblasts
6
(5×10 )
7

BMNCs (2×10 )

3 weeks

Endothelial cells

4 weeks

Injection
Volume

Evaluation
Time (postdelivery)

Ref.

50 μL

5 weeks

30,31

8 weeks

127

2 months

129

100 μL x
2 sites
800 μL x
3 sites

5

Immediate

150 μL x
2 sites

90 minutes

128

6

1 week

70 μL

4 weeks

133

6

Immediate

50 μL

2 weeks

55

6

Immediate

125 μL

2 weeks

134

ESCs (1×10 )

7

1 week

100 μL

4 weeks

57

Adipose-derived
6
MSCs (4×10 )

1 week

100
(via
sites)

4 weeks

58

8

Immediate

50 μL x
40 sites

4 weeks

135

7

1 week

50 µL x 4
sites

1 month

78

7

1 week

50 μL x 4
sites

4 weeks

136

4 weeks

137

30 days

138

MSCs (5×10 )
MSCs (2×10 )
ESCs (1×10 )
ESCs (2×10 )

Selfassembling
peptides
Dex-PCLHEMA/
PNIPAAm
αCD/MPEG
-PCLMPEG

Minipigs;
Mid-LAD
ligation
Rabbit;
Proximal
LCA ligation
Rat;
LCA
ligation

BMNCs (2×10 )

Oligo(PEG
fumarate)

Rat;
LAD
ligation

ESCs (1×10 )

1 week

100
(via
sites)

PEGylatedfibrinogen

Rat;
Proximal
LAD ligation

Neonatal cardiomyocytes
6
(3×10 )

1 week

300 μL

BMNCs (1×10 )
BMNCs (1×10 )

6

μL
3

μL
3

* BMNCs = bone marrow-derived mononuclear cells, MSCs = mesenchymal stem cells, ESCs =
embryonic stem cells, CPCs = cardiac progenitor cells, ELC = endothelial-like cells, SMLC =
smooth muscle-like cells (see Table 3.1 for additional abbreviations)

42

Fibrin: Injectable fibrin has been used to deliver a variety of cell types, including skeletal
myoblasts,
118

CSCs,

30,31

BSCs,
128

MSCs,

125

bone marrow mononuclear cells (BMNCs),

endothelial cells,

129

126,127

and adipose-derived stem cells.

bone marrow-derived

130,131

Regardless of the

cell source, delivery of cells encapsulated in fibrin leads to enhanced neovascularization,
improved LV function, and attenuated LV remodeling.

132

Christman et al. demonstrated the

benefits of injectable hydrogels for cell delivery over traditional cellular cardiomyoplasty.

31

Injection of skeletal myoblasts encapsulated in fibrin glue in rats one week post-MI (temporary
occlusion) led to a significantly greater cell area relative to myoblasts injected in BSA five weeks
after delivery, indicating that fibrin increases cell survival by potentially serving as a temporary
ECM for the injected cells.

31

Similar to previous studies,

30

fibrin glue, with or without cells, induced

neovascularization in the ischemic myocardium and reduced infarct expansion.
Ryu et al. delivered BMNCs with and without fibrin encapsulation to rats three weeks
following MI (cryoinjury).

127

Eight weeks after delivery, histological evaluation revealed increased

neovascularization when cells were delivered using fibrin hydrogels, including significantly
increased microvessel density and larger internal vessel diameters, as compared to delivery of
cells alone or culture medium controls.

127

However, it is unclear if the improvements were due to

fibrin alone or BMMC delivery due to lack of a fibrin control. Chekanov et al. reported similar
results when delivering endothelial cells with and without a fibrin matrix to an ovine chronic
ischemia cardiomyopathy model.

129

Finally, Martens et al. delivered labeled MSCs encapsulated

in fibrin to rats immediately post-MI (permanent occlusion) using a minimally invasive,
percutaneous catheter.

128

Ninety minutes after delivery, cells delivered using fibrin had

significantly increased retention in the heart and reduction of redistribution to the liver and kidney
128

as compared to cells delivered alone.

Alginate: Alginate hydrogels have also been utilized for cell delivery for cardiac repair. Yu
et al. used injectable, RGD modified, alginate hydrogel microspheres to deliver encapsulated
MSCs (temporary occlusion).

139

Alginate encapsulation improved cell attachment and growth and
43

increased angiogenic growth factor expression in vitro. Injection of alginate, with or without cells,
into rats one week post-MI (temporary occlusion) led to preserved wall thickness and significantly
improved FS at ten weeks after delivery as compared to baseline. Histology demonstrated that
each treatment group (alginate alone, cells alone, and alginate with cells) reduced infarct area
and increased arteriole density indicative of angiogenesis, with no significant differences between
the groups. Despite comparable functional outcomes between the groups, the use of alginate
significantly increased cell survival over cells alone or saline controls.

139

Collagen: Collagen has also been used to deliver cells for MI repair. Dai et al. delivered
nanoparticle labeled MSCs encapsulated in a commercially available collagen matrix to rats one
week post-MI (permanent occlusion).

133

Four weeks following injection, collagen encapsulation

significantly reduced MSC relocation to regions of non-infarcted myocardium and remote organs
relative to delivery of cells alone. However, cell delivery using collagen hydrogels did not
significantly improve LV EF as compared to saline controls. EF was significantly increased in
animals that received collagen alone, consistent with a previous study,
compared to saline.

133

51

as well as cells alone as

To assess the translational potential of collagen-cell systems, Thompson

et al. injected autologous BMCs encapsulated in a collagen hydrogel into the myocardium of pigs
using a composite catheter system (TransAccess).

140

Histology revealed hydrogel retention in the

myocardium immediately after injection and at 14 and 28 days following injection, indicating the
efficacy of intramyocardial catheter delivery. However, since this procedure was only performed
on non-infarcted hearts, it is difficult to assess the effects of this therapy on LV remodeling.

140

Matrigel: Several cell types have been delivered using Matrigel hydrogels, including
ESCs

55,134

and ESC-derived cardiomyocytes.

53

Laflamme et al. delivered human ESC-derived

cardiomyocytes encapsulated in Matrigel to rats four days post-MI (temporary occlusion) and saw
preserved cell retention in the infarct as compared to cell delivery in serum free medium at one
week after injection.

53

Kofidis et al. delivered labeled mouse ESCs encapsulated in Matrigel to a

rat heterotopic heart transplant model immediately post-MI (permanent occlusion).
44

134

Two weeks

later, delivery of Matrigel encapsulated ESCs led to significantly increased FS, increased
thickness in the posterior and septal walls, and reduced EDD as compared with controls
134

(infarcted, Matrigel alone, ESCs alone).

These functional and structural results were confirmed

in a subsequent study using a mouse MI model. In this study, the Matrigel encapsulated ESCs
showed expression of gap junction protein connexin 43 at intercellular sites, indicating possible
connections with the host myocardium.

55

Composites of collagen and Matrigel have also been used for MI repair. The Zimmerman
group developed a novel cardiac muscle construct known as engineered heart tissue (EHT),
which consists of neonatal cardiomyocytes with an artificial ECM made from collagen type I,
Matrigel and cell growth medium.

141

Due to the properties of collagen and Matrigel, EHT remains

a liquid at room temperature but solidifies at 37°C. Zhang et al. delivered liquid EHT as an
injectable hydrogel to rats three weeks post-MI (permanent occlusion). One month after delivery,
collagen-Matrigel encapsulated cardiomyocytes led to increased wall thickness, decreased LV
ESD, and enhanced FS as compared to matrix alone, cells alone, or medium controls.

142

Chitosan: Chitosan hydrogels have also been used for cell delivery post-MI. Lu et al.
delivered chitosan encapsulated ESCs to rats one week post-MI (permanent occlusion) and saw
significantly improved 24-hour cell retention and four-week graft size as compared to delivery of
ESCs alone.

57

In addition, delivery of ESCs encapsulated in chitosan led to significantly increased

microvasculature density in the infarct, increased wall thickness, reduced infarct area, decreased
EDD and ESD, and improved FS and EF at four weeks after injection as compared to chitosan
alone, ESCs alone, or saline controls.

57

These results were later confirmed by delivering a

chitosan hydrogel with encapsulated adipose-derived MSCs to a rat MI model. Even though
injection of chitosan or cells alone improved cardiac structure and function as compared to saline
controls, the combination of cells with chitosan further improved outcomes.

58

Self-assembling peptides: Self-assembling peptides consist of alternating hydrophilic and
hydrophobic amino acids that can form stable β-sheets. At physiological osmolarity and pH, these
45

peptides self-assemble to form nanofibrous hydrogels. Due to the ability of their structure to
promote cell organization, these biologically inspired materials have been used for cell delivery in
143,144

both small

cardiomyocytes,

and large

143,145

135

CPCs,

animal models. Various cells have been delivered, including

146

skeletal myoblasts,

144

135

and BMNCs.

Dubois et al. injected

skeletal myoblasts with self-assembling peptides into rats two weeks post-MI (permanent
144

ligation).

One month after injection, peptide nanofibers alone significantly increased

angiogenesis, but did not improve encapsulated skeletal myoblast survival. Consistent with the
decreased cell survival, no functional improvements were seen in any of the therapy groups
relative to culture medium controls.

144

In contrast, Lin et al. used self-assembling peptides to

deliver cells to a large animal MI model.

135

Injection of BMNCs and self-assembling peptides to

minipigs immediately post-MI (permanent occlusion) significantly increased EF as compared to all
other groups (cells alone, peptides alone, saline controls) and increased interventricular septum
(IVS) systolic and diastolic thickness relative to saline controls at four weeks after delivery. In
addition, peptide nanofibers alone significantly enhanced diastolic function as evidenced by
increased IVS diastolic thickness relative to BMNCs or saline controls, whereas BMNCs alone
significantly improved EF and increased IVS systolic thickness relative to saline controls. Overall,
the delivery of cells and nanofibers led to the greatest improvements in cardiac function.

135

3.3.3.2. Synthetic Hydrogels for Cell Delivery
Synthetic hydrogels can also be used as cell carriers post-MI. Due to their tunability,
small peptides can be added to promote cell interactions or degradation. Similar to acellular gels,
the primary synthetic materials used for cell delivery are PNIPAAm- and PEG-based hydrogels.
Poly(N-isopropylacrylamide) (PIPAAm): Thermoresponsive PIPAAm hydrogels have
successfully encapsulated and delivered cells post-MI in several studies.

77,78

Li et al. delivered

BMNCs encapsulated in a thermoresponsive Dex-PCL-HEMA/PNIPAAm hydrogel to rabbits one
78

week post-MI (permanent occlusion), as previously discussed in Section 3.2.2.2.

Histology

performed 48 hours after injection showed significantly increased cell retention in the infarct with
46

the presence of the hydrogel as compared to BMNCs alone. Thirty days post injection, delivery of
BMNCs in hydrogels significantly decreased infarct size, increased neovascularization, reduced
LV EDD and ESD, and increased EF as compared to cells alone, hydrogel alone, or culture
medium controls. Even though material alone led to improved structural and functional cardiac
outcomes relative to the medium control, there were no improvements in neovascularization,
78

providing motivation for cell encapsulation strategies to repair the damaged myocardium.

Similarly, Wall et al. injected bone marrow-derived MSCs encapsulated in p(NIPAAm-co-AAc)
hydrogels into mice immediately post-MI (permanent occlusion) and saw trends towards
increased FS and EF and decreased EDV at 2 weeks as compared to saline controls.

77

Figure 3.4. Synthetic hydrogel for cell delivery post-MI. Schematic of PEG-fibrinogen hydrogel
assembly (A). Infarct thickness (B) and Masson’s Trichrome staining (C) of infarcted hearts
injected with saline, PEG hydrogel alone, rat cardiomyocytes alone, or combined cell-hydrogel
therapy at 30 days post-MI. Scale bar = 3 mm. *p<0.05 vs. saline controls, †<0.005 vs. all other
groups. Figure adapted from [138].
47

Poly(ethylene glycol) (PEG): PEG hydrogels have delivered several cell types, including
84

ESC-derived vascular cells,

117,136

BMNCs,

and ESCs.

137

Wang et al. delivered BMNCs

encapsulated in an α-CD/MPEG-PCL-MPEG hydrogel to rabbits seven days post-MI (permanent
136

occlusion), as previously discussed in Section 3.2.2.2.

Four weeks after delivery, hydrogel

encapsulated BMNCs led to significantly increased cell retention and neovascularization in the
infarct, decreased LV EDD, reduced infarct size, and increased EF as compared to cells alone or
saline controls.

136

Similarly, Wang et al. delivered ESCs encapsulated in a biodegradable

oligo(poly[ethylene glycol] fumarate) (OPF) hydrogel to rats one week post-MI (permanent
occlusion) and showed significantly improved 24-hour cell retention and four-week graft size
relative to ESCs delivery alone.

137

Four weeks after injection, delivery of OPF encapsulated ESCs

significantly decreased infarct area, reduced collagen deposition in the infarct (fibrosis), increased
infarct neovascularization, decreased LV EDV and ESV, and increased FS as compared to ESCs
alone, OPF alone, or saline controls. Even though outcomes were most pronounced with the cellhydrogel system, delivery of OPF alone or ESCs alone led to significantly reduced infarct area,
decreased fibrosis, reduced LV volumes and enhanced FS as compared to saline controls. In
addition, each treatment group showed significantly decreased protease expression (i.e., MMP-2,
MMP-9) relative to saline controls, with the cell-hydrogel system leading to the greatest decrease,
which could favor infarct stiffening at later time points.

137

Building on the benefits of synthetic and natural systems, Habib et al. used a
photopolymerizable, biodegradable PEGylated-fibrinogen hydrogel
cardiomyocytes to rats one week post-MI (permanent occlusion).

to deliver neonatal rat
138

Thirty days following

injection, delivery of hydrogel encapsulated neonatal cardiomyocytes encapsulated led to
significantly increased FS as compared to all other groups (cells alone, hydrogel alone, saline
controls), decreased wall motion score index (measure of regional systolic function) relative to
saline controls, and preserved LV EDD as compared to hydrogel alone or saline. Histology
revealed that co-injection of the cells and hydrogel significantly increased the cell-graft area and
138

wall thickness as compared to all other groups (Figure 3.4).
48

Table 3.3. Summary of hydrogels for molecule delivery and their evaluation in animal MI models.
Material

Alginate

Animal/
MI Model
Rat;
LAD
ligation
Rat;
LAD
ligation

Chitosan
Hyaluronic
acid
Gelatin

Selfassembling
peptides
αCD/MPEG
-PCLMPEG
PVL-bPEG-b-PVL

Rat;
LAD
ligation
Mouse;
cryoinjury
Rat;
LAD
ligation
Dog; LAD
ligation

Molecules
Delivered
IGF-1
(250 ng), HGF
(250 ng)
VEGF
(3 μg), PDGF
(3 μg)
FGF (2 μg)

Injection
Time
(post-MI)

Injection
Volume

Evaluation
Time (postdelivery)

Ref.

6 days

120 μL

4 weeks

147

1 week

100 μL

4 weeks

148

1 week

100
(via
sites)

4 weeks

62

Immediate

25 μL

1 week

149

57 μL x 6
sites
1 mL x 5
sites

2 and 4
weeks
10 and 17
days

150

Immediate

50 μL (via
3 sites)

4 and
weeks

152

Immediate

80 μL (via
3 sites)

4 weeks

153

μL
3

Rat;
LCA
ligation

SDF-1α
(0.25 μg)
FGF
(120 μg)
FGF
(100 μg)
FGF
(40 ng), PDGF
(160 ng)
SDF-1α
(30 nmol/L)

Rat;
LCA
ligation

EPO
(600 U)

5 minutes

100 μL x
3 sites

1 month

82

Rat;
LAD
ligation

VEGF
(40 ng)

1 week

25 μL x 4
sites

1, 2, 3, and
5 weeks

83

Rat;
LCA
ligation

Immediate
Immediate

8

151

* IGF-1 = insulin-like growth factor 1, HGF = hepatocyte growth factor, VEGF = vascular
endothelial growth factor, PDGF = platelet derived growth factor, FGF = fibroblast growth factor,
SDF-1α = stromal cell derived factor-1 alpha, EPO = erythropoietin (see Tables 1 and 2 for
additional abbreviations)
3.4. Injectable Hydrogels for Molecule Delivery
In addition to providing mechanical stabilization to the injured myocardium and serving as
an exogenous cell delivery vehicle, injectable hydrogels can encapsulate and deliver therapeutic
molecules to the myocardium post-MI. Tissue repair is a complex process controlled in part by
growth factors and cytokines that regulate the pathways of wound healing and tissue generation.
Therefore, delivery of exogenous molecules, such as growth factors, cytokines, and stem-cell
49

mobilizing factors, can modulate endogenous biological responses post-MI.

154

Delivery of

therapeutic molecules alone, either by direct myocardial injection or systemic intravenous
circulation, has helped restore cardiac function in some animal models.

155

However, clinical trials

have been less conclusive and there are limitations with molecule delivery alone, such as the
need for high concentrations or repeated doses due to high diffusion rates and short half-lives.

156

In addition, systemic delivery introduces numerous safety concerns and off-target effects, such as
increased incidence of restenosis, elevated blood pressure and viscosity, and thrombolytic events
in congestive heart failure patients.

157

Due to limitations in molecule delivery alone, injectable

hydrogels have been used as vehicles to localize molecules and tailor release kinetics through
changes in polymer-molecule interactions, polymer hydrophobicity, and hydrogel degradation
158,159

(Figure 3.5).

Hydrogels can both sustain local molecule release and prolong molecule

160

For cardiac applications, injectable hydrogels deliver anti-apoptotic molecules,

bioactivity.

angiogenic factors, or chemoattractants to attenuate remodeling post-MI (Table 3.3).
3.4.1. Anti-Apoptotic Factors
Hydrogels have been used to deliver anti-apoptotic factors post-MI to attenuate further
cardiomyocyte loss. Ruvinov et al. delivered insulin-like growth factor 1 (IGF-1) and hepatocyte
growth factor (HGF) via alginate microparticles to rats six days post-MI (permanent occlusion).

147

This growth factor combination was selected due to the cytoprotective properties of IGF-1 and
pro-angiogenic and anti-fibrotic effects of HGF. To increase growth factor affinity to the hydrogel,
alginate was chemically modified with sulfate groups; due to differences in sulfate affinity between
IGF-1 and HGF, there was sequential release of IGF-1 then HGF. Four weeks post injection, the
dual IGF-1/HGF affinity-bound alginate

hydrogel

significantly

decreased

fibrosis,

reduced

apoptosis, increased vessel density and area, and increased cardiomyocyte proliferation relative
to IGF/HGF alone and hydrogel alone. Compared to saline controls, the hydrogel system
significantly increased scar thickness, limited infarct expansion and reduced fibrosis. There was
also evidence of cardiogenesis (GATA-4-positive cells) indicative of endogenous regeneration.
50

147

Davis et al. used self-assembling peptide nanofibers to deliver IGF-1 to rats immediately
post-MI (permanent occlusion).

143

To sustain IGF-1 release, biotinylated IGF-1 was tethered to

biotinylated self-assembling peptides using a streptavidin linker complexed to the IGF-1. This
strategy enables IGF-1 binding but does not prevent peptide self-assembly into hydrogels. A
preliminary study in healthy rats demonstrated that tethering of IGF-1 to peptide nanofibers led to
significant retention in the myocardium for 28 days and preserved bioactivity for 14 days as
compared to untethered IGF-1 or IGF alone. However, when delivered to the rat MI model, no
differences in cardiac function were observed between treatment groups at 1 or 21 days post143

MI.

In contrast, Kraehenbuehl et al. demonstrated improvements in cardiac function with

hydrogel-based growth factor delivery. Thymosin ß-4 (Tβ4), a pro-angiogenic and pro-survival
factor, was encapsulated in an MMP degradable PEG-VS hydrogel and injected into rats one
84

hour post-MI (permanent occlusion).

Six weeks later, PEG hydrogels with or without Tβ4 led to

significantly decreased LV ESV and increased EF as compared to saline controls, with a trend
towards decreased infarct size and reduced LV EDV. However, outcomes were more pronounced
with Tβ4. Interestingly, delivery of Tβ4 using PEG hydrogels led to a significantly smaller LV ESV
84

as compared to hydrogels alone, demonstrating the beneficial effects of growth factor delivery.
3.4.2. Angiogenic Factors

Hydrogels can also deliver pro-angiogenic factors to increase vascularization to the
ischemic myocardium and generate an environment more conducive to cell infiltration for repair.
Basic fibroblast growth factor (bFGF) is a powerful angiogenic molecule that has been delivered
using hydrogels to sustain its release and prolong its activity.

60,62,150-152,161-164

For instance, bFGF

encapsulation in gelatin hydrogel microspheres increases its in vivo half-life from days to
weeks.

161-163

Hence, gelatin has been used to deliver FGF in both small

150

and large

151

animal

models. Shao et al. delivered gelatin encapsulated bFGF to rats immediately post-MI (permanent
occlusion) and saw significantly increased capillary and arteriolar density in the BZ, reduced
cardiomyocyte apoptosis, increased infarct thickness, and reduced infarct expansion as
51

compared to saline controls at four weeks after delivery.

150

Similarly, Liu et al. delivered gelatin

encapsulated bFGF microspheres to dogs immediately post-MI (permanent occlusion) and found
significantly increased microvessel density and improved EF as compared to controls of gelatin
microspheres in saline at 10 and 17 days post-MI.

151

Similar improvements in vascularization and
62,164

cardiac function have been shown for bFGF delivery from chitosan hydrogels post-MI.

Figure 3.5. Molecule release from injectable, natural hydrogels. Growth factor release of VEGF
and PDGF (A) tracks with alginate hydrogel degradation (B) in vitro. Figure adapted from [148].
Despite increased neovascularization with pro-angiogenic factor delivery, there is
concern that the newly formed vessels lack stability and connectivity.

165

To enhance vessel

stability, multiple pro-angiogenic factors can be simultaneously or sequentially released from
hydrogels.

148,152,166

Kim et al. delivered both bFGF and platelet derived growth factor (PDGF)

using self-assembling peptides to rats immediately post-MI (permanent occlusion).

152

The goal is

to first stimulate vessel formation using bFGF, then recruit smooth muscle cells to form stable
vasculature using PDGF. In addition, self-assembling peptide nanofibers alone recruit endothelial
cells and vascular smooth muscle cells,

145

where both cell types are needed for stable vessel

formation. Dual bFGF/PDGF delivery from peptide nanofibers significantly reduced infarct size,
52

increased wall thickness, decreased cardiomyocyte apoptosis, and increased capillary and
arteriole density at four and eight weeks after delivery and significantly improved cardiac function
and contractility (LV EDP, +dP/dt, -dP/dt) after four weeks relative to sucrose controls. Similarly,
Hao et al. sequentially delivered vascular endothelial growth factor (VEGF) then PDGF from
alginate hydrogels (Figure 3.5) to rats one week post-MI (permanent occlusion).

148

Four weeks

later, sequential release of VEGF then PDGF significantly increased α-actin positive vessels
density, indicating smooth muscle cell vessel stabilization, and increased the systolic velocity148

time integral, a marker of myocardial function, as compared to VEGF or PDGF alone.

To further control angiogenic factor delivery, Wu et al. conjugated VEGF to a PVL-bPEG-b-PVL hydrogel (as discussed Section 3.2.2.2) and injected the system into rats one week
post-MI (permanent occlusion).

83

Five weeks after delivery, animals that received VEGF tethered

to the hydrogel had improved EF and FE, increased contractility (+dP/dt, -dP/dt), preserved EDV
and ESV, increased wall thickness, and increased vessel density as compared to VEGF mixed
with the hydrogel, hydrogel alone, or saline controls.

83

Similar to previous studies,

143,147

conjugating biomolecules to injectable hydrogels prolongs their release and biological effects.
3.4.3. Chemoattractants
In addition to promoting cell survival and angiogenesis, therapeutic molecule delivery
from injectable hydrogels can also focus on recruiting endogenous cells to repair the damaged
myocardium. Stromal cell derived factor-1 alpha (SDF-1α) is a chemokine shown to selectively
recruit stem and progenitor cells.

149,153

Segers et al. locally delivered SDF-1α to rats immediately

post-MI (permanent occlusion) using self-assembling peptide nanofibers.

153

SDF-1α release was

tailored by tethering it to the hydrogel using a peptide sequence susceptible to endogenous
protease cleavage. Four weeks following injection, delivery of SDF-1α tethered to peptide
nanofibers significantly increased recruitment of cells expressing the SDF-1α receptor
(CXCR4+/c-Kit+ cells), increased capillary and arteriole density in the infarct, and improved EF
relative to infarct controls.

153

Similar to self-assembling peptides being well-suited for molecule
53

delivery due to their ability to tether proteins,
mediated BMC homing

167

154

HA has been shown to cooperate with SDF-1α

and thus, may be well-suited for SDF-1α delivery. In addition to their

native binding affinity, both SDF-1α and HA stimulate BMC chemotaxis in vitro through their
CXCR4 and CD44 receptors, respectively.

149

Purcell et al. delivered SDF-1α encapsulated in a

degradable HA hydrogel to mice immediately post-MI (cryoinjury) to assess their synergistic
effects on cell homing.

149

Seven days after delivery, HA hydrogel encapsulation of SDF-1α led to

significantly increased endogenous BMC homing and engraftment in the infarct as compared to
149

SDF-1α alone or hydrogel alone.

In a subsequent study, MacArthur et al. demonstrated that

sustained release of an engineered SDF-1α analog (ESA) from degradable HA hydrogels causes
both endogenous EPC recruitment to the myocardium and preserved LV function.

168

3.5. Combined Hydrogel Delivery of Cells and Molecules
Building from the benefits of delivery of hydrogels alone and hydrogels with encapsulated
cells or molecules, optimal therapies may rely on a combination of all three. Growth and
differentiating factors can further improve encapsulated cell survival and differentiation and
impact the nearby environment to facilitate graft integration. Relative to other material delivery
systems, hydrogels are advantageous due to their ability to simultaneously mechanically support
the myocardium and serve as a controlled delivery platform. By improving long-term cell survival
and engraftment, myocardial reconstruction and/or stem-cell mediated regeneration can occur.
Both natural and synthetic hydrogels have been used to simultaneously deliver cells and
anti-apoptotic or angiogenic therapeutic molecules to the infarct post-MI (Table 3.4). Laflamme et
al. delivered Matrigel encapsulated human ESC-derived cardiomyocytes with pro-survival growth
factors, including IGF-1, cyclosporine A, anti-apoptotic peptide Bcl-XL BH4, caspase inhibitor
ZVAD-fmk and vasodilator pinacidil, to rats four days post-MI (temporary occlusion).

53

Delivery of

Matrigel with both cells and growth factors led to significantly increased cell engraftment in the
infarct as compared to delivery of cells with Matrigel alone one week following injection. Four
weeks after delivery, the hydrogel-cell-growth factor system significantly increased FS and
54

preserved LV EDD as compared to non-cardiac cells with growth factors, growth factors alone, or
culture media controls.

53

In a subsequent study, Fernandes et al. delivered the same system to

rats one month post-MI (temporary occlusion) and saw successful cell engraftment into the infarct
three months after injection. Despite improved cell engraftment, there were no significant
differences in LV EDD, EDV and ESV, SV, or FS between any of the groups at any time point.

120

Davis et al. delivered neonatal cardiomyocytes and IGF-1 tethered to self-assembling
peptide nanofibers to rats immediately post-MI (permanent occlusion).

143

A preliminary study in

healthy rats demonstrated that peptide tethered IGF-1 delivery significantly decreased activation
of caspase-3, an apoptosis marker, in the encapsulated cardiomyocytes and increased
transplanted cell area, as compared to untethered IGF-1 or no IGF-1 controls two weeks after
delivery. Three weeks after delivery to the rat MI model, the tethered IGF-1 cell therapy
significantly decreased apoptosis of the encapsulated cardiomyocytes compared with peptides
alone or untethered IGF-1 and overall, significantly decreased LV dilatation and increased FS as
143

compared with all other groups.

In another study by the same group, Padin-Iruegas et al.

delivered rat CPCs with IGF-1-modified self-assembling peptide nanofibers to rats immediately
post-MI (permanent occlusion).

146

One month following delivery, CPCs encapsulated in IGF-1

tethered peptides significantly enhanced myocardial regeneration (as indicated by increased
cardiomyocyte mass, volume, and number), decreased infarct size, decreased wall stress,
enhanced contractility (+dP/dt, -dP/dt), and increased EF as compared to CPCs or IGF-1 tethered
146

peptides alone.

In contrast to previous studies,

169

Dubois et al. delivered skeletal myoblasts

encapsulated in PDGF loaded self-assembling peptide nanofibers to rats two weeks post-MI
(permanent occlusion) and saw no improvements in LV EF or encapsulated cell survival despite
144

increases in angiogenesis as compared to medium controls at one month after injection.

55

Table 3.4. Summary of hydrogels for cell and molecule delivery and their in vivo assessment.
Material

Animal/
MI Model

Cells
and
Molecules
Delivered

Fibrin with
PLGA
nanospheres

Rat;
LCA
ligation

BMNCs (2×10 ),
TGF-β1 (2 ng)

Matrigel

Rat:
LAD
ligation/
reperfusion

Rat;
LCA
ligation
Selfassembling
peptides

Rat;
LCA
ligation
Rat;
LCA
ligation

PEG-VS

Rat;
LAD
ligation

PEGylatedfibrinogen

Mouse;
LAD ligation

Injection
Time
(post-MI)

Injection
Volume

Evaluation
Time (postdelivery)

Ref.

1 week

100 μL

4 weeks

126

4 days
or
1
128
month

70 μL

1and
4
61
weeks
or 1, 2, and
128
3 months

7, 11,
50

2 weeks

200
μL
(via
3-4
sites)

1 month

144

Immediate

80 μL

1, 14, 21,
and
28
days

143

Immediate

5
μL/
injection
(multiple
sites)

1 month

146

1 hour

60 μL

3 days and
6 weeks

84

Immediate

50 μL

2 and
weeks

117

7

ESC-derived
cardio-myocytes
7
(1×10 ), IGF-1 (7
ng), pinacidil
(50
μM),
cyclosporine A
(0.2 μM), BclXL BH4 (50 nM),
ZVAD
(100 μM)
Skeletal
myoblasts
6
(5×10 ),
PDGF
(100 ng)
Neonatal
cardiomyocyte
5
(5×10 ),
IGF-1 (25 ng)

61

5

CPCs (1×10 ),
IGF-1 (1 ng)
ESC-derived
5
ELCs (6.6 ×10 )
and SMLCs (3.3
5
×10 ) ,
Tβ4 (2.5 μg)
5
BMNCs (5×10 ),
HGF (100 ng)

4

* PLGA = poly(lactic-co-glycolic acid), CPCs = cardiac progenitor cells, ELC = endothelial-like
cells, SMLC = smooth muscle-like cells, TGF-β1 = transforming growth factor-beta 1, Bcl-XL BH4
= cell-permeable TAT peptide, ZVAD = benzyloxycarbonyl-Val-Ala-Asp(O-methyl)-fluoromethyl
ketone, FGF = fibroblast growth factor, Tβ4 = thymosin beta-4 (see Tables 1, 2, and 3 for
additional abbreviations).
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Synthetic hydrogels have also been used to simultaneously deliver cells and
biomolecules for MI repair. Kraehenbuehl et al. delivered human ESC-derived endothelial- and
smooth muscle like cells (ELCs, SMLCs) encapsulated in an MMP degradable, PEG-VS hydrogel
loaded with Tβ4 to rats one hour post-MI (permanent ligation).

84

Six weeks post-MI, delivery of

ELCs/SMLCs encapsulated in a Tβ4-loaded hydrogel significantly increased neovascularization
in the infarct, decreased infarct size, reduced LV EDV ESV, and increased EF relative to saline
controls. Also, the combined cell-Tβ4 delivery from PEG hydrogels significantly increased EF
84

compared to PEG hydrogels with Tβ4 or PEG hydrogels alone.

Zhang et al. delivered murine

BMNCs and HGF covalently bound to PEGylated-fibrinogen hydrogels to mice immediately postMI (permanent occlusion) and saw significantly decreased apoptosis in the BZ and infarct,
increased angiogenesis, decreased fibrosis, decreased LV EDV and ESV, and increased EF as
117

compared to saline controls at four weeks post-MI.

Delivery of BMNCs alone led to significantly

decreased apoptosis in BZ regions, increased angiogenesis, and decreased fibrosis whereas
delivery of HGF-bound hydrogel led to significantly decreased apoptosis and increased
angiogenesis in the infarct relative to saline controls. In addition, BMNCs delivery using a HGFloaded hydrogel significantly increased cell engraftment in the infarct 15-fold relative to delivery of
BMNCs alone. All treatment groups (BMSCs, hydrogel+HGF, hydrogel+HGF+BMNCs) improved
LV volumes and FS relative to controls, with no statistical difference in FS between groups.

117

3.6. Future Directions and Conclusions
As discussed throughout this chapter, a range of injectable hydrogels, cell types, and
molecules have been delivered with the intent of attenuating remodeling post-MI. Although many
hydrogels have shown positive outcomes in animal models, only one material has progressed to
39,40,42,44,45

advanced clinical trials (NCT01226563, NCT01311791).

Therefore, several areas must

be explored prior to clinical translation. For example, the exact mechanism by which injectable
biomaterials lead to positive functional outcomes is not fully understand and is likely quite
complex, involving both mechanical (e.g., stress reduction) and biological (e.g., exogenous cell
57

delivery, endogenous cell recruitment, angiogenesis, inflammatory response) interactions. It is
32,37,48,80,81

evident that increased myocardial wall thickness,
increased angiogenesis

51,79,136

decreased infarct size,

32

and/or

do not directly correlate with improved cardiac function; thus,

finding specific correlations may improve future therapy design. Theoretical FE models provide
some insight into the mechanisms by which injectable materials impact LV remodeling

22,24,25

and

further development of such models may improve our understanding of material injection post-MI.

Figure 3.6. Percutaneous catheter delivery of decellularized ventricular ECM to healthy rats.
NOGA maps representing injection sites (A) and representative H&E stain indicating presence of
hydrogel within the myocardium (B). Scale bar = 1 mm. Figure adapted from [71].
From a translational perspective, it is important to elucidate the effects of hydrogel
properties (e.g., mechanics, degradation), injection parameters (e.g., volume, number of
injection), mode of delivery (e.g., direction injection vs. catheter delivery) (Figure 3.6), and timing
of delivery (e.g., acute vs. chronic MI) on LV remodeling. Much of this can be explored through
both experimental and modeling approaches and by selecting the most appropriate mimic of
clinical scenarios to enhance our understanding of outcomes. Future studies should further
investigate the mechanisms by which hydrogels act on the heart, including both biological and
mechanical effects, and focus on clinically relevant parameters, such as the mode of delivery.
This information has considerable clinical impact with respect to improved therapies to attenuate
LV remodeling and ultimately, to aid patients by preventing progression to heart failure.
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CHAPTER 4

In Vitro Characterization of Hydrolytically Degradable Hyaluronic Acid Hydrogels

4.1. Introduction
Injectable biomaterials have become an attractive therapy to attenuate LV remodeling.
Particularly, acellular hydrogels have been explored to limit infarct expansion by bulking the
1

myocardial wall to modulate myocardial remodeling. Hydrogels are water-swollen networks of
2

polymer chains with a high degree of flexibility, similar to natural tissue and, as a result, have
been explored for a variety of tissue engineering and drug delivery applications.

3-6

For cardiac

repair post-MI, hydrogels can be used to mechanically stabilize the myocardial wall as well as
modulate maladaptive biological processes through delivery of therapies, such as cells and
growth factors,

7-11

as thoroughly discussed in Chapter 3. Moreover, recent work from our group

was the first to demonstrate the importance of injectable biomaterial properties, specifically
mechanical stiffness and degradation, on attenuating LV remodeling in an ovine infarct model.

12,13

However, despite the wide range of materials investigated for MI repair, there is still a need for
tunable hydrogel systems to further investigate the correlation between specific hydrogel
properties and the resulting in vivo outcomes.
One such tunable biomaterial is hyaluronic acid (HA). HA is a linear, negatively charged,
non-sulfated glycosaminoglycans (GAG) ubiquitously found in the extracellular matrix (ECM) of
tissues.

14

More specifically, HA is an ideal candidate for cardiac repair because it is found in the

native cardiac ECM and plays a role in cardiac embryogenesis, angiogenesis, cell migration and
scar reduction. It helps maintain myocardial homeostasis both structurally through its mechanical
properties and functionally through cell and growth factor interactions.
be readily modified with numerous reactive groups (e.g., aldehydes,
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15-17

18,19

Furthermore, HA can

malemides,

20

hydrazides

and

dihydrazides,

19,21,22

thiols,

methacrylates and acrylates

23,24

norbornenes,

24

adamantanes,

25

cyclodextrins,

25

and

12-14,26-28

) at the carboxyl and hydroxyl groups on each repeat unit to

enable tunability of material properties towards specific applications,

14,29,30

including MI repair.

12,13

In addition to the type and degree of HA modification, the macromer molecular weight and
concentration can also be varied to tailor material properties.

13,14,27,28

The addition of reactive groups not only enables tunability of material properties but also
crosslinking into hydrogels, where the mechanism of gelation depends on the specific functional
31

group.

Hydrogels form by various gelation mechanisms, including self-assembly, ionic

crosslinking, covalent crosslinking through chemical reactions, and inherent phase transition
behavior.

32

Due to their unique gelation properties, hydrogels offer the advantage of initially being

in a viscous form during delivery and then solidifying into a stable gel once delivered to the
intended target tissue. One crosslinking approach is to radically polymerize the methacrylate
groups on HA using an initiator or stimulus, such as light, temperature, or oxidation-reduction
(redox) species; the radicals propagate through the methacrylate vinyl groups to form kinetic
chains to crosslink the macromer.

12-14,26-28,31

The properties of the resulting hydrogel thus depend

on the concentration of the initiator as well as the macromer modification and concentration.
Previous studies have demonstrated that the mechanical properties of methacrylated HA (MeHA,
Figure 4.1B) hydrogels can be tuned through both the macromer modification and initiator
concentration: as the amount of reactive methacrylates or free radicals increases, the crosslinking
density and thus, mechanics increase.
initiators

12,13,33

12,13

In addition, crosslinking via redox chemical

circumvents the depth penetration limitations of photopolymerization

14,28,31

and

increases the potential for clinical translation because the pre-polymer solution can be
administered (ideally via catheter) directly to the target organ.
To further tune hydrogel properties (i.e., degradation), HA can also be modified to include
a hydrolytically degradable functional group, hydroxyethyl methacrylate (HeMA), to produce the
gel precursor HeMA-HA (Figure 4.1A). Similar to MeHA, HeMA-HA contains a reactive
81

methacrylate for free-radical initiated crosslinking: when the macromer is mixed with chemical
initiators, stable hydrogels form within minutes.

12

In contrast to MeHA, HeMA-HA contains ester

bonds that are hydrolytically unstable. While HA is enzymatically degraded in the body by
hyaluronidases,

16,34

this process occurs over the time frame of months to years and is dependent

on the physiological concentration of hyaluronidase in vivo. The addition of HeMA enables finelytuned, multimodal hydrogel degradation: enzymatic degradation through the HA backbone and
hydrolysis through the ester groups of HeMA. In this tunable system, the rate of crosslinking, and
therefore gelation onset, can be controlled through the initiator concentration whereas the rate of
degradation and maintenance of mechanical properties can be controlled through the HeMA
modification on HA and the HA concentration.

Figure 4.1. Chemical structures of HeMA-HA (A) and MeHA (B) macromers.
In this chapter, the tunability of HA hydrogels was examined in two systems: 1) pure
HeMA-HA hydrogels and 2) copolymer hydrogels consisting of HeMA-HA and MeHA. A two
component

redox

initiator

system

of

ammonium

persulfate

(APS)

and

N,N,N,N’,N’-

tetramethylenediamine (TEMED) was used to induce polymerization of both macromers into
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hydrogels. In addition to offering the potential for noninvasive, catheter-based delivery, the use of
redox initiators for crosslinking provides enhanced control over gelation timing.

12,13

Kinetic chains

were formed through crosslinking the reactive methacrylate groups on all macromers to generate
hydrogel networks where the bulk properties depended on three parameters: initiator
concentration, macromer modification, and macromer concentration. The effect of altering each of
these material parameters on the resulting hydrogel properties (i.e., gelation, degradation, and
mechanics) was investigated to provide insight into the design and material properties of HA
hydrogels towards the identification of optimal material properties for targeted MI therapies.
4.2. Materials and Methods
4.2.1. Synthesis of Hydroxyethyl Methacrylated HA (HeMA-HA) Macromer
HA

was

modified

with

hydroxyethyl

methacrylate

(HeMA)

by

coupling

HA-

tetrabutylammonium salt (HA-TBA) to 2-hydroxyethyl-methacryl-succinate (HeMA-COOH), as
previously described.

12

HA-TBA was synthesized by converting HA-sodium salt (HA-Na, 75 kDa,

Lifecore) to a TBA salt using an acidic ion exchange (25°C, 8hrs) with Dowex resin (50W×8-200,
Sigma), followed by neutralization with TBA hydroxide (TBA-OH, Sigma) to pH 7.02-7.05 and
subsequent lyophilization.

30

The conversion of Na to TBA enabled HA-TBA to be soluble in
1

dimethyl sulfoxide (DMSO). H-NMR (Bruker, 360 MHz) was used to determine the amount of
TBA coupled to HA. HeMA-COOH was synthesized by reacting 2-hydroxyethyl-methacrylate
(Acros) with succinic anhydride (Sigma) in dichloroethane (DCE) via a ring opening
polymerization (65°C, 16hrs) catalyzed by N-methylimidazole (Sigma). HeMA-COOH was purified
by washing with hydrochloric acid then deionized (DI) water. Excess DCE was removed by rotary
1

evaporator. H-NMR (Bruker, 360 MHz) was performed to confirm HeMA-COOH formation and
purity. Finally, HA-TBA was coupled to HeMA-COOH in anhydrous DMSO (Acros) through an
esterification reaction (45°C, 20hrs) using 4-dimethylaminopyridine (DMAP, Sigma) and the
coupling agent di-tert-butyl dicarbonate (BOC2O, Sigma) (Figure 4.2A). The macromer was
purified by dialyzing against DI water, acetone precipitating, and dialyzing again. The macromer
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1

was then lyophilized and the HeMA modification on HA was assessed with H-NMR (Bruker, 360
MHz) (Figure 4.2B). Modification was altered by varying the ratio of BOC 2O to HeMA-COOH.

Figure 4.2. HeMA-HA macromer synthesis. HeMA-HA was synthesized by coupling HeMACOOH to HA-TBA using DMAP and the coupling agent BOC2O in DMSO (A). Methacrylation
1

were assessed with H-NMR by normalizing to the integral of peak 4 (B).
4.2.2. Synthesis of Methacrylated HA (MeHA) Macromer
As previously described, methacrylated HA (MeHA) was synthesized by reacting a 1 wt%
solution of Na-HA (75 kDa, Lifecore) with a 20-fold excess of methacrylic anhydride (MA; Sigma)
in DI H2O on ice.

14

The solution was titrated with concentrated sodium hydroxide (Sigma) to

maintain a constant pH of 8.0 (4°C, 24hrs) (Figure 4.3A). The macromer was purified by
1

dialyzing against DI H2O and subsequently lyophilized. H-NMR (Bruker, 360 MHz) was used to
assess purity and the extent of methacrylation on the HA backbone (Figure 4.3B). Modification
was altered by varying the amount of MA relative to HA.
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Figure 4.3. MeHA macromer synthesis. MeHA was synthesized by reacting Na-HA with a excess
of methacrylic anhydride (MA) at 4°C in DI water. The pH was maintained at 8.0 using NaOH (A).
1

Methacrylation was assessed with H-NMR by normalizing to the integral of peak D (B).
4.2.3. HA Hydrogel Formation
HA macromers were crosslinked into hydrogels and characterized in vitro for gelation,
degradation, and initial and temporal mechanics. Hydrogel formation was induced by crosslinking
the methacrylate groups on HA using a redox radial initiator system of APS (Sigma) and TEMED
33

(Sigma) (Figure 4.4A).

APS and TEMED were mixed with HA macromers dissolved in PBS to

initiate gelation. For initial characterization studies of 10% and 35% modified HeMA-HA, 10 mM
APS and 10 mM TEMED was used to induce crosslinking. For all subsequent studies, an initiator
concentration of 5 mM APS and 5 mM TEMED was used (Tables 4.1, 4.2). Gel onset and
completion were quantified using an AR2000ex Rheometer (TA Instruments) by monitoring the
storage (G’) and loss (G”) moduli over time at 37°C under 1% strain and a frequency of 1 Hz in a
12

cone-plate geometry (1°, 20 mm diameter) (Figure 4.4B).

Gel onset was defined as the time

where G’ and G” intersect and the viscosity (|n*|) was greater than one. Gel completion was
85

defined as the time where the percent change in both G’ and |n*| were less than 1% for ten
consecutive time steps.

Figure 4.4. Mechanism of hydrogel formation. Hydrogel formation was induced using a two
component radical initiator system of APS and TEMED (A). Representative rheological time
sweep after mixing HeMA-HA macromer initiators, where the intersection of the storage (G’) and
loss (G”) moduli is defined as gel onset (B).
4.2.4. In Vitro Hydrogel Characterization
For in vitro characterization of degradation and compressive mechanics, hydrogels (~50
μL) were formed in between two glass slides within a Teflon mold sealed with vacuum grease by
mixing macromer solutions with APS and TEMED and incubating at 37°C for 30 minutes. Unless
otherwise specified, degradation was monitored in PBS at 37°C. In all cases, HA mass loss was
quantified using an uronic acid assay.

35,36

Hyaluronidase (Sigma) was added to PBS solutions

surrounding the hydrogels at 0.3 mg/mL to completely enzymatically degrade the hydrogels after
20 weeks, if necessary. Compressive mechanical testing was performed using a Dynamic
Mechanical Analyzer (DMA, Q800 TA Instruments) at a strain rate of 10%/min and compressive
moduli were calculated from 10 to 20% strain.

37
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Degradation and mechanics were assessed

immediately after gelation (day 0) and at desired time points throughout the degradation process
(i.e., 1, 7, 14, 28, 56, 84 days, etc. after gelation).
Table 4.1. In vitro characterization studies of pure HeMA-HA hydrogels.
Macromer
Study

Chemical Initiators

Mod. (%)

Conc. (wt%)

APS Conc. (mM)

TEMED Conc. (mM)

10

4, 7, 10

5, 7.5, 10

5, 7.5, 10

35

4, 7, 10

5, 7.5, 10

5, 7.5, 10

10

4, 7, 10

10

10

2

35

4, 7, 10

10

10

3

25

7

5, 7.5, 10

5, 7.5, 10

10

2, 4, 6, 8, 10, 12

5

5

25

2, 4, 6, 8, 10, 12

5

5

40

2, 4, 6, 8, 10, 12

5

5

10

8, 10, 12

5

5

40

4, 5, 6

5

5

1

4

5

Characterization studies were performed on two hydrogel systems 1) pure HeMA-HA
hydrogels (Table 4.1) and 2) HeMA-HA/MeHA copolymer hydrogels (Table 4.2). Initial HeMA-HA
hydrogel characterization studies examined the effect of altering macromer concentration and
modification on hydrogel properties using 10% and 35% modified HeMA-HA at 4, 7, and 10 wt%
gelled using 10 mM APS/TEMED. To select a single initiator concentration for gelation, the
compressive modulus at one day after hydrogel formation was measured for hydrogels formed at
three initiator concentrations (5 mM, 7.5 mM, 10 mM APS/TEMED) for the two modifications at
the three macromer concentrations. A subsequent study examined differences in crosslinking
density due to initiator concentration using three initiator concentrations (5 mM, 7.5 mM, 10 mM
APS/TEMED) at a single macromer modification (25% modified) and macromer concentration (7
wt%). After varying the initiators, a concentration of 5 mM APS and 5 mM TEMED was selected
for use in all subsequent studies (Table 4.1). To further examine the tunability of HeMA-HA
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hydrogels, a more extensive study was performed with varying both the macromer modification
(10%, 25%, 40% modified HeMA-HA) and concentration (2, 4, 6, 8, 10, 12 wt%). Based on this
study, six hydrogel formulations at various macromer modifications and concentrations (10%
modified at 8, 10, 12 wt%; 40% modified at 4, 5, 6 wt%) were selected for temporal assessment.
Table 4.2. In vitro characterization studies of HeMA-HA and MeHA copolymer hydrogels.
Macromer
Study

1

2

Mod. (%)

25% HeMA-HA,
30% MeHA

25% HeMA-HA,
30% MeHA

Copolymer Ratio (v/v)

Conc. (wt%)

4, 6, 8, 10

5, 6, 7

Chemical Initiators

HeMA-HA

MeHA

APS Conc.
(mM)

TEMED Conc.
(mM)

100

0

5

5

75

25

5

5

50

50

5

5

25

75

5

5

0

100

5

5

75

25

5

5

25

75

5

5

To further evaluate the tunability of hydrogel degradation in this HA system, copolymers
of HeMA-HA and MeHA were formulated into hydrogels by mixing different volumetric ratios of
the macromers dissolved at the same concentrations in PBS. The amount of MeHA introduced
into HeMA-HA hydrogels (100:0, 75:25, 50:50, 25:75, 0:100 HeMA-HA:MeHA) was varied at
various macromer concentrations (4, 6, 8, 10 wt%). Based on this initial study, six copolymer
hydrogel formulations at three macromer concentrations (5, 6, 7 wt%) and two copolymer ratios
(75: 25, 25:75 HeMA-HA:MeHA) were selected for assessment of temporal mechanics.
Macromer modification (25% modified HeMA-HA; 30% modified MeHA) and initiator
concentration (5 mM APS/TEMED) were maintained throughout these copolymer hydrogel
characterization studies (Table 4.2).
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4.2.5. Statistical Analysis
Data is presented as mean ± standard deviation (SD) or mean ± standard error of the
mean (SEM), as indicated in each figure legend. Statistical differences between groups were
assessed using a one-way ANOVA with Tukey’s post hoc evaluation (JMP Statistical Software;
SAS Institute; Cary, NC). A p<0.05 was considered statistically significant.
4.3. Results
4.3.1. HA Macromer Synthesis and Characterization
Two HA macromers were synthesized for evaluation in in vitro characterization studies
(Figure 4.1). First, HA was chemically modified to include a hydrolytically degradable group,
HeMA, to enable both free-radical initiated crosslinking through the methacrylate and tunable
degradation through the ester bond hydrolysis (Figure 4.2). Secondly, a non-hydrolytically
degradable methacrylate group was added to the HA backbone to facilitate free radial initiated
crosslinking in a stable hydrogel system as a comparison to the hydrolytically degradable
1

macromer described above, HeMA-HA (Figure 4.3). As described above, H NMR was used to
evaluate the degree of modification on all macromers (Figures 4.2B, 4.3B). Each macromer was
synthesized at a range of modifications for subsequent in vitro characterization (Tables 4.1, 4.2).
4.3.2. In Vitro Characterization of HeMA-HA Hydrogels
For the initial HeMA-HA in vitro characterization study, initiator concentration, macromer
modification, and macromer concentration were simultaneously varied to assess their impact on
initial compressive mechanics. Two macromer modifications (10%, 35%) were investigated at
three macromer concentrations (4, 7, 10 wt%) and three initiator concentrations (5 mM, 7.5 mM,
10 mM APS/TEMED) (Table 4.1). An increase in any of the three parameters led to an increase
in compressive moduli (Figure 4.5). At each initiator concentration, increased modification
resulted in significantly increased (p<0.05) mechanics for all groups. Similarly, increased moduli
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due to increased macromer concentration were statistically significant except when comparing 4
wt% and 7 wt% gels formed using 5 mM and 10 mM APS/TEMED with 10% modified HeMA-HA.
At each modification, differences in moduli based on initiator concentration were not statistically
significant (p>0.05) whereas differences due to macromer concentration were statistically
significant except for comparison between 4 wt% and 7 wt% gels formed from 10% modified
HeMA-HA. Finally, at each macromer concentration, changes in initiator concentration did not
result in statistically significant changes in mechanics whereas changes in macromer modification
did. The largest differences in mechanics with changes in initiator concentration were seen with
35% modified gels at 10 wt% (Figure 4.5). However, due to minimal changes in mechanics with
changes in initiator concentration, subsequent experiments investigated simultaneously altering
the macromer modification and concentration at a constant initiator concentration.

Figure 4.5. Tunability of mechanical properties of HeMA-HA hydrogels. Compressive moduli at
day 1 after hydrogel formation, n=3-4/group, as a function of initiator concentration, macromer
modification, and macromer concentration. Data presented as mean ± SD. See Appendix 4.1 for
statistics information.
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Figure 4.6. Initial in vitro characterization studies of pure HeMA-HA hydrogels at various
macromer modifications and concentrations. Gel onset and completion, n=3-4/group, as a
function of macromer modification and concentration gelled using 10 mM APS/TEMED (A).
Degradation time and initial (day 0) compressive moduli, n=3-4/group (B). Temporal degradation
(C) and mechanics (D), n=3-4/group. Data presented as mean ± SD. *p<0.05 vs. 10% modified
HeMA-HA at 4 wt% in panel A. All groups were significant (p<0.05) in panel B. In panel C,
+

#

*p<0.05 for 4 vs. 7 wt%, p<0.05 for 7 vs. 10 wt%, and p<0.05 for 4 vs. 7 wt% for 10% modified
δ

gels and p<0.05 for 7 vs. 10 wt% for 25% modified gels. See Appendix 4.1 for more statistics.
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Hydrogel properties (i.e., gelation, degradation, and mechanics) were then examined for
the two macromer modifications and three macromer concentrations but a single initiator
concentration of 10 mM APS/TEMED (Table 4.1). Assessment of gelation demonstrated that as
macromer modification or macromer concentration increased, the time to gel onset or completion
decreased (Figure 4.6A). Within a single modification (i.e., 10% modified HeMA-HA), increased
macromer concentration led to a statistically significant decrease in gel onset. Similar to gelation,
as the macromer modification or concentration increased, the time to degradation and the initial
compressive modulus increased (Figure 4.6B). All final degradation times and initial moduli were
statistically significant for each time point, both between modifications at a single macromer
concentration and between macromer concentrations within a single modification.

Figure 4.7. Effect of initiator concentration on HeMA-HA hydrogel gelation and mechanics. Gel
onset and completion, n=3-4/group, as a function of initiator concentration at a single modification
(25%) and macromer concentration (7 wt%) (A). Initial (day 0) compressive moduli, n=3-4/group
(B). Data presented as mean ± SD. All values were statistically significant (p<0.05) aside from
comparison of gel onset between 7.5 mM and 10 mM APS/TEMED in panel A.
Degradation assessment revealed that increased modification led to a statistically
significant decrease in hydrogel mass loss at each time point except for 4 wt% gels one week
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after gelation (Figure 4.6C). Temporal degradation (Figure 4.6C) and mechanics (Figure 4.6D)
further showed that increased macromer modification or concentration led to gels that degraded
more slowly and maintained their mechanics longer. Formulations with a higher modification but
lower macromer concentration degraded slower than formulations with a lower modification but
higher macromer concentration (Figure 4.6C,D). Thus, altering the macromer modification along
with the concentration can tailor hydrogel degradation while maintaining similar initial mechanics.
Simultaneously, the effect of altering the initiator concentration was examined in
hydrogels at a single macromer modification (25%) and concentration (7 wt%) (Table 4.1). As
predicted from the initial study using 10% and 35% modified HeMA-HA, as initiator concentration
increased, the time to gel onset and completion decreased whereas the mechanics increased
(Figure 4.7A). All gel onset times, gel completion times, and initial compressive moduli were
statistically significant (p<0.05) between initiator concentrations aside from comparison of gel
onset between hydrogels gelled using 7.5 mM and 10 mM APS/TEMED (p>0.05). Based on this
study, a single initiator concentration of 5 mM APS/TEMED was selected for subsequent studies.
To further explore the effect of altering the macromer modification and concentration on
hydrogel gelation, degradation, and mechanics, a more thorough study was performed with gels
formed from three macromer modifications (10%, 25%, 40%) each at six concentrations (2, 4, 6,
8, 10, 12 wt%) (Table 4.1). As anticipated from Figure 4.7, increased macromer modification or
concentration resulted in decreased time to gel onset or completion (Figure 4.7A). Statistically
significant differences in gelation were observed for comparisons between modifications relative
to 10% modified gels at each macromer concentration. Similarly, as predicted from Figure 4.6,
increased macromer modification or concentration led to increased degradation time and initial
compressive mechanics (Figure 4.7B). The majority of degradation and mechanics comparisons
between modifications at a given macromer concentration and between macromer concentrations
at a single modification were statistically significant (Appendix 4.1).
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Figure 4.8. Extensive analysis of the effect of macromer modification and concentration on
HeMA-HA hydrogel properties. Gelation onset and completion, n=3-4/group, for gels formed with
5 mM APS/TEMED (A). Degradation time and initial compressive moduli, n=3-4/group, (B). Data
+

presented as mean ± SD. In panel A, *p<0.05 vs. 2 wt% and p<0.05 vs. 12 wt% for gel
completion comparisons at the same modification. See Appendix 4.1 for additional statistics.
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Figure 4.9. Tuning HeMA-HA hydrogel degradation by altering the macromer modification and
concentration. Temporal degradation profiles of hydrogels, n=3-4/group, formed from 10%
modified (A), 25% modified (B), and 40% modified (C) HeMA-HA at various macromer
concentrations. Data presented as mean ± SD. See Appendix 4.1 for statistical information.
Hydrogel mass loss over time showed that increased macromer modification or
concentration prolonged hydrogel degradation (Figure 4.8). Comparisons between modifications
at each macromer concentration showed that all 10% modified gels had a statistically significant
increase in mass loss at each time point as compared to both 25% and 40% modified gels.
Comparisons between 25% and 40% modified hydrogels became progressively more significantly
different over time: at day one, mass loss of 25% and 40% modified gels was not statistically
significant (p>0.05) but past day one, mass loss between 25% and 40% modified gels diverged
and remained significantly different (p<0.05) for the remainder of the study. These differences
arose at 1 week for 6 wt% gels, 2 weeks for 2 wt% gels, 8 weeks for 4 wt% and 8 wt% gels, 12
weeks for 10 wt% gels, and 16 weeks for 12 wt% gels. Within each modification, comparisons
between macromer concentrations were statistically varied but gradually became more
statistically significant with time in all three groups (Appendix 4.1).
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Figure 4.10. In vitro characterization of selected HeMA-HA hydrogel formulations with similar
gelation and initial mechanics but different rates of degradation. Gelation onset and completion,
n=3-4/group, as a function of HeMA-HA modification and macromer concentration gelled using 5
mM APS/TEMED (A). Degradation time and initial compressive moduli, n=3-4/group (B).
Temporal degradation (C) and mechanics (D) profiles, n=3-4/group. Data presented as mean ±
SD. In panels A and B, *p<0.05. Additional statistical information is present in Appendix 4.1.
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Figure 4.11. Effect of combining non-degradable MeHA and degradable HeMA-HA into a single
copolymer hydrogel system at various macromer concentrations. Gel onset and completion, n=34/group, as a function of HeMA-HA:MeHA ratio (v/v) at various macromer concentrations (A).
Degradation time and initial compressive moduli, n=3-4/group (B). All remaining hydrogels were
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degraded at 20 weeks after formation. Data presented as mean ± SD. In panel A, *p<0.05 vs.
+

100:0 and p<0.05 vs. 75:25 for gel onset comparisons at each macromer concentration. For gel
δ

completions comparisons between concentrations, p<0.05 for all 4 vs. 10 wt% ratios, 4 vs. 8
wt% at 25:75 and 50:50, and 6 vs. 10 wt% at 25:75 and 50:50. In panel B, all degradation values
+

were statistically significant (p<0.05). For initial moduli comparisons, *p<0.05 vs. 100:0, p<0.05
#

vs. 75:25, and p<0.05 vs. 0:100 copolymers. See Appendix 4.1 for more statistical information.
The thorough HeMA-HA characterization study (Figures 4.8, 4.9) was used to select a
limited number of formulations to investigate temporally for changes in mechanics. By altering a
combination of the macromer modification and concentration, the goal was to examine
mechanical changes in hydrogels with similar gelation and initial mechanics but different rates of
degradation. Therefore, the properties of following pairs of formulations were compared: 1) 10%
modified HeMA-HA at 8 wt% vs. 40% modified at 4 wt%, 2) 10% modified at 10 wt% vs. 40%
modified at 5 wt%, and 2) 10% modified at 12 wt% vs. 40% modified at 6 wt% (Table 4.1).
Comparing between the hydrogels in each pair, in vitro assessment demonstrated similar gelation
properties that were not statistically significant (p>0.05) for the first hydrogel pair for time to
gelation onset (Figure 4.10A). In addition, initial compressive mechanics were similar within the
pairs and not statistically significant for both the second and third pairs (Figure 4.10B). As
anticipated, despite similarities in gelation and mechanics, the degradation was significantly
different (p<0.05) between the formulations in all three hydrogel pairs (Figure 4.10B).
The degradation (Figure 4.10C) and temporal mechanics (Figure 4.10D) were then
examined for three pairs of hydrogel formulations out to 12 weeks. Degradation for 40% modified
hydrogels was statistically less than 10% modified gels at each time point (Figure 4.10C). As the
study progressed, differences in degradation between the gels within each pair became evident.
In contrast, compressive moduli were not statistically significant within the pairs at the earlier time
points, but became statistically different (p<0.05) at 2 weeks and beyond (Figure 4.10D). Thus,
there was a narrow window during which the degradation was varied but mechanics maintained.
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The mechanics for all 10% modified gels were not statistically significant throughout the study
regardless of macromer concentration. As predicted from Figure 4.9, all 10% modified gels had
statistically greater mass loss and significantly lower (p<0.05) mechanics than all 40% modified
gels at each time point. Despite similarities in initial mechanics within each pair (Figure 4.10B),
as the hydrogels degraded, the moduli became gradually different over time (Figure 4.10D),
demonstrating the interdependence between degradation and mechanics in HeMA-HA hydrogels.
4.3.3. Characterization of HeMA-HA/MeHA Copolymer Hydrogel Properties
To further explore the tunability of HA hydrogels, the properties of a HeMA-HA and MeHA
copolymer system of were assessed. Copolymer blends were generated using macromers of
approximately the same modification (i.e., 25% modified HeMA-HA, 30% modified MeHA) but
different ratios of HeMA-HA to MeHA (i.e., 75:25, 50:50, 25:75 for HeMA-HA:MeHA). The three
copolymers were also compared to pure HeMA-HA (i.e., 100:0) and pure MeHA (i.e., 0:100) gels
(Table 4.2). For the initial study, the properties were examined at four macromer concentrations
(4, 6, 8, 10 wt%), which were selected based on the previous HeMA-HA studies (Section 4.3.2).
At each macromer concentration, the gel onset and completion time decreased as the amount of
MeHA increased (Figure 4.11A). The accelerated gelation with increased MeHA was statistically
significant relative to pure HeMA-HA hydrogels, particularly for the 4 wt% and 10 wt% gels. Gel
completion was relatively unaffected by MeHA content, with statistically significant differences
only seen between macromer concentrations (Appendix 4.1). As anticipated, pure HeMA-HA
hydrogels degraded at the quickest rate and pure MeHA gels at the slowest, with copolymers
falling in between; as the ratio of MeHA increased, degradation significantly increased (p<0.05)
(Figure 4.11B). In contrast, the initial moduli decreased as the amount of MeHA increased, with
hydrogels made from HeMA-HA alone having the highest mechanics and those made from MeHA
alone displaying the lowest mechanics (Figure 4.11B). Pure HeMA-HA hydrogels had statistically
higher mechanics relative to MeHA homopolymer hydrogels at all macromer concentrations aside
from 6 wt% and relative to certain copolymer hydrogels at 4 wt% and 10 wt%.
99

Figure 4.12. Tuning hydrogel degradation by altering the ratio of HeMA-HA to MeHA at various
macromer concentrations. Temporal degradation of HeMA-HA:MeHA copolymer hydrogels, n=34/group, formed using different copolymer ratios at macromer concentrations of 4 wt% (A), 6 wt%
(B), 8 wt% (C), and 10 wt% (D). All remaining hydrogels were degraded at 20 weeks after
formation. Data presented as mean ± SD. Refer to Appendix 4.1 for statistical assessment.
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Quantification of hydrogel mass loss as a measure of degradation over time
demonstrated that HA release from hydrogels containing MeHA was minimal throughout the 20
week study whereas pure HeMA-HA hydrogels degraded prior to the final time point (Figure
4.12). The degradation rate of HeMA-HA homopoloymers was statistically higher than MeHA
homopolymer hydrogels at all time points for 4 wt% gels, past week 2 for 6 wt% gels, past week 4
for 8 wt% gels, and past week 8 for 12 wt% gels. As the amount of MeHA incorporated into the
copolymer hydrogels increased, the amount of HA released at each time point decreased,
particularly at later time points (prior to gel degradation at week 20). For the earlier time points,
hydrogel mass loss was similar between both the homopolymer and copolymer hydrogels. At 8
weeks, a burst of HA release was observed in the HeMA-HA hydrogels that was statistically
significant relative to all copolymer ratios and for all macromer concentrations aside from 10 wt%
(which reached statistical significance for all copolymer ratios by 12 weeks).
Similar to the previous HeMA-HA characterization studies (Section 4.3.2), specific
formulations were selected for temporal mechanical assessment. Two copolymer ratios (75:25,
25:75, HeMA-HA:MeHA) were examined at three macromer concentrations (5, 6, 7 wt%) (Table
4.2). These particular ratios and macromer concentrations were selected for temporal
assessment with the goal of having similar initial mechanics but different rates of degradation: the
ratios were used to tune the degradation where as the macromer concentrations were used to
target different mechanical profiles. At each macromer concentration, the gelation onset times
were significantly greater (p<0.05) for the 75:25 copolymer hydrogels as compared to the 25:75
hydrogels whereas the gel completion times were not statistically significant (Figure 4.13A). As
intended, statistically significant (p<0.05) degradation times were generated by altering the
copolymer ratio (Figure 4.13B). The initial mechanics were similar between the copolymer ratios
for all macromer concentrations and statistically significantly so for 6 wt% and 7 wt% hydrogels
(Figure 4.13B). In addition, statistically significant differences in initial moduli were generated by
altering the macromer concentration at each copolymer ratio.
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Figure 4.13. In vitro characterization of selected HeMA-HA/MeHA copolymer hydrogels. Gel
onset and completion, n=3-4/group, as a function of copolymer ratio and macromer concentration
gelled using 5 mM APS/TEMED (A). Degradation time and initial compressive moduli, n=34/group (B). Temporal degradation (C) and mechanics (D) profiles, n=3-4/group. All remaining
25:75 hydrogels were degraded at 20 weeks. Data presented as mean ± SD. For panel A,
+

p<0.05 vs. 5 wt% gels at the same ratio. For panels A and B, *p<0.05 for 75:25 vs. 25:75

copolymers. See Appendix 4.1 for additional statistical comparisons.
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As predicted from the previous copolymer study (Figure 4.12), temporal assessment of
degradation (Figure 4.13C) and mechanics (Figure 4.13D) demonstrated that copolymer ratio
had a larger impact on the rate of hydrogel degradation and decline in mechanics over time than
macromer concentration. When comparing between the two copolymer ratios, the 5 wt%
copolymer hydrogels had statistically significant (p<0.05) amounts of hydrogel mass loss at each
time point whereas the 6 wt% and 7 wt% copolymer hydrogels developed statistically significant
differences after 8 and 12 weeks, respectively (Figure 4.13C). These differences in degradation
were maintained for the rest of the study. In addition, the initial (day 0) compressive moduli were
not statistically significant (p>0.05) for comparison between the two copolymer ratios at each
macromer concentration and this was maintained until 12 weeks, at which time the moduli for the
ratios diverged and became statistically significant (Figure 4.13D). More importantly, statistically
significant differences in compressive moduli based on changes in macromer concentration
persisted until week 8 for both copolymer ratios, where higher macromer concentration led to
prolonged retention of mechanics. Thus, degradation was successfully tuned based on the
copolymer ratio whereas mechanics were tuned using differences in macromer concentration.
4.4. Discussion
In this chapter, characterization studies were performed to better understand techniques
to tune hydrogel properties and to select formulations for subsequent imaging (Chapters 5, 6) and
in vivo (Chapter 7) studies. The initial characterization experiment simultaneously investigated the
effect of altering the initiator concentration, macromer modification, and macromer concentration
to tune HeMA-HA hydrogel mechanics. As the concentration of APS and TEMED increased,
more free radicals were generated in the pre-polymer solution, leading to accelerated kinetic
chain formation between methacrylate groups on the HA backbone (Figure 4.5). Initiator
concentration had a larger impact on hydrogels formed at higher macromer modifications and
concentrations (i.e., 35% modified HeMA-HA at 10 wt%). As more potential crosslinking options
became available (due to an increase in modification or concentration), the initiator concentration
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became the rate limiting step in hydrogel formation. This suggests that a portion of the
methacrylates remained unreacted in the lower initiator concentration groups for the 10 wt%, 35%
modified hydrogels, leading to lower mechanics. Particularly at lower modifications or macromer
concentrations, initiator concentration within the range investigated played a minor role in altering
hydrogel mechanics, implying that all possible methacrylates were crosslinked using the lowest
initiator concentration of 5 mM APS/TEMED. Therefore, subsequent characterization studies
focused on altering the macromer modification and concentration at a single initiator
concentration. Based on previous in vivo work from our group,

12,13

an initiator concentration of 5

mM APS/TEMED was selected so the resulting hydrogels would form instantaneously upon
delivery to the target site (i.e., myocardium) but allow sufficient time for injection prior to gelation.
In pure HeMA-HA hydrogels, as either the modification or macromer concentration
increased, the number of reactive methacrylates available for crosslinking increased. For a single
initiator concentration, this led a decrease in the gelation time since crosslinks formed more
rapidly (Figures 4.6A, 4.8A). Similarly, an increase in the modification or macromer concentration
increased the total number of efficient crosslinks per unit volume (i.e., crosslinking density), which
resulted in stiffer gels that required a greater force to deform during bulk compression (Figures
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4.6B, 4.8B).

Past work by our group confirmed that changes in HA modification correlate with

changes in bulk hydrogel mechanics.

12,13

Furthermore, in HeMA-HA hydrogels, crosslinks are

formed through the HeMA groups, which are also the sites susceptible to hydrolysis at the ester
bonds. Thus, degradation and mechanics are intertwined. As anticipated, the increase in
crosslinking density with increased modification or macromer concentration led to more bonds
needing to hydrolyze and less free volume to accommodate water and hence, slower degradation
(Figures 4.6C, 4.9). For hydrogels with approximately the same initial mechanics, formulations
with a higher modification but lower macromer concentration maintained their mechanics for
longer and degraded slower than formulations with a lower modification but higher macromer
concentration (Figure 4.10). Thus, by altering the modification along with the macromer
concentration, the degradation and mechanics of HeMA-HA hydrogels were tailored.
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As another approach to tuning HA hydrogel properties, MeHA was introduced at different
ratios to examine the effect of introducing a non-hydrolytically degradable macromer into a
hydrolytically degradable HeMA-HA hydrogel system. Previous work by our group with MeHA and
α-hydroxy ester block copolymers demonstrated that hydrogel properties (i.e., mechanics,
degradation) can be tailored by adjusting the ratio of the MeHA block to the hydrolytically
degradable block.

12,39

Assessment of gelation demonstrated that increased MeHA incorporation

relative to HeMA-HA resulted in accelerated gelation times, potentially due to the smaller size of
the methacrylate (Me) functional group leading lower viscosity of the macromer solution and more
rapid crosslink formation (Figure 4.11A). However, the initial compressive moduli prior to swelling
decreased as the amount of MeHA present increased, indicating less overall crosslink formation
with MeHA hydrogels for the same modification of HeMA and Me on HA (Figure 4.11B). Due to
the difference in length between the two functional groups, this suggests that crosslinking was
preferenced to the HeMA groups since they extend further outward from the HA chains.
Degradation was tuned based the degree of MeHA incorporation, where more MeHA,
and thus, less hydrolytically susceptible ester bonds, led to prolonged degradation (Figure 4.12).
In all macromer concentrations, hydrogel mass loss was similar between the copolymer and
homopolymer hydrogels until about 8 weeks (Figure 4.12). After this point, a burst release of HA
was observed from the HeMA-HA hydrogels due to the bulk degradation exhibited by
hydrolytically degradable gels: as the hydrogels swell and crosslinks are moved farther apart, a
threshold in the number of crosslinks broken is reached, resulting in an exponential increase in
mass loss. Due to the extensive amount of time required for MeHA degradation, degradation was
evaluated out to 20 weeks, at which point the hydrogels were degraded via exogenous
hyaluronidase. Temporal changes in mechanics with degradation were then evaluated for two
copolymer formulations (Figure 4.13). The ratios of 75:25 and 25:75 for HeMA-HA:MeHA were
selected to generate differences in degradation (with similar initial mechanics within a given
macromer concentration, Figure 4.13B) whereas the different macromer concentrations were
selected to target different mechanical profiles that would be relevant to post-MI remodeling.
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As

anticipated, as more ester (HeMA) groups were present, the hydrogels became more susceptible
to hydrolysis and therefore, degraded and lost their mechanics at a faster rate (Figure 4.13C,D).
4.5. Conclusions
In summary, this chapter highlights the versatility of HeMA-HA-based systems to
generate hydrogels with a range of gelation, degradation and mechanical profiles to fit a specific,
desired application. Pure HeMA-HA hydrogels served as a platform to investigate changes in
macromer modification and concentration within a homopolymer system, where increases in
either macromer modification or concentration led to accelerated gelation, prolonged degradation,
and high mechanics. The incorporation of MeHA to form a copolymer hydrogel system provided
the opportunity to tune degradation based on the functional group manipulated for hydrogel
crosslinking. While both HeMA-HA and MeHA are enzymatically degradable through the HA
backbone, HeMA-HA hydrogels are also susceptible to hydrolysis of the HeMA side groups,
leading to more rapid degradation. Whereas the use of copolymers was effective in tuning
hydrogel properties, the remainder of this dissertation will focus primarily on the use of MeHA and
HeMA-HA homopolymers for simplicity in experimental design. The next two chapters will focus
on the ability to image injectable HA hydrogels in myocardial explants using MRI.
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4.7. Appendix 4.1. Statistical comparisons for selected in vitro characterization figures.
Figure 4.5. Tunability of mechanical properties of HeMA-HA hydrogels.
Within each initiator concentration, all comparisons between modifications were
statistically significant (p<0.05) except for 4 wt% hydrogels at 10 mM APS/TEMED. All
comparisons between macromer concentrations for a given initiator concentration were
statistically significant (p<0.05) aside from 4 vs. 7 wt% for 10% modified hydrogels formed using
5 mM and 10 mM APS/TEMED. Statistical comparison between initiator concentrations were
statistically significant (p<0.05) for all comparisons to 5 mM except for 35% modified HeMA-HA at
4 wt%. Between initiator concentrations, all comparisons to 5 mM were statistically significant
(p<0.05) except for 35% modified hydrogels at 4 wt% and 10% modified hydrogels at 10 wt%.
Comparisons in moduli for 7.5 vs. 10 mM were statistically significant (p<0.05) for 10 wt% gels at
both modifications and for 10% modified gels at 10 wt%.
Figure 4.6. Initial in vitro characterization studies of pure HeMA-HA hydrogels at various
modifications and macromer concentrations.
*p<0.05 vs. 10% modified HeMA-HA at 4 wt% in panel A. Between modifications, gel
onset at 4 wt% and gel completion at 7 wt% were statically significant (p<0.05). All groups were
statistically significant (p<0.05) in panel B. In panel C, comparisons between modifications are all
statistically significant (p<0.05) except for 4 wt% hydrogels at 1 week. For comparisons between
+

#

macromer concentrations, *p<0.05 for 4 vs. 7 wt%, p<0.05 for 7 vs. 10 wt%, and p<0.05 for 4
δ

vs. 7 wt% for 10% modified hydrogels and p<0.05 for 7 vs. 10 wt% for 25% modified hydrogels.
In panel D, all compressive moduli prior to normalization were statistically significant (p<0.05)
except for 10% vs. 35% mod for 4 wt% hydrogels at days 0, 14 and 28, 4 vs. 7 wt% for 10%
modified gels at days 7, 14, and 28, and 7 vs. 10 wt% for 10% modified gels at days 14 and 56.
Figure 4.8. Extensive analysis on the effect of macromer modification and concentration on
HeMA-HA hydrogel properties.
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In panel A, gelation comparisons between modifications were statistically significant
(p<0.05) for all macromer concentrations relative to 10% modification except for 10% vs. 25%
modified gels at 4 wt% for gel onset and 2 wt% for gel completion. For 25% vs. 40% modified
gels, values were significant (p<0.05) at 4 wt% for gel onset and at 8 wt% and 10 wt% for gel
completion. Gel onset comparisons between macromer concentrations were statistically
significant (p<0.05) for all 10% modified hydrogels except 6 vs. 8 wt%, 6 vs. 10 wt%, 8 vs. 10
wt%, 8 vs. 12 wt%, and 10 vs. 12 wt%. For the other two modifications, gel onset was statistically
significant (p<0.05) for all other macromer concentrations relative to 2 wt% except for 2 vs. 4 wt%
+

for 25% modified hydrogels. For gel completion comparisons, *p<0.05 vs. 2 wt% and p<0.05 vs.
12 wt% at the same modification. In panel B, all degradation comparisons were statistically
significant (p<0.05) except for 10% modified hydrogels at 2 vs. 4 wt% and 10 vs. 12 wt%.
Comparison of initial mechanics was statistically significant (p<0.05) between modifications aside
from 25% vs. 40% modified gels at 4 wt%. Between macromer concentrations, all moduli were
statistically significant (p<0.05) aside from 2 vs. 4 wt% gels at all modifications, 4 vs. 6 wt% gels
at 10% and 25% modifications, and 2 vs. 6 wt% hydrogels at 40% modification.
Figure 4.9. Tuning HeMA-HA hydrogel degradation by altering the macromer modification and
concentration.
Between modifications, all mass loss values were statically significant (p<0.05) aside
certain 25% vs. 40% comparisons: at day 1 - 2, 4, 6, 8, 10, and 12 wt%; at week 1 - 2, 4, 8, 10,
and 12 wt%; at week 2 - 4, 8, 10, and 12 wt%; at week 4 - 4, 8, 10, and 12 wt%; at week 8 - 8 and
12 wt%; at week 12 - 12 wt%; and at week 16 - 12 wt%. Comparisons between macromer
concentrations at each modification were statistically significant (p<0.05) except for the following
cases. For 10% modified hydrogels: day – 4 vs. 6 wt%, 6 vs. 10 wt%, 8 vs. 10 wt%, 8 vs. 12 wt%,
10 vs. 12 wt%; week 1 – 6 vs. 8 wt%, 6 vs. 10 wt%, 6 vs. 12 wt%, 8 vs. 10 wt%, 8 vs. 12 wt%, 10
vs. 12 wt%; week 2 – 6 vs. 8 wt%, 6 vs. 10 wt%, 8 vs. 10 wt%, 10 vs. 12 wt%; and week 4 – 8 vs.
10 wt%, 10 vs. 12 wt%. For 25% modified hydrogels: day 1 – 2 vs. 4 wt%, 2 vs. 6 wt%, 2 vs. 8
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wt%, 4 vs. 6 wt%, 6 vs. 8 wt%, 6 vs. 10 wt%, 8 vs. 12 wt%, 10 vs. 12 wt%; week 1 – 2 vs. 4 wt%,
4 vs. 6 wt%, 8 vs. 10 wt%, 10 vs. 12 wt%; week 2 – 4 vs. 6 wt%, 8 vs. 10 wt%, 10 vs. 12 wt%;
week 4 – 4 vs. 6 wt%, 10 vs. 12 wt%; and week 8 – 10 vs. 12 wt%. For 40% modified hydrogels:
day 1 and week 1 – 2 vs. 4 wt%, 6 vs. 8 wt%, 6 vs. 10 wt%, 6 vs. 12 wt%, 8 vs. 10 wt%, 8 vs. 12
wt%, 10 vs. 12 wt%; week 1 – 6 vs. 8 wt%, 6 vs. 10 wt%, 6 vs. 12 wt%, 8 vs. 10 wt%, 8 vs. 12
wt%, 10 vs. 12 wt%; weeks 2 and 4 - 6 vs. 8 wt%, 8 vs. 10 wt%, 8 vs. 12 wt%, 10 vs. 12 wt%;
weeks 8, 12, and 16 – 8 vs. 10 wt%, 10 vs. 12 wt%; and week 20 – 10 vs. 12 wt%.
Figure 4.10. In vitro characterization of selected HeMA-HA hydrogel formulations with similar
gelation and initial mechanics but different rates of degradation.
In panels A and B, *p<0.05. In panel C, comparisons between similar formulations (i.e.,
10% mod at 8 wt% vs. 40% mod at 4 wt%) at each time point were statistically significant
(p<0.05). At each time point, differences in degradation between 10% and 40% modified
hydrogels were statistically significant (p<0.05). In panel D, comparisons between similar
formulations were statistically significant (p<0.05) at 2, 4, 8, and 12 weeks. Differences in moduli
between the two modifications were significant (p<0.05) at 1, 2, 4, 8, and 12 weeks.
Figure 4.11. Effect of combining non-degradable MeHA and degradable HeMA-HA into a single
copolymer hydrogel system at various macromer concentrations.
In panel A, gel onset comparisons between macromer concentrations at each ratio were
statistically significant (p<0.05) except for 6 vs. 8 wt% at all ratios, 8 vs. 10 wt% in 0:100 and
75:25 copolymers, and all pure HeMA-HA (100:0) hydrogels. For gel onset comparisons between
+

ratios at each macromer concentration, *p<0.05 vs. 100:0 and p<0.05

vs. 75:25. For gel

δ

completions comparisons between modifications, p<0.05 for all 4 vs. 10 wt% ratios, 4 vs. 8 wt%
at 25:75 and 50:50, and 6 vs. 10 wt% at 25:75 and 50:50. No gel completion comparisons
between ratios were statistical significant (p<0.05). In panel B, all degradation comparisons
between ratios at a single macromer concentration (aside from at 20 weeks) and all comparisons
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between macromer concentrations at a given copolymer ratio were statistically significant
+

#

(p<0.05). For initial moduli comparisons, *p<0.05 vs. 100:0, p<0.05 vs. 75:25, and p<0.05 vs.
0:100 copolymers.
Figure 4.12. Tuning hydrogel degradation by altering the ratio of HeMA-HA to MeHA at various
macromer concentrations.
Comparisons between the copolymer ratios at each macromer concentration gradually
became more statistically significant (p<0.05) with additional time points of assessment. In panel
A, mass loss differences between ratios for 4 wt% hydrogels were significant (p<0.05) except for
the following: 75:25 vs. 50:50 and 75:25 vs. 25:75 at day 1; 50:50 vs. 25:75 at day 1 and weeks
1, 2, 4, 8, and 12; 100:0 vs. 75:25 at weeks 1, 2, and 4; and 25:75 vs. 0:100 at weeks 4, 8, 12, 16
and 20. In panel B, no comparisons for 6 wt% hydrogels were statistically significant at day 1 or
week 1. At weeks 2 and 4, the only significant (p<0.05) comparisons were between 100:0 vs.
75:25 at both weeks and 100:0 vs. 0:100 at week 4. At weeks 8 and 12, all comparisons were
statistically significant (p<0.05) except for the following: 75:25 vs. 50:50, 75:25 vs. 25:75, 50:50
vs. 25:75, and 25:75 vs. 0:100 at week 8; 75:25 vs. 50:50 and 50:50 vs. 25:75 at week 12. At
weeks 16 and 20, all comparisons were statistically significant (p<0.05). For panels C and D, no
comparisons for were statistically significant at day 1 or weeks 1, 2, or 4. For 8 wt% hydrogels, all
comparisons at 8 and 12 weeks were statistically significant (p<0.05) except for the following:
75:25 vs. 50:50, 75:25 vs. 25:75, 50:50 vs. 0:100, 25:75 vs. 50:50, and 25:75 vs. 0:100 at week 8;
50:50 vs. 25:75 at week 12. For 10 wt% hydrogels, all comparisons at 8 and 12 weeks were
statistically significant (p<0.05) except for the following: 100:0 vs. 0:100 and 100:0 vs. 25:75 at
week 8; 25:75 vs. 0:100 at week 12. For both panels C and D, all comparisons between ratios
were statistically significant (p<0.05) at weeks 16 and 20. General comparisons between the
macromer concentrations were statistically significant (p<0.05) for the following: day 1 - 4 vs. 6
wt%, 4 vs. 10 wt%, 6 vs. 8 wt%; weeks 1, 2, and 4 - 4 vs. 6 wt%, 4 vs. 8 wt%, 4 vs. 10 wt%;
week 8 – 4 vs. 10 wt%; and week 16 – 4 vs. 10 wt%, 6 vs. 10 wt%, 8 vs. 10 wt%.
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Figure 4.13. In vitro characterization of selected HeMA-HA/MeHA copolymer hydrogels.
+

For panel A, p<0.05 vs. 5 wt% gels at the same ratio. All comparisons between ratios
were statistically significant (*p<0.05) for gel onset. There were no statistical differences in gel
completion. For panel B, degradation was statistically different (p<0.05) between macromer
concentrations for 75:25 hydrogels and between ratios at the same concentration (*p<0.05). Initial
moduli were statistically significant (p<0.05)

for

all comparisons

between macromer

concentrations at each ratio and between ratios for 5 wt% hydrogels (*p<0.05). In panel C,
comparisons in hydrogel mass loss between ratios statistically significant (p<0.05) for 5 wt%
copolymers at all time points, 6 wt% gels at weeks 8, 12, and 16, and 7 wt% gels at weeks 12
and 16. Differences between macromer concentrations statistically significant (p<0.05) for 75:25
copolymers at 5 vs. 7 wt% at all time points, 5 vs. 6 wt% at day 1, week 1, and week 2, and 6 vs.
7 wt% at week 4. In panel D, comparisons between ratios were statistically significant (p<0.05) at
week 12 for all macromer concentrations. At each ratio, all differences between macromer
concentrations were statistically significant (p<0.05) except for 5 vs. 6 wt% gels at both ratios at
week 8, 6 vs. 7 wt% gels at 25:75 at week 8, and 6 vs. 7 wt% gels at both ratios at week 12.
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CHAPTER 5

Using MRI to Visualize and Quantify Hyaluronic Acid Hydrogel Distribution in
Cardiac Tissue

5.1. Introduction
Injectable hydrogels have become an attractive therapy for many biomedical applications,
including the attenuation of left ventricular (LV) remodeling after myocardial infarction (MI) by
1

mechanically stabilizing the myocardial wall to reduce stress. Theoretical finite element (FE)
models have shown that the ability of injectable hydrogels to decrease myocardial stress post-MI
depends on their material properties, such as mechanics and volume.

2-5

A FE model of injections

into the borderzone region that were 20% greater than the stiffness of the native myocardium and
4.5% of the LV wall volume led to a 20% reduction in myocardial stress in the fiber direction as
2

compared to control simulations with no injections. Another FE model of simulated polymeric
inclusions illustrated the importance of both the injection pattern and the volume of material
dispersion, with larger numbers of injections and larger injections volumes having the greatest
3

potential to decrease myocardial fiber stress following infarction. These theoretical models
illustrate the correlation between positive mechanical outcomes and material properties,
particularly the material distribution volume. However, the optimal material volume necessary to
maximize the mechanical benefit remains unclear. One challenge in identifying optimal material
distribution is the ability to noninvasively assess material properties in tissues.
Traditional assessment of hydrogel dispersion centers on the use of histological and
immunohistochemical techniques that, while effective, are ultimately invasive, destructive, and
limited to two-dimensional slices which prevent accurate three-dimensional volume assessment.
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In contrast, imaging offers a noninvasive approach to temporally obtain information regarding the
presence and distribution of hydrogels throughout tissue. Various imaging techniques have been
show to be useful for material assessment. Optical imaging can be used for both two- and threedimensional in vivo material visualization, either through multiphoton microscopy with the use of
coupled fluorescent dyes or optical coherence tomography, respectively. However, optical
imaging of materials is limited to small animals

6-8

or superficial locations within centimeters of the

9

tissue surface since light intensity decays exponentially with increasing tissue depth, thus
decreasing image sensitivity and resolution.

10,11

Similarly, x-ray imaging can also be used to assess materials in both two- and threedimensions using standard radiographic or computed tomography (CT) techniques, respectively,
where image contrast is generated based on difference in the amount of x-rays exiting adjacent
objects of interest. Therefore, the ability to detect materials using x-rays is dependent on their
atomic make-up, or density, which is often similar to that of native soft tissues.

12

has thus been used extensively to monitor materials for bone applications

Micro-CT (μCT)

13-15

incorporation of contrast agents with high atomic numbers, such as iodine or gold,

but requires
12,16,17

for soft

tissue applications. Unlike fluorophores for optical imaging, x-ray contrast agents require
relatively high concentrations for visualization leading to concerns with toxicity and potential
alteration of materials properties.

16,18

Moreover, for in vivo applications, frequent temporal

material assessment using x-ray imaging is challenging due to the increased risk of biological
19

(more specifically, carcinogenic) damage with repeated exposure to ionizing radiation.

To circumvent the depth limitations of optical imaging and ionizing radiation concerns of
x-ray imaging, magnetic resonance imaging (MRI) can be used to image injectable materials. MRI
is particularly well-suited for material assessment due to its ability to provide accurate and
reproducible images with high spatial and temporal resolution in three dimensions.

20

As

discussed in Chapter 1, image contrast in MRI is based on differences in the response of water
protons in materials or tissues to the presence of magnetic fields. Due to their intrinsic spin
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property, when protons are placed in a static magnetic field of strength B (referred to as B 0), they
act like a bar magnet and align themselves with the main B0 magnetic field oriented along the z21,22

axis.

To generate a signal from the protons, the protons must be rotated to the x-y plane

using a secondary magnetic field (B1) that is applied with a radiofrequency (RF) coil within the
main magnet.

23

As the protons relax back to their equilibrium state, they give off the energy they

obtained from the applied RF pulse in the form of a free-induction decay (FID) echo, which is
detected by the RF coil as the MR signal.

23

Differences in signal between adjacent materials or

tissues are due to differences in the rate at which their protons relax to equilibrium (i.e., relaxation
properties). Transverse (T2) and longitudinal (T 1) relaxation are processes that describe the rate
of proton dephasing in the transverse (i.e., x-y) plane and return to alignment with the B0 field
along the longitudinal (i.e., z-) axis.

21,22

Differences in T1/T2 relaxation can be exposed based on

the degree of rotation of the protons caused by the B1 field, which is specified in the pulse
sequence, or series of RF pulses. Therefore, tuning the RF pulse sequence can be used to
enhance differences in relaxation properties, and thus, endogenous MR image contrast.
Pulse sequences commonly used for conventional MRI include spin echo, gradient echo,
o

and inversion recovery sequences. In a spin echo sequence, a 90 RF pulse is applied to rotate
the protons into the x-y plane, at which point they begin dephasing from one another by T 2
o

relaxation. An 180 pulse is then applied to rapidly rephase the protons and result in signal (i.e.,
FID echo) generation.

21

o

The time between when the 90 pulse is applied and the echo acquired is
o

o

referred to as the echo time (TE). Multiple 90 -180 RF pulse trains are needed to generate an
image and to improve the image signal-to-noise ratio (SNR); the time between pulse train
repetitions is called the repetition time (TR).

22

In contrast to a spin-echo sequence, an inversion
o

recovery sequence involves first rotating the protons 180 . As the protons relax along the z-axis
o

by T1 processes, a 90 RF pulse is applied to rotate the protons into the x-y plane where the
signal can be detected.

21

Finally, in a gradient echo sequence, the RF pulse produces an angle of
o

o

proton rotation between 0 and 90 ; since the protons are only partially flipped into the x-y plane,
some of the longitudinal magnetization is maintained, leading to rapid signal generation.
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21

Each

pulse sequence has its benefits. Whereas gradient echo imaging enables rapid acquisition, spin
echo imaging introduces a T 2 dependence and gradient echo imaging highlights differences
based on T1. Thus, tailoring the pulse sequence, both through the type and selection of the TE
and TR times, can result in differences in image contrast based on intrinsic MR properties.
Conventional MRI has been used to image injectable biomaterials based on their intrinsic
MR properties (e.g., T1/T2 relaxation times, proton density) in both animals and humans.

24

However, much of the work has been limited to synthetic injectable materials, such as poly(lactic
acid),

25

poly(L-lactide),

26

or poly(ethylene glycol),

24

since their intrinsic MR properties often differ

from those of the surrounding tissue. An alternative approach is to incorporate an exogenous
contrast agents into the biomaterial, such as iron oxide (FeO)

27

+3 28

or gadolinium (Gd ),

to

generate or enhance the differences in relaxation properties and thus, increase image contrastto-noise (CNR). However, similar to the x-ray contrast agent concerns discussed above, high
concentrations of MR contrast agents are required to generate an effect due to inherent
sensitivity limitations with MRI. These high concentrations not only have the potential to alter the
injected biomaterials’ properties and disturb the physiologic environment surrounding the injection
site but also will produce local toxicity if not properly coated or chelated for the duration of their
29

time in vivo.

Thus, there remains a need to develop MRI techniques to image natural, injectable

materials without the use of contrast agents.
Towards this goal, this chapter used non-contrast based MRI to image injectable
hyaluronic acid (HA) hydrogels and assess their material properties following injection into
myocardial tissue. As discussed in Section 4.1, HA is a linear polysaccharide found in native
cardiac extracellular matrix and can be modified with numerous reactive groups. The addition and
amount of these reactive groups enables both hydrogel formation and tuning of hydrogel
properties (e.g., distribution volume). This chapter builds off the previous characterization chapter
to investigate the ability to tailor hydrogel three-dimensional volume distribution in tissue by
altering material properties. Ultimately, the use of MR imaging as a tool to noninvasively
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investigate material properties could provide insight on material design criteria for injectable
biomaterials to attenuate LV modeling.
5.2. Materials and Methods
5.2.1. Synthesis and Gelation of MeHA Macromers
Methacrylated HA (MeHA) was synthesized as previously discussed in Section 4.2.2
through the reaction of HA (75 kDa, Lifecore) and methacrylic anhydride (MA, Sigma) in
deionized (DI) water at pH 8.0 (4°C, 24hrs), followed by dialysis against DI water for purification.
The macromer was then frozen and lyophilized.
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HA methacrylation was altered by varying the

1

amount of MA to HA and assessed with H-NMR (Bruker, 360 MHz), as shown in Section 4.2.2.
Two MeHA functionalizations were examined in subsequent ex vivo MR imaging applications:
~30% (i.e., low MeHA) and ~60% (i.e., high MeHA) modification of the HA repeat units.
For gelation, the methacrylate groups on MeHA were crosslinked using a two-component
redox radial initiator system of ammonium persulfate (APS, Sigma) and N,N,N,N’,N’tetramethylenediamine (TEMED, Sigma).
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APS and TEMED were mixed with MeHA dissolved in

PBS (4 wt%) to induce hydrogel formation. Macromers were crosslinked using two concentrations
of the initiators (low A/T: 5 mM APS and 5 mM TEMED or high A/T: 12.5 mM APS, 6.25 mM
TEMED) to form the following four hydrogel formulations: 1) low MeHA, low A/T, 2) high MeHA,
low A/T, 3) low MeHA, high A/T, and 4) high MeHA, high A/T. Gelation was evaluated by
monitoring the storage (G’) and loss (G”) moduli over time at 37°C using an AR2000ex
Rheometer (TA Instruments) under 1% strain and a frequency of 1 Hz in a cone-plate geometry
(1°, 20 mm diameter),

32

as in Section 4.2.3. Gelation onset was defined as the time point when

the G’ and G” intersected and the viscosity (|n*|) was greater than one. Gel onset times were
subsequently used to dictate the timing for hydrogel injection into myocardial explants.
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5.2.2. Synthesis and Gelation of Guest-Host HA Macromers
In collaboration with another graduate student in our group (Christopher Rodell), guesthost macromers were synthesized by functionalizing HA (90 kDa, Lifecore) with either
adamantine (guest) or β-cyclodextrin (host), as previously described.

33

Briefly, adamantine

modified HA (Ad-HA) was formed by coupling 1-adamantane acetic acid to HA-tetrabutylammonium salt (HA-TBA) through an esterifiction reaction in dimethyl sulfoxide (DMSO)
mediated by 4-dimethylaminopyridine (DMAP, Sigma) and the coupling agent di-tert-butyl
dicarbonate (BOC2O, Sigma) (45°C, 24hrs).

33

Purification was carried out by dialyzing against DI

water, acetone precipitating, and dialyzing again. Cyclodextrin modified HA (CD-HA) was
synthesized by coupling 6-(6-aminohexyl)amino-6-deoxy- β-cyclodextrin (β-CD-HAD) to HA-TBA
through

an

amidation

reaction

with

(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium

hexafluorophosphate (BOP, Sigma) as the coupling agent in DMSO (25°C, 2hrs).

33

The

macromer was then purified by extensive dialysis against DI water and filtration to remove
insoluble byproducts from the reaction. Both guest-host macromers were frozen, lyophilized, and
1

assessed using H-NMR (Bruker, 360 MHz) to determine the functionalization. For subsequent
imaging work in this chapter, adamantine and cyclodextrin modifications of ~50% and ~20% of
the HA repeat units were selected, respectively.
Hydrogel formation occurred by supramolecular self-assembly of the guest-host
components on HA upon mixing solutions of the two macromers dissolved in PBS. Manual stirring
was used to ensure homogenous interaction and assembly (Figure 5.1). Entrapped air bubbles
were removed by brief centrifugation. Hydrogels were formed such that the net polymer
concentration

was

5

wt%

and

the

adamantine

and

cyclodextrin

components

were

stoichiometrically balanced. Rheology properties were assessed at 37ºC using the cone and plate
geometry (1°, 20 mm diameter) discussed in Section 5.2.1 above to obtain oscillatory time
sweeps under 1% strain and a frequency of 1 Hz.

33
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Figure 5.1. Formation of self-assembling, guest-host HA hydrogels with shear-thinning
properties. Reversible interaction of adamantane (Ad, guest) and β-cyclodextrin (CD, host)
functionalized HA to form a guest-host complex (A). Schematic of guest-host hydrogel formation
by supramolecular self-assembly and disassembly in the presence of shear forces (B). Figure
adapted from [33].
5.2.3. Synthesis and Gelation of HeMA-HA Macromers
As described previously in Section 4.2.1, HA was modified with hydrolytically degradable
hydroxyethyl methacrylate (HeMA) to form the gel precursor HeMA-HA by coupling HA-TBA (75
kDa HA) to 2-hydroxyethyl-methacryl-succinate (HeMA-COOH).
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Similar to the synthesis of Ad-

HA above, the reaction was performed in DMSO using DMAP (Sigma) and BOC2O (Sigma)
(45°C, 20hrs). The macromer was purified by dialyzing against DI water at 4°C, acetone
precipitating, and dialyzing again. The solution was then frozen and lyophilized to obtain the final
1

product. The HeMA modification on HA was evaluated using H-NMR (Bruker, 360 MHz) and
found to be ~25% of the HA repeat units, as shown in Section 4.2.1.
Similar to MeHA gelation, HeMA-HA hydrogel formation was induced by crosslinking the
macromer dissolved in PBS (8 wt%) with the chemical initiators APS (5 mM, Sigma) and TEMED
(5 mM, Sigma).
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As in Section 4.2.3, rheology was used to assess gelation, where the gel onset
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and completion times were defined on the time sweeps as when G’ and G” intersected and when
there was less than a 1% change in both G’ and viscosity (|n*|) for ten time steps, respectively.
5.2.4. MRI of MeHA in Myocardial Explants
MeHA hydrogel distribution volume within the myocardium was assessed in healthy lamb
LV tissue obtained from a local butcher shop. Ex vivo samples were prepared by simulating the in
vivo injection protocol that will be described in Section 5.2.6. In general, the MeHA macromer
(low: 30%, high: 60% modified) was dissolved in PBS (4 wt%) and mixed with the specified
chemical initiators (low: 5/5 mM APS/TEMED, high: 12.5/6.25 mM APS/TEMED). Three minutes
after adding the initiators (based on rheology, as discussed in Section 5.2.1), 0.3 mL of the
prepolymer solution was injected into the myocardial LV explant at a depth of approximately 1 cm
from the epicardial surface. After waiting thirty minutes to ensure sufficient time for gelation, the
composite hydrogel/tissue samples (about 2 x 2 cm) were collected from the LV to include the
transmural injection site from the epicardium to endocardium. Prior to initial imaging session
(which occurred less than 2 hrs following injection), tissue samples were stored in PBS (Life
Technologies) supplemented with Penicillin-Streptomycin (1%, P/S; Life Technologies).
Explants containing MeHA hydrogel injections were imaged using a 9.4 T horizontal bore
small animal MR scanner (Varian, Palo Alto, CA) using a 35-mm diameter commercial quadrature
1

H coil (m2m Imaging Corp., Cleveland, OH). Imaging parameters were adjusted to exploit the

differences in intrinsic MR properties between the material and myocardium. A T2-weighted spinecho pulse sequence was used and the echo time (TE) was varied (30, 40, 50, 60 ms) at a
constant repetition time (TR, 5.8 sec) to generate optimal image contrast by visual inspection.
3

3

Similarly, the voxel size was adjusted (0.23 x 0.23 x 1.00 mm vs. 0.23 x 0.23 x 0.23 mm ) to
5

optimize image resolution. As described in Kichula et al., the final imaging parameters selected
following optimization were as follows: echo time = 40 ms, repetition time = 5.8 sec, averages =
2

2, field of view = 30 x 30 mm , matrix size =128 x 128, slices = 128, slice thickness = 0.23 mm,
3

voxel size = 0.23 x 0.23 x 0.23 mm .
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Prior to assessing differences in hydrogel distribution between the four MeHA hydrogel
formulations (introduced in Section 5.2.1), uncrosslinked MeHA was injected into myocardial
explants (n=3 samples) and imaged at various time points following injection (i.e., at days 0, 1, 2,
3, 4, and 5) to assess changes in the MR signal of the macromer alone relative to the background
myocardial signal using the selected imaging parameters. Between scans, the uncrosslinked
macromer-explant samples were immersed in 50 mL of sterile PBS (Life Technologies)
supplemented with Penicillin-Streptomycin (1%, P/S; Life Technologies). While at room
temperature, the solution of sterile PBS with P/S was changed six times each day to remove the
uncrosslinked macromer by diffusion. Overnight, tissue samples were stored at 4°C in 200 mL of
sterile PBS. To assess differences in signal intensity, images were first converted into NIFTI files
using ImageJ software (NIH; Bethesda, MD) and then converted to their correct dimensions with
34

the medical imaging processing tool convert3D (c3D ). Subsequently, a MRI bias correction was
performed with an N4 intensity normalization algorithm (Insight Segmentation and Registration
Toolkit, ITK; NIH; Bethesda, MD), as previously described,

35,36

and the difference in signal

intensity between the injected uncrosslinked macromer and surrounding background myocardial
tissue was quantified over the 6 day time course (i.e., days 0-5). For each sample, the percent
change in intensity was calculated for five slices in three regions throughout the transmural crosssection of the LV wall (i.e., near the epicardium, myocardium, and endocardium).
Based on the uncrosslinked macromer study, differences in hydrogel distribution between
the four MeHA hydrogel formulations (n = 4/formulation) were assessed three days following
injection into myocardial explants. As described previously, samples were maintained at room
temperature in 50 mL of sterile PBS with P/S that was changed 6 times per day and stored
overnight at 4°C in 200 mL of sterile PBS. Similarly, images were converted to a NIFTI file format,
the dimensions were corrected with c3D, and the MRI bias correction was performed to normalize
intensity. The volumes of the injected hydrogels were quantified using a combination of
automated and manual segmentation schemes. An automated segmentation was first performed
using Atropos software (an ITK-based multivariate n-class open source segmentation algorithm
125

distributed with ANTs)

37,38

where the input domain was chosen to be only the tissue portion of the

images. The segmentation was initialized by specifying that three different tissue spaces (i.e.
segmentation regions) were present: 1) myocardial tissue, 2) hydrogel, and 3) tissue/hydrogel
composite. After applying a smoothing factor of 0.1 (Markov random field value 1.0, 1x1x1), each
voxel was then assigned to one of the three tissue labels depending on its intensity. Based on a
comparison to the uncrosslinked MeHA studies at day 3, the crosslinked hydrogel was defined to
be regions where the percent change in intensity between the hydrogel and myocardium was
above 7%. A manual segmentation was then performed to further distinguish the crosslinked
hydrogel from the myocardium, particularly in the edges of the questionable composite label
regions from the automated segmentation. From the segmentations, hydrogel distribution
volumes were quantified and 3D reconstructions generated using ITK-SNAP software.

34

5.2.5. MRI of Guest-Host Hydrogels in Myocardium
Similar to the ex vivo MeHA studies, explanted healthy porcine hearts were acquired from
a local distributor for MRI assessment of guest-host hydrogel distribution in myocardial tissue.
Guest-host HA hydrogels were pre-formed in ½ cc syringes by manually mixing the two
components (Ad-HA and Cd-HA) and centrifuging to remove air. Hydrogels were formed at a final
HA concentration of 5 wt% using 50% modified Ad-HA and 20% modified CD-HA. Guest-host
hydrogels were injected into LV wall of explanted hearts at a depth of about 1 cm from the
epicardial surface using a 28G ½” needle to generate high shear forces for injectability. For
imaging at 9.4 T, the sites of hydrogel injection were then isolated from the myocardial explant
and included the transmural thickness of the LV wall. For 3 T MR scans, the entire heart
remained intact. Tissue samples were stored in PBS with P/S (1%, Life Technologies) before
initial imaging (<2 hrs post-injection) and between subsequent time points, if applicable, with the
same rinsing protocol as above (Section 5.2.4).
Explants with guest-host hydrogel injections were first imaged using the 9.4 T horizontal
1

bore MR scanner (Varian) and 35-mm H coil utilized for ex vivo MeHA hydrogel imaging (Section
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5.2.4). A T2-weighted spin echo pulse sequence was used with the following imaging parameters:
2

echo time = 40 ms, repetition time = 4 sec, averages = 4, field of view = 36 x 36 mm , matrix size
3

= 256 x 256, slices = 32, slice thickness = 0.25 mm, voxel size = 0.14 x 0.14 x 0.25 mm . The TE
was selected from the previously optimized 9.4 T imaging parameters (Section 5.2.4) due to its
impact on the contrast generated in a T2-weighted sequence. The remaining parameters were
altered from the previous 9.4 T scans based on sample size and scan time considerations. To
examine differences in hydrogel dispersion with injection volume, guest-host hydrogels were
injected at three volumes (50 μL, 150 μL, and 300 μL) and imaged at three time points over the
course of a week (days 0, 3, and 7 following injection).
To move towards more clinically relevant scan parameters, an array of nine, 300 μL
guest-host hydrogels were injected into full porcine explants and imaged using a clinical 3 T Tim
1

Magnetom Trio Scanner (Siemens Medical Solutions; Malvern, PA) with an 8-channel H head
coil (Nova Medical; Wilmington, MA). Unlike at 9.4 T where the tissue samples were maintained
under ambient conditions, samples imaged at 3T were submerged in PBS for the duration of the
scan time to minimize dielectric artifacts near the tissue surface. However, similar to imaging at
9.4 T, a T2-weighted turbo spin echo pulse sequence was used and the scan parameters were
first optimized by varying the TE (51, 61, 71, 81, 91 ms) at a constant TR (7 sec) as well as
varying the TR (6, 7, 8 sec) at a constant TE (71 ms). Based on this optimization study and in
consideration with sample size and scan time limitations, the following scan parameters were
used to obtain T2-weighted short-axis images: echo time = 71 ms, repetition time = 6 sec,
2

averages = 2, field of view = 100 x 100 mm , matrix size = 320 x 320, slices = 50, slice thickness
3

= 1 mm, voxel size = 0.31 x 0. 31 x 1.00 mm .
The MR images from both the 9.4 T and 3 T scans were analyzed by segmenting the
guest-host hydrogels from the myocardial tissue in the T 2-weighted short-axis images acquired
from apex to base and reconstructing the 3D volumes of the injected hydrogels. To do so, images
were first converted into NIFTI files using ImageJ for use in ITK-SNAP segmentation software.
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Each short-axis image was first pre-processed by altering signal intensity thresholds to define the
boundary between the hydrogel from the surrounding myocardium. An automated snake (i.e.
active contour) segmentation algorithm

34

was initialized from within each hydrogel injection site

and allowed to deform until the boundary between the hydrogel and myocardium was met.
Manual edge corrections were then performed, where necessary, to adjust the hydrogel
segmentation based on visual inspection. Subsequently, ITK-SNAP was used to reconstruct the
segmented two-dimensional slices containing hydrogel injection sites into 3D hydrogel distribution
volumes. The volume of each injected guest-host hydrogel was then quantified from its 3D
reconstruction. Unlike the MeHA hydrogel/myocardial composites which required an initial
automated segmentation using Atropos to fully detect the injected hydrogel (Section 5.2.4), all
segmentations, reconstructions, and quantifications were performed in ITK-SNAP.
5.2.6. Ex Vivo MRI of HeMA-HA Hydrogels from In Vivo Injections
To investigate the translational potential of this imaging technique for hydrogel
assessment, HeMA-HA hydrogels were injected in vivo into a healthy ovine heart and imaged ex
vivo following sacrifice. A single HeMA-HA hydrogel formulation was used: 25% modified HeMAHA at 8 wt% gelled using 5 mM APS and 5 mM TEMED. The animal received care in compliance
with the University of Pennsylvania’s Institutional Animal Care and Use Committee’s protocols in
accordance with guidelines for human case (National Institutes of Health, Publication 85-23,
revised 1996). For material injections, one male Dorset sheep (35-40 kg) was sedated
(intramuscular ketamine, 25-30 mg/kg), intubated, and mechanically ventilated. General
anesthesia was maintained using a mixture of inhaled isoflurane (1.5-3.0%) and oxygen.
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The

animal underwent a left thoracotomy to expose the LV free wall and received three 500 μL
injections of the HeMA-HA prepolymer solution that was mixed for 2 minutes (based on rheology)
prior to injection and gelation in the posterolateral wall. Following material injection, wire markers
were sutured to the epicardium near the injection sites for aid in material localization and the
chest wall was closed. A few hours following injection (~4 hrs), the sheep was euthanized by an
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over dose of potassium chloride and sodium thiopental while under general anesthesia. The
animal was pronounced dead after ECG silence was seen for 3-5 minutes and cardiac arrest
confirmed. The heart containing the in vivo injections was removed and prepared for ex vivo MRI.
The full heart explant was placed in a MR compatible container and immersed in Fomblin
Y (Sigma) to fill the void spaces and reduce susceptibility artifacts. The container holding the
explant was then submerged in a second, larger phantom filled with PBS to aid in shimming to
correct for magnetic field (B0) inhomogeneity. Similar to the guest-host ex vivo hydrogel imaging,
HeMA-HA hydrogels were imaged in the explanted myocardial heart using the 3 T MR Scanner
1

(Siemens) with an 8-channel H head coil (Section 5.2.5). T2-weighted short-axis images were
acquired from the apex to base for hydrogel volume reconstructions during post-processing. As
determined from the previous 3 T scan (Section 5.2.5), the whole explanted heart was imaged
using the following parameters: echo time = 71 ms, repetition time = 6 sec, averages = 4, field of
2

view = 100 x 100 mm , matrix size = 320 x 320, slices = 40, slice thickness = 1 mm, voxel size =
3

0.31 x 0. 31 x 1.00 mm . The volumes of the injected HeMA-HA hydrogels were subsequently
segmented, reconstructed, and quantified using ITK-SNAP software,

34

as described above in

Section 5.2.5. Briefly, an automated segmentation was initially performed to isolate the hydrogel
injection sites from the surrounding myocardium for each short-axis slice, followed by edge
manual corrections. 3D reconstructions of the segmented hydrogels were generated and the
corresponding volumes calculated for each injection using ITK-SNAP.
Relaxation time mapping was performed using a spin-echo-prepared FLASH sequence
with scan parameters identical to the corresponding T 2-weighted image acquisition above to
generate T1, T1ρ and T2 maps of a single short-axis slice for each hydrogel injection. For the T 1
maps, the inversion time (TI) was varied as follows: 50, 100, 300, 500, 700, 1000, 1300, 1600,
and 2000 ms. Using a custom MATLAB (Natick, MA) code, the signal intensity in each TI image
was fit to the longitudinal magnetization (M z) equation to calculate the T 1 for each pixel, where t is
21

the inversion time (Equation 5.1 ):
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(5.1)

Similarly, the T1ρ and T2 maps were generated from scans with the following spin-lock (TSL) and
echo (TE) times, respectively: 0, 20, 40, 60, 80, and 100 ms. In this case, the signal in each TSL
or TE image was fit to the transverse magnetization (Mxy) equation to calculate the T1r or T2 for
21

each pixel, where t is the spin-lock or echo time, respectively (Equation 5.2 ):

(5.2)

5.2.7. Statistical Analysis
Data is presented as mean ± standard deviation (SD) or mean ± standard error of the
mean (SEM), as indicated in each figure caption. Differences were assessed using a one-way
ANOVA with Tukey’s post hoc evaluation. A p<0.05 was considered to be statistically significant.
5.3. Results
5.3.1. MRI Visualization and Quantification of Ex Vivo MeHA Hydrogel Distribution
Four MeHA hydrogel formulations were selected based on varying a combination of the
macromer modification and redox initiator concentrations (Figure 5.2A). As anticipated from
previous studies by our group,

40

the material properties (i.e., gelation) were tuned such that

higher methacrylation and higher initiator concentrations led to accelerated hydrogel formation
(Figure 5.2B). Hydrogels formed from a highly modified MeHA using a high concentration of
initiators gelled most rapidly (1.75 ± 0.03 min) whereas hydrogels formed using a less modified
MeHA with a low initiator concentration gelled the slowest (5.2 ± 0.2 min). Moreover, initiator
concentration had a greater impact on gelation than macromer modification. These formulations
(which have been used previously

5,32,40

) were applied for subsequent ex vivo imaging studies due

to statistically significant (p<0.05) differences in their gelation onset times for all comparisons.
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Figure 5.2. Selection and gelation of MeHA hydrogel formulations applied for ex vivo MRI
assessment. MeHA hydrogels with varying properties formed by altering a combination of the
macromer modification and initiator concentration (A). Gelation onset as a function hydrogel
formulation, n=3-4/group (B). Data presented as mean ± SD. p<0.05 for all comparisons.
Prior to examining differences in hydrogel distribution in myocardial explants between the
four formulations, the imaging parameters were optimized at 9.4 T. Using a T 2-weighted spin
echo pulse sequence, the TE was varied at a constant TR (5.8 sec). Higher TE values (i.e., 60
ms) led to images with overall lower signal intensity whereas lower TE values (i.e., 30 ms)
resulted in images with higher overall signal intensity (Figure 5.3A). Based on visual inspection of
the differences in image contrast between the injected hydrogel and surrounding myocardium, an
intermediate TE of 40 ms was selected for subsequent hydrogel distribution assessment. In
addition, the image resolution was optimized by altering the voxel size, where the slice thickness
was decreased to obtain images with smaller voxels.

Reconstruction and quantification of

hydrogel distribution volume demonstrated that the hydrogel volume calculated from MRI
decreased as the voxel size decreased, suggesting that use of larger voxels for imaging
overestimated the hydrogel volume (Figure 5.3B). Thus, the smaller, isotropic voxel size (i.e.,
3

0.23 x 0.23 x 0.23 mm ) was selected for further imaging.
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Figure 5.3. Optimization of MR imaging parameters for MeHA hydrogels in explants at 9.4 T.
Representative cross-sections of T2-weighted MRI of a single MeHA hydrogel formulation (high
MeHA, low A/T) injected into myocardial explants and imaged using different echo time (TE)
values, as indicated (A). Representative 3D reconstructions (left) and quantified volumes (right)
as a function of slice thickness for a 300 μL MeHA hydrogel (high MeHA, low A/T) injection
3

imaged using different voxel sixes (low resolution: 0.23 x 0.23 x 1.00 mm , high resolution: 0.23 x
3

0.23 x 0.23 mm ), n=1 (B). Scale bars = 1 cm.
To determine the optimal day for imaging myocardial explants after MeHA hydrogel
injections, a study was performed where uncrosslinked MeHA was injected into explants and
imaged over five days following injection. At each time point, the image contrast between the
hydrogel and surrounding myocardium was assessed both qualitatively (Figure 5.4A) and
quantitatively (Figure 5.4B) by calculating the percent change in signal intensity between the
injection area (dictated from day 0) and the background myocardial tissue. Assessment at day 0
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(i.e., <2 hours after injection) demonstrated the uncrosslinked MeHA macromer could be clearly
discerned initially, with a greater than 30% higher signal intensity than the myocardium. As the
study progressed, the difference in signal intensity between the uncrosslinked macromer and the
surrounding myocardium decreased with time. A plateau was reached by day 3 following
injection, where the difference in intensity remained less than 5% for all additional time points
(Figure 5.4B). Thus, this time point was chosen to evaluate differences in hydrogel distribution.

Figure 5.4. Determination of optimal day for imaging MeHA hydrogels in myocardial explants.
Representative cross-sections of T2-weighted MRI of uncrosslinked MeHA macromer injected into
a myocardial explant and imaged over 5 days following injection (day 0) (A). Scale bars= 1 cm.
Quantification of the percent change in signal intensity between the uncrosslinked injection site
(outlined at day 0, dashed shape) and the surrounding myocardial tissue as background, n=3 (B).
Data presented as mean ± SD.
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Figure 5.5. Visualization and quantification of MeHA hydrogel distribution volumes in myocardial
explants at 9.4 T. Representative cross-sections of each MeHA hydrogel formulation at day 3
following injection into myocardial LV tissue (A). Representative 3D reconstructions of hydrogel
distribution volume for 300 μL injections of each formulation (B). Scale bars = 1 cm in panels A
and B. Volume quantification of the injection region as a function hydrogel formulation, n=4/group
(C). Data presented as mean ± SEM. *p<0.05 vs. low MeHA, low A/T hydrogel formulation.
Differences in hydrogel distribution in myocardial tissue between the four crosslinked
MeHA formulations were then investigated using MRI. Visual (Figure 5.5A,B) and quantitative
(Figure 5.5C) assessment of the dispersion volumes of the crosslinked portion of the hydrogels
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demonstrated that increased macromer modification or initiator concentration led to higher
volumes. Macromer modification had a pronounced impact on the distribution volumes,
particularly at the lower initiator concentration where a lower modification led to smaller
crosslinked volumes.

Moreover, comparing between initiator concentrations within each

modification, lower amounts of initiators led to smaller crosslinked volumes as compared to
higher initiator concentration. This trend was most pronounced in the lower modification case
where the difference was statistically significant (p<0.05). Furthermore, the quantified volumes of
the crosslinked portions of the hydrogels were higher than the injected volume (300 μL) for all
formulations aside from the low MeHA, low A/T hydrogels (Figure 5.5C). In addition, while the
hydrogel dispersion geometries varied both within and between formulations, generally most
injections took on an ellipsoidal shape, as demonstrated by the cross-sectional slices (Figure
5.5A) and corresponding 3D volume reconstructions (Figure 5.5B).
5.3.2. Guest-Host HA Hydrogel Distribution in Explants from MRI Assessment
After examining differences in hydrogel dispersion based differences in the rate of
hydrogel formation, an alternative HA hydrogel system was introduced to examine differences in
hydrogel distribution based on the gelation mechanism. Through collaboration with another
student in our group, guest-host hydrogels were formed through the supramolecular self33

assembly of adamantine (Ad, guest) and β-cyclodextrin (CD, host) modified HA (Figure 5.1).

Previous rheological studies demonstrated that both dissolved macromers were viscous solutions
individually, but upon mixing of Ad-HA and CD-HA, near-instantaneous hydrogel assembly
occurred with an increase in moduli (i.e., G’, G”) of several orders of magnitude.
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Similar to the MeHA hydrogel studies, guest-host hydrogels were injected into myocardial
explants and imaged using a 9.4 T MR scanner to obtain T 2-weighted images. Visualization of the
hydrogels in both 2D cross-sectional slices (Figure 5.6A) and 3D volume reconstructions (Figure
5.6B) revealed distinct, solid plugs in the myocardium that were relatively spherical in geometry.
Quantification of hydrogel dispersion volumes from the 3D reconstructions demonstrated that
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differences in injection volume (e.g., 50 μL, 150 μL, 300 μL) could be accurately detected with
little variation between the calculated and injected volumes, particularly at day 0 (i.e., <2 hours
after injection) (Figure 5.6C). To assess changes in hydrogel distribution over time, the samples
were imaged at various times over a week (i.e., days 0, 3, and 7) with continual washing and
buffer exchange throughout to remove uncrosslinked material, if it were present. Regardless of
the injected volume, 3D reconstructions revealed minimal changes in hydrogel surface features
over time (Figure 5.6B) and corresponding quantifications demonstrated little changes in guesthost hydrogel distribution volumes (Figure 5.6C). The slight increase in the calculated hydrogel
volume over time was most observable in the hydrogel with the smallest injection volume (50 μL),
where an approximately 20% increase was seen by day 7 relative to day 0. The larger injection
volumes (150 μL or 300 μL) had about a 13% increase in calculated volume by day 7.

Figure 5.6. Visualization and quantification of guest-host HA hydrogel distribution in myocardial
explants at 9.4 T. Representative cross-sections of T2-weighted MRI of guest-host hydrogels at
day 3 after injection into myocardial explants at different volumes, as indicated (A). Scale bars = 2
cm. Representative 3D reconstructions of the 50 μL guest-host hydrogel distribution volume at
different time points following injection, as indicated (B). Scale bars = 1 cm. Quantification of
volumes from reconstructions of each hydrogel imaged at different times after injection, n=1 (C).
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Figure 5.7. Optimization of MR parameters for imaging HA hydrogels in explants at 3 T.
Representative short axis, T2-weighted MRI slices of 300 μL guest-host hydrogel injections in an
explanted porcine heart. To optimize the echo time (TE), images were acquired at various TE
values but a constant repetition time (TR), as indicated (A). MR images were also acquired at
various TR values but a constant TE, as indicated, to opmize the TR (B). Scale bars = 2 cm.
The imaging principles utilized at 9.4 T where then applied to clinical field strength of 3 T
to assess guest-host hydrogel distribution. Prior to visualizing and quantifying hydrogel dispersion
volumes in the myocardium, the imaging parameters were first optimized by making systematic
changes in the TE and TR for a T2-weighted spin echo pulse sequence. Similar to the parameter
optimization scans at 9.4 T (Figure 5.3A), overall image signal intensity was altered with changes
in TE at a constant TR (7 sec), where the intensity of the PBS surrounding the explants increased
with increased TE (Figure 5.7A). Visual assessment of the differences in image contrast between
the hydrogel and myocardium led to the selection of an intermediate TE of 71 ms for subsequent
scans. In addition, minimal differences in signal intensity were observed when altering the TR at a
constant TE (71 ms) (Figure 5.7B). Thus, to minimize scan times, a TR of 6 sec was selected for
assessment of hydrogel distribution. Based on the voxel size optimization scans at 9.4 T above
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(Figure 5.3B), the slice thickness was minimized as much as possible within the scanner
limitations and considering the necessary field of view for the larger tissue size.

Figure 5.8. Examination of guest-host HA hydrogel distribution in whole heart explant at 3 T.
Whole explanted porcine heart indicating array of 9 sites for 300 μL guest-host hydrogel
injections (A). 3D reconstruction of distribution volume of 9 hydrogel injections in explant (B).
Representative short axis cross-section of 3D reconstructed hydrogel volumes in the axial plane
(C). Representative long axis slices in the coronal and sagittal planes of the reconstructed
hydrogel injections (D, E). Average reconstructed volume = 316.4 (± 58.9) μL. Scale bars = 2 cm.
Using the optimized scan parameters, an array of nine guest-host hydrogel injections in a
full heart explant (Figure 5.8A) was visualized using a 3T MR scanner. The pattern of nine
injections was clearly observed in the 3D volume reconstruction (Figure 5.8B) and corresponding
short- and long-axis cross-sections of the reconstruction (Figure 5.8C,D,E). Similar to the 9.4 T
assessment of guest-host hydrogels in myocardial explants (Figure 5.6), each of the nine
hydrogel injections formed a solid, spherical plug in the myocardial tissue that was distinct from
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the other injections.

The average reconstructed hydrogel distribution volume over the nine

injection sites was calculated to be 316.4 (± 58.9) μL, which differed from the injected volume of
300 μL by approximately 5.5%. Thus, at both 9.4 T and 3T, the reconstructed distribution
volumes of guest-host hydrogels in the myocardium were similar to those of the injected volume.

Figure 5.9. Assessment of HeMA-HA hydrogel distribution in myocardial explant from in vivo
injections at 3 T. Explanted ovine heart indicating three sites used for in vivo HeMA-HA hydrogel
injections (A). 3D reconstruction of distribution volume of three, 500 μL HeMA-HA injections
performed in vivo but imaged ex vivo (B). Average reconstructed volume = 463.5 (± 66.2) μL.
Representative short axis, cross-sectional T2 weighted MRI slices of each HeMA-HA hydrogel
injection (dashed lines) corresponding to 3D reconstruction (C). Representative slices of T 1, T1ρ,
and T2 maps of the first HeMA-HA hydrogel injection (dashed lines) (D). Scale bars = 2 cm.
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5.3.3. MRI Evaluation of HeMA-HA Hydrogel Distribution Ex Vivo from In Vivo Delivery
To further the translatability of using T2-weighted MRI to visualize and quantify HA
hydrogel distribution in the myocardium, HeMA-HA hydrogels were injected in vivo and evaluated
ex vivo using a clinical 3 T MR scanner. Prior to in vivo delivery, the gelation properties of HeMAHA hydrogel formulation selected for T2-weighed MRI were characterized. Rheological
assessment demonstrated that gelation onset occurred at 2.1 ± 0.5 min and gel completion
occurred at 15.9 ± 2.9 min after mixing the dissolved macromer and chemical initiators. The gel
onset time dictated the timing for in vivo injection. The three HeMA-HA injections performed in
vivo were clearly visible in both the 3D volume reconstruction (Figure 5.9B) and corresponding
T2-weighted short-axis slices for each injection site (Figure 5.9C). The sites of the markers
sutured to the epicardial surface immediately following injection (Figure 5.9A) correlated with the
3D locations of the hydrogels in the volume reconstruction (Figure 5.9B). Similar to the MeHA
hydrogels, HeMA-HA hydrogel injections took on an ellipsoidal geometry, as seen in both the
cross-sectional slices (Figure 5.9C) and 3D reconstruction (Figure 5.9B). The average
reconstructed hydrogel distribution volume of the three injections was determined to be 463.5 (±
66.2) μL, which suggested greater than 90% retention from the injected volume of 500 μL.
Relaxation time (i.e., T1, T1ρ, T2) maps were then generated to visualize differences in relaxation
between the hydrogel and myocardium, where each voxel is assigned to a relaxation time value
(Figure 5.9D). The greatest differences in voxel intensity between the hydrogel and myocardium
were seen in the T1ρ and T2 maps.
5.4. Discussion
In this chapter, non-contrast based MRI was used to visualize and quantify HA hydrogel
distribution in the myocardium based on intrinsic differences in the MR properties (i.e., T 2
relaxation) between the injected hydrogel and surrounding tissue. As discussed in Section 5.1,
these differences can be manipulated to increase image contrast by altering both the RF pulse
sequence as well as the imaging parameters (i.e., TE, TR, etc.). In this work, a spin-echo pulse
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sequence was used for all scans to introduce a T 2 dependence to the acquired images and the
scan parameters were optimized to generate T 2-weighted images through use of a long TR and
relatively long TE. A long TR (i.e., on the order of several seconds) reduces T 1 contamination by
allowing the excited protons to return to equilibrium (or near equilibrium) before subsequent RF
21

pulse application.

A long TE (i.e., on the order of the tissue’s TE) provides more time for the

magnetization to decay before measuring the signal (i.e., FID echo)

21

so materials or tissues that

have a longer T2 will have less magnetization decay and thus, a higher signal. Based on these
principles, T2-maps of HA hydrogels injected in vivo but imaged ex vivo confirmed the differences
in T2 values between the hydrogel and myocardium, in that the hydrogel has a longer T 2 than the
myocardium and thus, higher signal in T 2-weighted images (Figure 5.9D). Thus, T2-weighted MRI
was used to investigate differences in HA hydrogel dispersion in myocardial tissue based on
changes in material properties (i.e., gelation).
To introduce differences in injectable HA hydrogel distribution volume in myocardial
tissue, the materials properties were altered by either varying the time to gelation or the
mechanism of gel formation. As such, MeHA hydrogel formulations were selected with different
rates of gelation. To make the system injectable, macromers at different methacrylations were
crosslinked into hydrogels using a redox initiation system of APS and TEMED. As anticipated
from the previous characterization studies in Chapter 4, as the macromer modification or initiator
concentration increased, crosslinks were formed at a quicker rate and gelation onset decreased
(Figure 5.2B). These differences in gelation onset were used to introduce differences in the
volume of hydrogel distribution in myocardial explants as assessed by MRI, as supported by
previous work involving the visual inspection of HA hydrogels in myocardial tissue.

40

Prior to assessing differences in hydrogel distribution between the four MeHA hydrogel
formulations, a preliminary study was performed to better understand the portion of the injected
precursor solution (i.e., crosslinked vs. uncrosslinked) would be visualized using the optimized
imaging parameters (Figure 5.4). This study demonstrated that uncrosslinked macromer would
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no longer be detectable after rinsing the tissue samples for three days following injection. Thus,
since the imaging of the crosslinked formulations was performed at day 3 following injection, any
uncrosslinked macromer diffused out of the tissue and only the crosslinked portion of each
hydrogel was present for detection by 9.4 T MRI. As with the time to gelation, both the macromer
modification and initiator concentration played a role in the hydrogel volume distribution in
myocardial explants (Figure 5.5). Higher initiator concentration led to more rapid crosslinking,
which resulted in larger volumes of crosslinked hydrogel, as assessed by MRI. In addition, higher
macromer modification led to a larger distribution volume of crosslinked hydrogel. In both cases,
the increased volumes could be attributed to an increased density of macromer reactive groups
and radical initiators leading to more complete gelation and thus, measurability by MRI. Similarly,
the smaller volumes observed with low macromer modification and initiator concentration
formulations could be contributed to an increased susceptibility of the precursor solutions to be
diluted by the fluids within the tissue, thus leading to inefficient gel formation and lower
crosslinked hydrogel volumes. The injection of all formulations at 3 minutes after mixing the
dissolved macromers and initiators may have resulted in too much time lapse until gelation for the
low initiator formulations, leading to extensive dispersion of the precursor solution and limited
proximity of the reactive groups to one another to form crosslinks. Tailoring the injection timing to
the rheological properties may prevent this extensive dispersion, as seen in recent work.
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Differences in hydrogel formulation also led to differences in the distribution of the
hydrogels within the myocardial fibers. More specifically, hydrogels crosslinked using the high
initiator concentration exhibited more frequent “plugs” (i.e., areas of mostly hydrogel) than
hydrogels formed with the low initiator concentration. Hydrogels with the low initiator
concentration also dispersed more evenly within the fibers since the slower gelation times and
lower precursor solution viscosity enabled uniform penetration of the tissue prior to crosslinking.
Nevertheless, regardless of formulation, all MeHA hydrogels took on a similar ellipsoidal
geometry that was oriented such that the major axis of the ellipsoid was in the same direction as
the myocardial fibers. The ellipsoidal distribution of the MeHA injections combined with higher
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volume quantifications than the injection volume (300 μL) demonstrated that these materials
dispersed amongst the myocardial fibers during gelation and formed a composite with the
surrounding myocardial tissue rather than only forming a plug that displaced the tissue.
To examine differences in injected hydrogel dispersion based on the mechanism of gel
formation, an alternative hydrogel system was introduced based on guest-host chemistry. Unlike
MeHA hydrogels which formed by covalent crosslinking over the span of a few minutes (i.e., 2-5
min, based on rheology; Figure 5.2B), guest-host HA hydrogels self-assembled nearinstantaneously by reversible, physical interactions (Figure 5.1), as demonstrated by rheology in
previous work.
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This difference in hydrogel formation, in turn, led to differences in distribution in

myocardial tissue. In contrast to the previous in situ gelling MeHA hydrogels which dispersed
along the myocardial fibers forming a composite (Figure 5.5), guest-host hydrogels formed
distinct, solid plugs within the myocardial tissue due to their instantaneous formation and stable
interaction between the guest and host components (Figure 5.6). The volumes calculated from
the 3D reconstructions of the guest-host hydrogel injections were similar to the injected volume,
demonstrating retention of the hydrogels at the injection site independent of injection volume (50300 μL examined; Figure 5.6C). Furthermore, guest-host hydrogels also remained stable over
time with 3D reconstructions and corresponding volume quantifications demonstrating little
change in volumes over one week (Figure 5.6B,C). The slight increases in the calculated
volumes over time can be attributed to moderate hydrogel swelling since minimal changes in
surfaces features were observed. Some spreading between the muscle fibers was observed in
discrete small channels but not to the extent seen with MeHA hydrogels. To move towards
clinically relevant imaging settings, guest-host hydrogels were then injected into a whole heart
explant and imaged at 3 T. Despite the decrease in field strength from 9.4 T, guest-host HA
hydrogels formed discrete plugs within the myocardium with calculated volumes comparable to
the injected volume (Figure 5.8).
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To demonstrate the translational applications of T 2-weighted MRI of injectable hydrogels,
HA hydrogels were injected in vivo and imaged ex vivo at 3 T following animal sacrifice. A single
HeMA-HA hydrogel formulation was selected from previous characterization studies (Section
4.3.2) for in vivo delivery. The macromer concentration was selected to be relatively high (8 wt%)
to improve the T2-based MRI contrast between the hydrogel and myocardium but without the
precursor solution being too viscous to be injectable. The initiator concentrations (5 mM APS, 5
mM TEMED) were selected to balance the need for relatively rapid hydrogel formation (i.e., over
the time span of a few minutes) with providing sufficient time for in vivo delivery. Despite delivery
in an in vivo setting, each of the three injections was retained within the myocardium at the
injection site (Figure 5.9). In both the short-axis cross-sections and corresponding 3D
reconstruction, HeMA-HA hydrogels were elliptical in shape and oriented themselves to the
curvature of the contractile LV tissue that is known to move in both a radial (i.e., inward or
41,42

contractile) and circumferential (i.e., twisting) direction (Figure 5.9B,C).

The quantified

dispersion volumes were similar but slightly less than the injection volume (500 μL), suggesting a
lack of complete material retention following delivery into the contracting myocardium. However,
based on surgeon’s visual observation of ~75-80% material retention upon injection, the
calculated volumes were higher than the retained volumes, indicating that the HeMA-HA
hydrogels distributed along the myocardial fibers and formed a composite, similar to the MeHA
hydrogels previously examined. Finally, relaxation maps (combined with the T 2-weighted pulse
sequence utilized) confirmed that the differences in image contrast between the injected HA
hydrogels and surrounding myocardium were due to differences in T 2 relaxation (Figure 5.9D).
5.5. Conclusions
In this chapter, T2-weighted MRI was used to qualitatively and quantitatively assess
differences in injectable HA hydrogel distribution in the myocardium. Differences in hydrogel
dispersion in myocardial explants were introduced by changing the time to gelation and the
gelation mechanism. Gelation onset was altered in stable MeHA hydrogels by varying both the
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macromer modification and initiator concentration, which led to differences in the crosslinked
portion of the hydrogel volume that was reconstructed from MRI. The ability of covalently
crosslinked MeHA hydrogels to disperse through the myocardial fibers was then compared to the
tissue distribution of physically crosslinked guest-host hydrogels, which formed discrete plugs in
myocardial explants. Therefore, tuning of HA hydrogel material properties (i.e., gelation) can be
used to tailor hydrogel distribution in tissue for an intended application. In the case of LV
remodeling post-MI, previous modeling studies have shown that hydrogel dispersion correlates
3

with resulting cardiac outcomes and thus, the ability to noninvasively assess injectable material
properties following delivery into tissue could ultimately provide insight into their in vivo function.
The next chapter will address an alternative non-contrast MRI technique to visualizing injectable
HA hydrogels based on differences in exchangeable protons rather than relaxation times.
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CHAPTER 6

Visualization of Injectable Hyaluronic Acid Hydrogels using Chemical Exchange
Saturation Transfer MRI

(Adapted from: Dorsey SM, Haris M, Singh A, Witschey WRT, Rodell CB, Kogan F, Reddy R,
Burdick JA. ACS Biomaterials, in review.)
6.1. Introduction
Injectable hydrogels are useful for many biomedical and pharmaceutical applications,

1-4

offering the potential for minimally invasive, site-specific delivery of materials, cells, and
therapeutics directly into voids or tissues. Although numerous hydrogel systems have been
developed, tools are still needed to assess and monitor the performance of hydrogels after
injection. Conventional histological and immunohistochemical evaluation of injected hydrogels is
time-consuming, destructive, and limited to cross-sectional slices that prevent accurate
assessment of hydrogel features (e.g., distribution volume). Furthermore, to determine the
optimal material design components (e.g., degradation, molecule release), noninvasive
techniques to characterize hydrogels once implanted within tissues are needed.
To address this challenge, various imaging techniques can be used to noninvasively
characterize hydrogels. Optical and x-ray imaging have been used for in vivo material
visualization but optical imaging is restricted to superficial tissue locations
decay with increasing tissue depth
concentrations of contrast agents

11-13

9,10

5-8

due to light intensity

and x-ray imaging is limited by the need for high

which may produce toxicity or alter material properties.

12,14

As an alternative, magnetic resonance imaging (MRI) is well suited for in vivo material
assessment at any depth due to its ability to provide accurate and reproducible images with high
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spatial resolution in three dimensions.
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MR image contrast is generated by differences in the

response of bulk water protons in materials or tissues to oscillating magnetic fields; these MR
properties (i.e., T1/T2 relaxation times, proton density) are intrinsic to the material or tissue of
interest. In the case of biomaterials where the goal is to mimic native structures, their intrinsic MR
properties are often similar to those of the surrounding tissue, limiting accurate imaging at
clinically relevant magnetic field strengths. One approach is to incorporate exogenous contrast
agents

16,17

into the biomaterial to generate or enhance the differences in relaxation properties and

increase image contrast-to-noise ratio (CNR). However, due to inherent sensitivity limitations with
MRI, high concentrations of contrast agent are needed, which may alter the injected biomaterials’
properties, perturb the physiologic environment surrounding the injection site, or lead to toxicity.

18

Chemical exchange saturation transfer (CEST) is a new MRI technique that generates
contrast from protons in specific molecules or metabolites based on their exchange with bulk
18,19

water protons (Figure 6.1).

Since MR signal is generated from magnetic field manipulations

of bulk water protons, CEST is an indirect approach to image smaller pools of non-water protons
based on their impact on the water proton signal. More specifically, CEST imaging involves
saturating exchangeable protons, such as those in the material, using a frequency selective
radiofrequency (RF) pulse. This pulse equalizes the number of protons aligned with and against
the magnetic field, leading to zero net magnetization, which is termed “saturation” and the result
of which is zero MR signal. The saturated protons then exchange with the bulk water protons and
their zero (saturated) magnetization is thereby transferred to the bulk water protons, resulting in a
proportionate decrease in the bulk water signal.

20

It is this decrease in the bulk water signal

intensity that is detected in CEST imaging (Figure 6.1).
Manipulation of the CEST effect to enhance biomaterial image contrast is particularly
appealing because it relies completely on the presence of exchangeable protons within the
hydrogel. Unlike MRI with the use of exogenous contrast agents, CEST imaging does not perturb
the intrinsic MR properties of native tissues and the image contrast generated by CEST can be
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selectively turned on or off through gating the RF pulse.

21-23

In contrast to conventional T1- and

T2-weighted MRI, since the frequency of the saturation pulse is selected to be the resonance
frequency of the specific exchangeable proton group within the hydrogel, it enables the imaging
technique to be highly specific for the biomaterial and thus easily distinguished from native
tissues. Moreover, CEST imaging provides the opportunity for detection of different injectable
biomaterials based on their specific functional groups by selectively saturating at the resonance
frequency of the protons in the dominate functional group (Figure 6.1).

Figure 6.1. Principles of CEST for imaging hydrogels. CEST imaging can distinguish hydrogels
based on their dominant exchangeable proton groups (e.g., -OH for Hydrogel A or –NH2 for
Hydrogel B). The exchangeable protons are saturated at their specific resonance frequency. The
saturated magnetization is then transferred to the larger pool of bulk water protons, which causes
a decrease in the bulk water signal that is detected as a decrease in the MRI signal.
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One biomaterial of particular interest to CEST imaging is hyaluronic acid (HA). HA is a
linear polysaccharide used for a variety of injectable hydrogel systems due to its native role as an
extracellular matrix molecule and its ability to be modified with numerous functional groups.

24,25

The addition and amount of these groups enables hydrogel formation and tuning of both hydrogel
(e.g., mechanics, degradation) and CEST properties. In addition, CEST MRI has been used in
vivo to image endogenous glycosaminoglycans (GAGs), such as HA, through manipulation of
26

both the amide (-NH-R) and hydroxyl (-OH) protons (Figure 6.2).

However, CEST has yet to be

applied to imaging GAG-based biomaterials. In contrast to conventional GAG MRI, such as
23

sodium ( Na), T1ρ-weighted, and delayed gadolinium-enhanced MRI, CEST MRI enables direct
GAG mapping specifically and without contrast agent administration.

27

Therefore, towards the

goal of developing a non-contrast MRI approach for visualizing injectable HA hydrogels in vivo,
CEST MRI experiments were performed to characterize the CEST effect of hydroxyethyl
methacrylate-modified HA (HeMA) hydrogels in vitro and ex vivo and demonstrate the clinical
potential of this imaging technique for biomaterial assessment.

Figure 6.2. Chemical structure of HeMA-HA, indicating the exchangeable hydroxyl (dashes, red
circles) and amide (solid, blue circles) protons targeted for CEST imaging.
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6.2. Materials and Methods
6.2.1. HeMA-HA Macromer Synthesis
As previously described in Section 4.2.1, hydroxyethyl methacrylate-modified HA (HeMAHA) was synthesized by coupling HA-tetrabutylammonium salt (HA-TBA) to HeMA succinate
(HeMA-COOH) in dimethyl sulfoxide (DMSO) using 4-dimethylaminopyridine (DMAP, Sigma) and
the coupling agent di-tert-butyl dicarbonate (BOC2O, Sigma) (45°C, 20hrs).

28

The macromer was

purified by dialyzing against deionized (DI) water at 4°C, precipitating in acetone, and dialyzing
again. The macromer was then frozen and lyophilized. The extent of HA methacrylation was
1

assessed with H-NMR (Bruker, 360 MHz) and determined to be ~25% of the HA repeat units
(Figure 6.2), as discussed in Section 4.2.1.
6.2.2. Peptide Coupling to HeMA-HA and Characterization
HeMA-HA was converted back to a TBA salt using an acidic ion exchange (25°C, 1hr)
with Dowex resin (50W×8-200, Sigma), followed by neutralization with TBA hydroxide (TBA-OH,
29

Sigma) to pH 7.02-7.05

to solubilize in DMSO. HeMA-HA-TBA was then dissolved in DMSO,

reacted with N-(2-aminoethyl)maleimide trifluoroacetate salt (AEMa, Sigma) in the presence of
benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP, Sigma) (25°C,
2hrs), dialyzed against DI water (4°C), filtered to remove insoluble byproducts, frozen, and
1

lyophilized. Malemide functionalization of HeMA-HA was ~10% by H-NMR (Bruker, 360 MHz).
An arginine dominated (for enhanced CEST contrast

30,31

) peptide GCRRR (MW 646.35 Da) with

>95% purity (per manufacturer HPLC analysis) was purchased from GenScript (Piscataway, NJ,
USA) and coupled to Ma-HeMA-HA through a thiol–maleimide click reaction (1.2:1 molar ratio of
cysteine:maleimide) in DI water (4°C, 4hrs).
water (4°C), frozen, and lyophilized.

32

The macromer was purified by dialysis against DI

1

H-NMR (Bruker, 360 MHz) confirmed the complete

consumption of malemide with peptide, resulting in a ~10% peptide modification of HeMA-HA.

155

High-resolution spectroscopy was performed on solutions of HeMA-HA (8 wt%), HeMAHA-Peptide (8 wt%; 17.5-18.5 mM Peptide), and Peptide alone (18 mM). Solutions were prepared
in double distilled water (Millipore) or 99.8% D2O (Acros) and the pH was adjusted to 7.00.1
using 1 N HCl/NaOH. Solutions were transferred to 5-mm NMR tubes. A capillary containing a
mixture of D2O and tetramethylsilane (TMS) was inserted for signal locking of H 2O samples
during scans and standardization of chemical shifts during post-processing, respectively. Non–
1

water-suppressed high-resolution H-NMR spectroscopy (Bruker, 400 MHz) was performed using
a single pulse-acquire sequence (TR, 8.84 sec; number of averages, 32) with a 5-mm
radiofrequency probe at room temperature (2950.1 K). Water suppression was not used
because it would mask the bulk water signal and prevent observation of exchange with the
exchangeable protons via changes in spectra peaks. The temperature was varied (2800.1 K and
2950.1 K) for the HeMA-HA-Peptide sample to examine temperature-induced changes in the
1

exchangeable proton peak. H-NMR spectra were obtained from the raw free induction decay
data by Fourier transformation, phase correction, and baseline removal.
6.2.3. Hydrogel Formation and Characterization
As previous described (Section 4.2.3), HA hydrogels were formed using a radical initiator
system of ammonium persulfate (APS, 5mM, Sigma) and N,N,N,N’,N’-tetramethylenediamine
(TEMED, 5 mM, Sigma). Hydrogel formation was assessed by monitoring the storage (G’) and
loss (G”) moduli at 37°C using an AR2000ex Rheometer (TA Instruments) at 1% strain and 1 Hz
frequency in a cone-plate geometry (1°, 20 mm diameter).
6.2.4. CEST Imaging Principles
CEST images were acquired with a specially optimized saturation pulse sequence, as
previously described.

33-35

CEST effects were assessed using a z-spectrum, which is generated by

sweeping the frequency of saturation pulse across the proton spectrum

18,20,36

and plotting the

resulting water signal amplitude as a function of the saturation pulse frequency. Z-spectral data
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was collected by acquiring images from –5.0 ppm to +5.0 ppm around the bulk water resonance
(0 ppm) with a 0.1 ppm or 0.2 ppm shift in offset frequency per step. The degree of asymmetry in
the z-spectra was assessed using asymmetry (CEST asym) plots, which represent the normalized
difference in magnetization between the exchangeable proton resonance frequency S(+) and
the corresponding reference frequency on the opposite and symmetrical side of the water
resonance S(-). One approach is to normalize to the bulk water signal (S0) after saturation at a
large frequency offset (i.e., +20 ppm or +100 ppm), where  is the frequency difference relative
26,37

to water (Equation 6.1

):







(6.1)

However, saturation pulses are not perfectly frequency selective and may lead to saturation of
protons at nearby frequencies.

19

The smaller the , the greater chance for direct saturation of

water protons, causing a decrease in the water signal due to pulse application and not exchange.
To account for the effect of partial direct water saturation, the CEST effect can be normalized to
S(-) (Equation 6.2

26,37

):








(6.2)

As with all CEST methods, B0 and B1 field inhomogeneities may be of concern.

19,26

Localized B0 shimming was manually performed using the Siemens MR scanners’ product
interactive shim program to ensure that B0 inhomogeneity was less than ±0.3 ppm. To further
correct for field inhomogeneities, water saturation shift reference (WASSR) images and B 1 maps
were collected, as previously described,

35,38,39

for use in image post-processing. WASSR images

were acquired from –0.6 ppm to +0.6 ppm with a step size of 0.05 ppm using a B1 saturation
pulse amplitude of 20 or 30 Hz and duration of 200 ms and with the same sequence and readout
parameters as the corresponding CEST scans.
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Table 6.1. MRI scan parameters optimized for each study.

Figure

Imaging Parameters

B1 Amplitude
and Duration

6.4

Slice thickness = 10 mm, GRE flip angle = 10°, readout TR = 6.2
2
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

200 Hz, 4 sec

6.5

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 7.3
2
ms, TE = 3.6 ms, 1 average, field of view = 100 × 100 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

400 Hz, 300 ms

6.6

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 7.3
2
ms, TE = 3.6 ms, 1 average, field of view = 100 × 100 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

Varied

6.7

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9
2
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm ,
matrix size = 192 × 192, 1 saturation pulse train every 10 sec

400 Hz, 300 ms

6.8A

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9
2
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm ,
matrix size = 192 × 192, 1 saturation pulse train every 10 sec

300 Hz, 300 ms

6.8B

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.2
2
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

300 Hz, 300 ms

6.9,
6.10

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.2
2
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

Varied

6.11

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.2
2
ms, TE = 3.0 ms, 1 average, field of view = 100 × 100 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

300 Hz, 300 ms

6.12A

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.6
2
ms, TE = 3.2 ms, 1 average, field of view = 122 × 122 mm ,
matrix size = 192 × 192, 1 saturation pulse train every 10 sec

300 Hz, 300 ms

6.12B

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 5.6
2
ms, TE = 2.7 ms, 1 average, field of view = 140 × 140 mm ,
matrix size = 128 × 128, 1 saturation pulse train every 10 sec

300 Hz, 300 ms

6.13

Slice thickness = 3 mm, GRE flip angle = 10°, readout TR = 6.2
2
ms, TE = 3.0 ms, 8 averages, field of view = 96 × 96 mm , matrix
size = 128 × 128, 1 saturation pulse train every 4 sec

200 Hz, 250 ms

6.14

Slice thickness = 3 mm, GRE flip angle = 10°, readout TR = 6.2
2
ms, TE = 3.0 ms, 8 averages, field of view = 96 × 96 mm , matrix
size = 128 × 128, 1 saturation pulse train every 4 sec

200 Hz, 250 ms

6.17

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9
2
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm ,
matrix size = 192 × 192, 1 saturation pulse train every 10 sec

400 Hz, 300 ms

6.18

Slice thickness = 5 mm, GRE flip angle = 10°, readout TR = 6.9
2
ms, TE = 3.4 ms, 1 average, field of view = 110 × 110 mm ,
matrix size = 192 × 192, 1 saturation pulse train every 10 sec

400 Hz, 300 ms
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6.2.5. MR Imaging of Phantoms at 3 T and 7 T
Macromer was dissolved at different concentrations in sterile PBS (Life Technologies)
and the pH of the prepolymer solution was adjusted using 1 N HCl/NaOH (Fisher) to ensure a
final pH of 7.0 upon hydrogel formation. The dissolved macromer was mixed with chemical
initiators (5 mM APS, 5 mM TEMED) to induce hydrogel formation. Samples of prepolymer
solution were added to 10-mm NMR tubes and immersed in a PBS phantom surrounded by a
custom designed Styrofoam chamber to maintain the temperature at 371C. To measure the pH
dependence of CEST, hydrogels were formed at a single concentration of 8 wt% while varying
final pH values within a physiologic range (6.0, 7.0, 7.5). To assess the effect of temperature on
the CEST contrast, hydrogels of varying concentration (2, 4, 6, 8 wt%) were also scanned at 25C
as a comparison to 37C. Phantoms of PBS at pH 7.0 were used for background normalization.
Phantom CEST imaging was performed on 7 T and 3 T whole body scanners (Siemens
1

Medical Solutions, Erlangen Germany) with 32-channel and 8-channel H head coils (Nova
Medical, Wilmington, MA), respectively. The imaging parameters were optimized based on the
magnetic field strength, coil, sample size, and required field of view (Table 6.1). The readout
repetition time (TR) and echo time (TE) were minimized for each scan, but varied with changes in
the field of view or image matrix size. For all phantom studies, the total repetition time was set to
10 sec, meaning one saturation pulse train was initiated every 10 seconds. CEST images were
acquired at varying saturation pulse (B1) amplitudes and durations to empirically optimize the
CEST saturation parameters: i) 200 Hz, 250 Hz, 300 Hz, 350 Hz, 400 Hz at 300 ms saturation
duration for 7 T, ii) 100 Hz, 200 Hz, 300 Hz, 400 Hz, 500 Hz at 300 ms saturation duration for 3 T,
and iii) 300 Hz for 75 ms, 150 ms, 225 ms, 300 ms, 375 ms saturation duration at 3 T.
6.2.6. MR Imaging of Ex Vivo Tissue at 3 T
Normal lamb and swine left ventricular (LV) myocardial samples were obtained from a
local distributor (<24 hrs post mortem) and maintained in PBS until imaging. Ex vivo samples
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were prepared by mixing the macromer and initiators (5 mM APS, 5 mM TEMED) and injecting
0.3 mL of the prepolymer solution after 2 minutes (based on rheology, as discussed in Section
4.2.3) into the LV of the explants. After waiting 30 minutes to provide sufficient time for gelation,
transmural sections of the injection site were isolated. Samples were placed into test tubes (30
mm diameter) and immersed in Fomblin Y (Sigma) to fill the void spaces and reduce susceptibility
artifacts. The test tube was submerged in a larger phantom filled with PBS to aid in shimming for
B0 homogeneity. CEST images were acquired using a 3 T Tim Magnetom Trio Scanner (Siemens
1

Medical Solutions; Malvern, PA) with an 8-channel knee coil or 8-channel H head coil (Nova
Medical; Wilmington, MA). Ex vivo scans were performed at 25°C to avoid potential tissue
degradation at 37°C and due to minimal temperature differences observed in phantoms. Scan
parameters were optimized based on the coil, sample size, and required field of view (Table 6.1).
For all explant studies, the total repetition time was set to 4 seconds to minimize overall scan time
towards the goal of using the same imaging parameters for ex vivo and future in vivo scans.
Localization of CEST contrast to the site of hydrogel injection in cardiac explants was
confirmed by traditional T 1-, T1ρ- and T2-weighted MR imaging. A spin-echo-prepared FLASH
sequence with scan parameters identical to the corresponding CEST images was utilized to
generate T1, T1ρ and T2 maps. For T1 maps, the inversion time (TI) was varied as follows: 50, 100,
300, 500, 700, 1000, 1300, 1600, and 2000 ms. T 1ρ and T2 maps were generated from scans with
the following spin-lock (TSL) and echo (TE) times, respectively: 0, 20, 40, 60, 80, and 100 ms. A
spin-lock pulse amplitude of 500 Hz was used for T 1ρ image acquisition.
6.2.7. Processing CEST MRI Data
All image processing and data analysis was performed using a custom MATLAB (Natick,
MA) code. B0 and B1 maps were generated to correct for magnetic field inhomogeneity by
estimating the local field variations to center and scale all CEST data on a voxel-by-voxel basis,
as previously described.

27,35,38,39

Z-spectra were generated by plotting the signal intensity from

bulk water as a function of the saturation frequency with respect to water resonance. Asymmetry
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curves were generated from the z-spectral data according to Equation 6.2 above by plotting the
relative water signal difference normalized to S(-) at frequency offsets of 0 to 4.8 ppm.

Figure 6.3. Processing of CEST data. A region of interest (ROI) was first isolated to adjust for
noise (A). B0 and B1 maps were then used to correct for magnetic field inhomogeneity (B). CEST
contrast was then calculated using the equation shown (C). Finally, the corrected CEST contrast
was overlaid on the initial anatomical image (D). Scale bar = 2 cm.
To generate CEST maps, background noise was first removed by applying a signal
intensity threshold, generating a mask to isolate the initial region of interest (i.e., phantom or
tissue), and applying an averaging kernel to minimize spatial noise artifacts in the masked region
(Figure 6.3A). B0 inhomogeneity was accounted for using a combination of B 0 map and multiple
CEST data acquired in the neighborhood of ±0.4 ppm off the target chemical shift.

33-35

For this B0

correction, CEST images were analyzed from +0.6 to +1.4 ppm and +1.4 to +2.2 ppm for hydroxyl
and amine proton exchange, respectively, with a step size of 0.1 ppm for phantoms and 0.2 ppm
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for explants. Each voxel in the ±1.0 ppm image or ±1.8 ppm image was then replaced by the
35

neighborhood of CEST data fit to a linear curve (Figure 6.3B).

CEST contrast was then

calculated by further segmenting the region of interest (i.e., hydrogel), measuring the mean signal
intensity, and inputting the intensities into Equation 6.1 or 6.2 above, where S(-) and S(+)
are the B0 corrected signals from saturating at –1.0 ppm and +1.0 ppm or –1.8 ppm and +1.8
ppm for hydroxyl and amine proton exchange, respectively. CEST maps were then normalized to
S(-) for phantoms or S0 for explants (Figure 6.3C). Finally, maps were further corrected for B1
inhomogeneity, as discussed above, and the effect overlaid on the initial image (Figure 6.3D).
6.2.8. Statistical Analysis
All data is presented as mean ± standard deviation (SD). Standard deviations were
generated from variations in pixel intensity within the region of interest (i.e., hydrogel).
6.3. Results

Figure 6.4. HeMA-HA as a CEST imaging agent. Z-spectrum (A) and asymmetry plot (B) of
HeMA-HA hydrogel (1 wt%) at 7 T. Vertical dashed line on (B) indicates the chemical shift of the
dominate exchangeable proton group (-OH). CEST map of phantom from saturation at 1.0 ppm
(C). B1 pulse parameters were an amplitude of 200 Hz and duration of 4 sec. Scale bar = 2 cm.
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Figure 6.5. Characterization of the CEST effect of HeMA-HA hydrogels. Z-spectrum (A) and
asymmetry plot (B) of HeMA-HA hydrogels at varying macromer concentrations at 7 T and 37°C.
CEST map (C) and CEST effect quantification (D) of phantom from saturation at 1.0 ppm. A B 1
pulse of 400 Hz for 300 ms was used. Data presented as mean ± SD. Scale bar = 2 cm.
6.3.1. Characterization of CEST Effect of Hydrogel Phantoms
Initial CEST studies were performed using a 7 T MR scanner with a single HeMA-HA
hydrogel formulation: 25% methacrylation at 1 wt% in PBS, gelled using 5 mM APS and 5 mM
TEMED. The hydrogel phantom was scanned at 37°C using a long B1 pulse duration of 4 sec (to
generate the maximum CEST contrast) and a pulse amplitude of 200 Hz. The z-spectrum was
symmetric around the bulk water resonance at 0 ppm (Figure 6.4A) while asymmetry analysis
revealed a peak around 1 ppm (Figure 6.4B). The peak in the asymmetry plot indicated that the
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chemical shift of the dominant exchangeable proton group was 1 ppm downfield from the bulk
water signal. Unless specified, all frequency offsets in this work are reported with respect to the
water proton resonance frequency at 0 ppm. Saturation of the protons at 1.0 ppm generated a
CEST effect of 11.57±2.71%, as demonstrated in the CEST map (Figure 6.4C).

Figure 6.6. Saturation pulse dependence of CEST effect at 7T. CEST maps (A) and
corresponding quantification (B) of HeMA-HA hydrogel phantoms at varying macromer
concentrations from saturation at 1.0 ppm with varied B1 pulse amplitudes but a constant
duration of 300 ms. Scans performed at 37°C. Data presented as mean ± SD. Scale bars = 2 cm.
Characterization studies were performed to assess the effect of altering hydrogel
macromer concentration on the CEST contrast. As the macromer concentration increased, the zspectra became increasingly broader (Figure 6.5A), which may have resulted from increased
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steric locking of protons with increased hydrogel stiffness. This trend was also reflected in the
asymmetry plots where increased z-spectral broadening led to higher peak heights (Figure 6.5B).
Regardless of the macromer concentration, the asymmetry plots had a peak at ~1 ppm to
indicate the chemical shift for saturation. CEST maps (Figure 6.5C) and contrast quantification
(Figure 6.5D) from saturation at 1.0 ppm demonstrated an increase CEST contrast with
increasing macromer concentration. A B1 of 400 Hz for 300 ms was selected for this study and all
subsequent phantom studies at 7 T based on optimization studies where the pulse amplitude was
varied at a constant duration (Figure 6.6). The saturation duration was decreased from 4 sec to
300 ms to decrease specific absorption rate (SAR) concerns at 7 T and to enable comparison to
scans performed using lower field strengths (i.e., 3 T), where hardware limitations arise for longer
pulse durations. Of the amplitudes examined, 400 Hz generated the highest CEST effect.

Figure 6.7. Effect of hydrogel pH and temperature on the CEST effect at 7T. In vitro study
assessing the effect of gelation on final hydrogel pH (A). CEST map at 1.0 ppm of HeMA-HA
hydrogels at a single macromer concentration (8 wt%) and uniform temperature (37°C) but
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varying pH (B). Quantification of the effect of hydrogel pH on the CEST effect at 7T (C). CEST
maps at 1.0 ppm of HeMA-HA hydrogels at varying concentration but uniform pH (7.0) at 25°C
(D) and 37°C (E). Quantification of the effect of temperature on the CEST contrast (F). Protons
saturated using a B1 of 400 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.

Figure 6.8. CEST effect of HeMA-HA hydrogel phantoms at varying field strengths. CEST maps
at 1.0 ppm of hydrogels at varying concentration at 37°C using a magnetic field strength of 7T (A)
or 3T (B). Quantification of the CEST effect at different field strengths (C). Protons saturated
using a B1 pulse of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.
The impact of pH and temperature on CEST contrast was then assessed at 7 T. Prior to
the CEST imaging study, the impact of hydrogel formation on pH was investigated due to the
acidic and basic pH of the APS and TEMED used for crosslinking, respectively. To do so, the pH
of the macromer dissolved in PBS was varied and the final pH of the resulting hydrogel was
measured (Figure 6.7A). The line of best fit was used to determine the starting pH of the
precursor solution needed to generate a hydrogel at a desired final pH. Hydrogels could be
formed within the final pH range of ~5.75 to 7.25. CEST maps at 1.0 ppm of HeMA-HA hydrogels
formed at varying final pH within that range (Figure 6.7B) and the corresponding quantification
(Figure 6.7C) demonstrated that as hydrogel pH increased, the CEST effect decreased linearly.
Similarly, CEST maps at 1.0 ppm of hydrogels at different temperatures (Figure 6.7D,E) and the
quantification (Figure 6.7F) showed that as temperature increased, the CEST effect decreased.
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Figure 6.9. Saturation pulse amplitude dependence of CEST effect at 3T. CEST maps (A) and
corresponding quantification (B) of HeMA-HA hydrogels at varying macromer concentrations from
saturation at 1.0 ppm with varied B1 pulse amplitudes but a constant duration of 300 ms. Scans
performed at 37°C. Data presented as mean ± SD. Scale bars = 2 cm.
To move towards clinically relevant scan parameters, the CEST effect of HeMA-HA
hydrogels was assessed using at 3 T. CEST maps at 1.0 ppm (Figure 6.8A,B) and contrast
quantification (Figure 6.8C) showed that as the field strength decreased, the CEST effect at each
macromer concentration decreased. However, the trend of increased CEST contrast with
increased macromer concentration was maintained regardless of field strength. To directly
compare the results between the two fields, a B1 pulse of 300 Hz and 300 ms was used for both
the 7 T and 3 T scans. The pulse parameters were selected based on optimization studies at 3 T
(Figures 6.9 and 6.10). A B1 of 300 Hz for 300 ms was used for all subsequent 3 T phantom
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studies. In addition, pH and temperature characterization studies were performed to confirm that
as pH or temperature increased, the CEST effect also decreased at 3 T (Figure 6.11).

Figure 6.10. Saturation pulse duration dependence of CEST effect at 3T. CEST maps (A) and
corresponding quantification (B) of HeMA-HA hydrogels at varying macromer concentrations from
saturation at 1.0 ppm with varied B1 pulse durations but a constant amplitude of 300 Hz. Scans
performed at 37°C. Data presented as mean ± SD. Scale bars = 2 cm.
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Figure 6.11. Effect of hydrogel pH and temperature on the CEST effect at 3T. CEST map at 1.0
ppm of HeMA-HA hydrogels at a single macromer concentration (8 wt%) and uniform
temperature (37°C) but varying pH (A). CEST maps at 1.0 ppm of HeMA-HA hydrogels at varying
concentration and uniform pH (7.0) but varying temperatures of 25°C (B) and 37°C (C).
Quantification of the effect of pH (D) and temperature (E) on the CEST contrast at 3T. Protons
saturated using a B1 of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.
6.3.2. Ex Vivo Imaging of Injectable Hydrogels
To further facilitate translation of this biomaterial imaging technique, the CEST effect of
HeMA-HA hydrogels was assessed after injection into cardiac explants. CEST maps at 1.0 ppm
demonstrated the ability to detect the injected hydrogel over the myocardial signal at both field
strengths. At 7T (Figure 6.12A), a higher CEST contrast was generated from the injected
hydrogel compared to that obtained at 3T (Figure 6.12B) due to a lower direct water saturation
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effect at 7T. When the CEST effect of the hydrogel was background corrected using the
surrounding myocardial signal at the corresponding field strength, the CEST contrast was similar
between the two field strengths (Figure 6.12C). Similar to the phantom studies, a B1 saturation
pulse of 300 Hz and 300 ms was used at both field strengths. In contrast to the phantom studies
performed at 37°C, explant studies were performed at 25°C due to minimal differences in the
CEST effect with temperature at both 7 T (Figure 6.7F) and 3 T (Figure 6.11E).

Figure 6.12. Ex vivo CEST effect of HeMA-HA hydrogels at varying field strengths. CEST maps
at 1.0 ppm of 8 wt% HeMA-HA hydrogels injected into cardiac explants at 7 T (A) and 3 T (B).
Dashed circles indicate hydrogel injection. Quantification of the CEST effect with the surrounding
myocardium used for background correction (C). Ex vivo scans performed at 25°C. Protons
saturated using a B1 of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.
The chemical shift dependence of the CEST effect was then compared in myocardial
samples with and without HeMA-HA hydrogel injections at 3 T. CEST maps were generated for
explants at 1.0 ppm, 1.5 ppm, and 2.0 ppm using a saturation pulse of 200 Hz for 250 ms. At 1.0
170

ppm, the hydrogel CEST contrast was greater than that of the surrounding myocardium (Figure
6.13A), as expected due to saturation of the HA hydroxyl protons. As the chemical shift difference
from water () increased, the background myocardial CEST effect increased, decreasing the
difference in contrast between the hydrogel and myocardium (Figure 6.13). The increased
background myocardial signal with increasing chemical shift was comparable between the
explant sample with (Figure 6.13C,E) and without (Figure 6.13D,F) hydrogel injections.
Conventional MRI (i.e., T1, T1ρ, T2) was used to confirm the location of increased CEST contrast
at 1.0 ppm corresponded to the site of hydrogel injection (Figure 6.14).

Figure 6.13. Chemical shift dependence of the CEST effect. CEST maps of a HeMA-HA hydrogel
(8 wt%) injected into cardiac explants (left) as compared to myocardial samples alone (right) at
1.0 ppm (A, B), 1.5 ppm (C, D), and 2.0 ppm (E, F). Dashed circles indicate hydrogel injection (A,
C, E). Scans performed at 25°C. A B1 pulse of 200 Hz for 250 ms was used. Scale bars = 2 cm.
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Figure 6.14. Comparison of CEST effect with traditional MRI based on relaxation properties.
CEST maps at 1.0 ppm of a HeMA-HA hydrogel (8 wt%) injected into an explant (A) relative to a
myocardial sample without injection (B). Protons were saturated using a B1 of 200 Hz for 250 ms.
T1 (C), T1ρ (D), and T2 (E) maps of the hydrogel-injected explant to demonstrate co-localization of
the CEST effect with MRI contrast generated based on relaxation times. Scale bars = 2 cm.
6.3.3. Alteration of CEST Effect with Peptide Coupling
A peptide (GCRRR) was coupled to HeMA-HA using the reaction of maleimide-modified
HA to the thiol on the cysteine of the peptide (Figure 6.15). This peptide sequence was selected
to alter the CEST contrast based on the presence of additional exchangeable proton groups with
30,31

1

altered chemical shift (Figure 6.15C).

Non–water-suppressed H-NMR spectra at room

temperature demonstrated that the additional peaks in the HeMA-HA-Peptide macromer
1

originated from the peptide (Figure 6.16A). H-NMR spectra of the HeMA-HA-Peptide dissolved
in H2O as compared to D2O indicated the presence of the exchangeable proton peaks in the
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~6.5-8.6 ppm range (with respect to TMS) when the macromer was dissolved in H2O (Figure
6.16B). Exchangeable protons peaks disappeared when the macromer was dissolved in D 2O
1

because the exchangeable protons interchanged with deuterium, which is not observable in HNMR spectra. Comparison of the non–water-suppressed spectra of the HeMA-HA-Peptide
solution at different temperatures highlighted that the exchangeable proton peak of interest for
CEST manipulation occurred at ~6.5 ppm with respect to TMS, which is ~1.8 ppm downfield from
40

water at 4.7 ppm (Figure 6.16B).

Thus, subsequent CEST imaging experiments of HeMA-HA-

Peptide hydrogels focused on saturating at 1.8 ppm downfield from water.

Figure 6.15. Synthesis of HeMA-HA-Peptide. HeMA-HA was converted to a TBA salt, then
reacted with N-(2-aminoethyl)maleimide trifluoroacetate salt and the coupling agent BOP to
1

introduce a malemide for subsequent coupling to the cysteine of a RRRCG peptide (A). H-NMR
was used to confirm the addition of TBA, the coupling of the malemide, and the consumption of
the malemide peak (solid, red circles) with the peptide (B). The arginines in the peptide introduce
additional amine functional groups (dashed, blue circles) to alter the CEST effect (C).
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Phantom studies were then performed at 7 T to confirm that altering HeMA-HA-Peptide
hydrogel macromer concentration alters the CEST contrast. Similar to the previous HeMA-HA
phantom studies, the z-spectra became more broad (Figure 6.17A) and the asymmetry plot peak
heights increased (Figure 6.17B) with increasing macromer concentration. Relative to the
asymmetry plots of HeMA-HA hydrogels (Figure 6.5B), the addition of the peptide led to a shift in
the asymmetry plots, resulting in a broad peak around ~1.8-2 ppm. CEST maps at 1.8 ppm
(Figure 6.17C) and contrast quantification (Figure 6.17D) confirmed an increase in the CEST
effect with increasing macromer concentration in HeMA-HA-Peptide hydrogels.

1

Figure 6.16. Spectroscopy characterization of HeMA-HA-Peptide. Non-water suppressed HNMR spectra of HeMA-HA, peptide, and HeMA-HA-Peptide solutions in H2O at room
temperature, 295 K (A). Spectra of HeMA-HA-Peptide solution in H2O at different temperatures
as compared to the macromer in D2O to identify the exchangeable protons peaks (B).
Temperature-induced changes in the exchange rate of the amine protons (dashed circles)
highlight their ability to generate a CEST effect. The amine protons resonate at 1.8 ppm downfield
from the bulk water protons at 4.7 ppm (relative to TMS).
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Figure 6.17. Characterization of the CEST effect of HeMA-HA-Peptide hydrogels. Z-spectrum (A)
and asymmetry plot (B) of HeMA-HA-Peptide hydrogels at varying macromer concentrations at
7T using a B1 of 400 Hz at 300 ms. CEST map from saturation at 1.8 ppm (C) and corresponding
quantification of the CEST effect (D). Data presented as mean ± SD. Scale bar = 2 cm.
To further compare the CEST effect of HeMA-HA and HeMA-HA-Peptide hydrogels,
phantom imaging studies were performed at 7 T, where the chemical shift of the saturation pulse
was varied to highlight the differences in exchangeable proton chemistry between the two
materials. CEST maps and quantification from saturation at 1.0 ppm showed a similar CEST
effect for both hydrogel formulations (Figure 6.18A-C). In contrast, CEST maps and
quantification from saturation at 1.8 ppm demonstrated that the CEST effect of HeMA-HA-Peptide
hydrogels was maintained (relative to their CEST effect at 1.0 ppm), whereas the CEST contrast
of HeMA-HA hydrogels decreased by a factor of two (Figure 6.18D-F).
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Figure 6.18. Altering the CEST effect by changing the chemistry and saturation frequency. CEST
maps at 1.0 ppm (left) and 1.8 ppm (right) of HeMA-HA (A, D) and HeMA-HA-Peptide (B, E)
hydrogel phantoms at 7 T and 37°C. CEST effect quantification at 1.0 ppm (C) and 1.8 ppm (F).
Protons saturated using 400 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.
6.4. Discussion
Initial CEST imaging studies of a HeMA-HA hydrogel at 7 T demonstrated that the
exchangeable protons present on the HA backbone could be manipulated using CEST MRI. More
specifically, the hydroxyl protons were targeted over the amide protons on HA due to their higher
concentration. Since CEST asymmetry analysis is based on the subtraction of images at
corresponding but opposite chemical shifts around the water resonance, a peak in the plot
indicates a decrease in the + signal due to saturation of the exchangeable protons resonating
at that frequency (Figure 6.4B). Since the peak in the asymmetry plot occurred around 1 ppm, it
confirmed that these exchangeable protons reside in the hydroxyl groups on HA (Figure 6.2),
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which is consistent with previous studies.

19,30

Even though both the hydroxyl protons and amide

protons on GAGs have been identified as suitable CEST agents, the high concentration and the
fast exchange rate of hydroxyl protons make them a favorable option.

26

To further confirm the

ability to visualize HA hydrogels using CEST imaging, saturation at the hydroxyl proton
resonance frequency resulted in a CEST effect >10% (Figure 6.4C).

Figure 6.19. CEST effect of HeMA-HA hydrogels tracks with degradation at both field strengths.
In vitro degradation of HeMA-HA hydrogels at varying macromer concentrations (A). CEST effect
quantification of hydrogels at decreasing macromer concentrations (B). CEST maps at 1.0 ppm of
hydrogels at varying concentration at 37°C using a field strength of 7T (C) or 3T (D). Protons
saturated using a B1 of 300 Hz for 300 ms. Data presented as mean ± SD. Scale bars = 2 cm.
Towards the goal of understanding injectable hydrogels in vivo, the ability to detect
differences in material properties (i.e., macromer concentration) based on altering the CEST
contrast is of great importance. As the concentration of the exchangeable proton pool increased
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(due to the increase in macromer concentration), a larger extent of saturated magnetization could
be transferred to the bulk water protons, leading to a greater decrease in the water signal. This
trend was observed in the characterization study at 7T through the asymmetry analysis (Figure
6.5B) and visualization of the CEST effect in overlaid maps (Figure 6.5C). Furthermore, at both 7
T and 3 T, the CEST effect increased linearly with increasing macromer concentration (Figure
6.8) and therefore, a diminishing macromer concentration would be reflected by a smaller CEST
effect. This decrease in macromer concentration could be used for future applications to mimic
diminished hydrogel crosslinking or hydrogel degradation in vitro (Figure 6.19). Previous studies
using injectable HA hydrogels demonstrated that their impact in vivo was dependent on both their
degree of crosslinking (i.e., mechanics) and degradation profile.

28

Thus, the ability to visualize

hydrogel crosslinking and/or degradation using CEST MRI could be used to predict hydrogel
outcomes in vivo and provide insight into identifying optimal material properties.
To enable future in vivo applications of this technique, CEST was used to image HA
hydrogels using clinically relevant scan parameters and in tissue explants. When initially
determining if CEST could be a viable tool for hydrogel imaging, a long B1 pulse duration was
used to maximize the CEST signal by ensuring the protons have sufficient time to relax back to
their steady state after manipulation.

19

After validating the use of CEST imaging, the pulse

duration was decreased for all subsequent scans due to increased SAR concerns for in vivo
injectable hydrogel applications

18

and hardware limitations at clinical field strength scanners. The

relationship between long pulse durations leading to increased signal outputs accounts for the
difference in CEST contrast generated between the initial characterization of a low macromer
concentration hydrogel using a long duration (Figure 6.4) and the subsequent characterization of
hydrogels at higher macromer concentrations using a shorter pulse duration (Figure 6.5). It is
also advantageous to have the ability to restrict the pulse duration but maintain generation of a
CEST contrast because the specific biological application may dictate time restraints, such as the
case for cardiac CEST imaging.

35

Finally, shorter pulse durations are suitable for CEST imaging

specific to hydroxyl protons due to their relatively rapid exchange rate.
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19,41

To further the translational value of CEST for biomaterial imaging, ex vivo scans were
performed to distinguish injectable HA hydrogels from surrounding tissue (Figures 6.6, 6.7).
Despite the decreased signal when transitioning from 7 T to 3 T (Figures 6.5, 6.6), the impact on
the ex vivo hydrogel CEST effect was minimal when background corrected with the myocardial
CEST signal (Figure 6.12C). Moreover, the large increase in power deposition at 7 T limits
clinical use.

18

In the subsequent 3 T ex vivo scans, comparison of CEST maps at 1.0 ppm of

myocardial samples with and without the hydrogel injections showed increased CEST contrast at
the hydrogel location (Figure 6.13A,B). Conventional MRI using of T 1, T1ρ, and T2 mapping
further confirmed the site of the injected hydrogel coincided with the location of increased CEST
contrast (Figure 6.14).
In contrast to conventional MRI contrast, such as T1- and T2-weighting, CEST probes
specific functional groups in biomaterials based on their exchangeable protons in a frequencyspecific manner.

42

This was evident in this study because the greatest difference in the hydrogel

to myocardial CEST contrast occurred at the HA hydrogel hydroxyl proton resonance frequency
(Figure 6.13A). As  increased such that saturation occurred further from the resonance
frequency of the hydroxyl protons, the background myocardial CEST effect increased (Figure
6.13). This endogenous myocardial CEST contrast was likely due to saturation of native
exchangeable protons, such as those present in extracellular matrix (ECM) molecules or in
cardiac metabolites. One such metabolite is creatine, which is involved in the production of
energy to power myocardial contraction.

35

The labile amine protons in creatine are known to

resonate at ~1.8 ppm downfield of bulk water,

34,35

which was confirmed in this work by the

increased CEST contrast when saturation occurred at 2.0 ppm (Figure 6.13E,F) relative to 1.5
ppm (Figure 6.13C,D) or 1.0 ppm (Figure 6.13A,B). Due to this chemical shift dependence,
injectable materials with different functional groups possessing exchangeable protons with
distinct chemical shifts could be designed such that CEST imaging could simultaneously visualize
and discriminate between these materials.

30,31,43
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To demonstrate the ability of CEST imaging to differentiate injectable hydrogels based on
the resonance frequency of their exchangeable protons, a peptide was coupled to HeMA-HA. The
peptide was chosen to contain three arginines because the amine protons in arginine are known
to resonate at 1.8 ppm downfield from the bulk water protons, which differs from the hydroxyl
proton resonance at 1.0 ppm.

30,31,34,35

Amine protons not only offer the advantage of being at a

chemical shift farther from water, which decreases direct water saturation and hence increases
CEST sensitivity, but they also exchange at a relatively slower rate than hydroxyl protons,
allowing more time for selective saturation before exchange, thus resulting in a larger CEST
effect.

19,41

In addition, amine-based CEST has recently been used to image endogenous

metabolites in vivo for cardiac and calf muscle applications.

35

Non-water suppressed spectroscopy was used to confirm the presence of additional
exchangeable protons in the HeMA-HA-Peptide macromer relative to HeMA-HA alone (Figure
6.16A) and highlight the potential for the arginine-based amine protons to generate a CEST effect
(Figure 6.16B). To do so, the HeMA-HA-Peptide solution was exposed to varying temperatures
since changes in temperature and pH are known to alter the exchange rate, and hence CEST
effect.

22,44

As the temperature or pH increase, the proton exchange rate increases, leading to less

time available for saturation and an overall decrease in the generated CEST contrast (Figures
6.7, 6.11). Similarly, as the temperature the HeMA-HA-Peptide solution was increased from 280
K to 295 K in the spectrometer, the exchange rate of the amine protons increased, resulting in
formation of a single broad peak at 295 K from two separate, resolved peaks at 280 K at ~6.5
ppm with respect to TMS. The two peaks evident at the lower temperature represent the two
equivalent amines in the guanidine group at the distal end of each arginine in the peptide where
the delocalization of the positive charge between the double bond and the nitrogen lone pair
facilitates exchange (Figure 6.15C).
The exchangeable proton and saturation frequency specificity of the CEST effect was
further confirmed by phantom studies comparing HeMA-HA and HeMA-HA-Peptide hydrogels
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(Figure 6.18). Since both macromers contain the same concentration of hydroxyl protons, they
generated a similar CEST effect when saturated at the hydroxyl resonance frequency of 1.0 ppm
(Figure 6.18A-C). In contrast, only the HeMA-HA-Peptide macromer contains the exchangeable
arginine-based amine protons shown to resonate ~1.8 ppm downfield of water protons (Figure
6.16B). Therefore, application of the saturation pulse at 1.8 ppm led to generation of a CEST
effect specific to the amine protons in the peptide. The two hydrogels were distinguished from
one another at the resonance frequency of the amine protons because HeMA-HA-Peptide
hydrogel generated a strong CEST effect whereas the HeMA-HA hydrogel did not (Figure 6.18DF). The ability to visualize differences in hydrogels based on modulation of the exchangeable
proton pool and chemical shift of saturation highlights the novelty of CEST as an imaging tool that
can be tuned to the properties of the injectable material of interest.
6.5. Conclusions
In summary, this chapter demonstrated that a new MRI technique based on saturation
transfer of specific exchangeable protons was successfully used to visualize injectable HA
hydrogels in vitro and ex vivo. Alteration of hydrogel properties (i.e., macromer concentration) led
to differences in the CEST contrast, indicating that this imaging approach could be used to
identify different compositions or to track dynamic changes in biomaterial properties. In addition,
the CEST effect was altered by changing the exchangeable proton group and saturation
frequency, demonstrating the ability of CEST imaging to specifically image and discriminate
between different injectable materials based on their chemistry. Moreover, the use of CEST MRI
to accurately detect injectable hydrogels in tissue explants using clinically relevant scan
parameters and magnetic field strengths highlights the potential for CEST imaging to be used as
tool to simultaneously visualize and assess material properties of injectable materials in vivo for
future biomaterial optimization. The next chapter will focus on applying injectable, degradable HA
hydrogels to an in vivo infarct model and assessing outcomes using MRI.
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CHAPTER 7

Investigation of Injectable Hyaluronic Acid Hydrogel Therapy to Alter Myocardial
Tissue Properties for Infarct Repair using MRI and FE Modeling

(Adapted from: Dorsey SM, McGarvey JR, Wang H, Nikou A, Arama L, Koomalsingh KJ, Kondo
N, Pilla JJ, Gorman JH III, Gorman RC, Wenk JF, Burdick JA. Biomaterials, in preparation.)
7.1. Introduction
Heart failure is a leading cause of morbidity and mortality, affecting almost 23 million
individuals worldwide and 6 million in the US alone.

1,2

Of these cases, nearly 70% are due to left
3

ventricular (LV) remodeling initiated by myocardial infarction (MI). LV remodeling is manifest by
progressive LV dilation which results in thinning of the LV wall and a change in heart shape that
4

can alter function. The mechanical phenomenon that both initiates and sustains the adverse LV
remodeling process is the initial infarct expansion. Infarct expansion is a progressive pathologic
process that results from abnormal loading of the noncontractile infarcted myocardium, leading to
increased mechanical stress in the perfused borderzone regions surrounding the infarct, altered
systolic contractile properties, and eventual progression to heart failure.

5-8

Limiting infarct

expansion has thus been identified as a potential therapy to reduce the morbidity associated with
LV remodeling. Previous strategies to limit infarct expansion include surgical reconstruction of the
dilated LV and physical LV restraint with polymeric meshes to prevent dilation.

9-13

In contrast to passive restraint devices, injectable biomaterials offer the potential for
minimally invasive delivery, which may limit tissue damage and enable rapid clinical translation.
As discussed in Section 3.2.2, injectable acellular hydrogels have been used to mechanically
stabilize the infarcted myocardial wall to prevent initial infarct thinning and attenuate remodeling
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14,15

post-MI.

Several natural and synthetic injectable materials have been successful in

maintaining cardiac structure and function in animal models,

16

but further information is needed to

understand the impact of injectable materials on myocardial tissue properties.

17

Recent studies

using injectable hyaluronic acid (HA) hydrogels were the first to investigate the importance of
material mechanics

18

and degradation

19

in attenuating remodeling. However, the specific

hydrogel properties for optimal in vivo outcomes are not clear.
To further elucidate how injectable hydrogels alter LV remodeling, tools are needed to
assess the effects of these therapies on the infarcted myocardium. However, traditional
histological analysis is invasive, thereby limiting temporal assessment, as it can ultimately only be
performed in an excised heart. Imaging modalities, such as magnetic resonance imaging (MRI),
can noninvasively provide information about the infarcted heart following treatment with injectable
hydrogels. Unlike other well-established cardiac imaging modalities, advances in cardiac MRI
offer the ability to not only assess standard geometrics but also depict myocardial wall motion
with high image contrast and spatial resolution without using ionizing radiation.

20-25

Cine MRI

continues to be the most accurate modality for evaluating LV structure and function with high
spatial and temporal resolution.

26,27

MRI with the use of gadolinium contrast agents enables

visualization of infarcted regions due to differences in tissue perfusion using late-gadolinium
enhancement (LGE) MRI.

28

Myocardial (SPAMM) tagging with MRI can be used to visualize

regional heart motion at high spatial resolution and quantify regional myocardial displacement
(strain) as a measure of LV contractility.

29,30

Thus, within a single scan period, MRI can monitor

changes in global LV structure and function, infarct properties, and regional wall motion to provide
insight into the impact of injectable hydrogels on myocardial tissue parameters post-MI.
Theoretical finite element (FE) models can also be used to provide information on how
injectable hydrogels attenuate LV remodeling. Previous FE models have shown that injectable
materials decrease myocardial stresses after remodeling with levels that depend on hydrogel
properties, such as mechanics and volume.

31-33

A FE model of injections into the borderzone

189

region with mechanical properties 20% greater than the stiffness of the native myocardium led to
a concomitant 20% decrease in myocardial fiber stress relative to controls.

31

In a subsequent

study, it was shown that this decreased stress depended on both the injection pattern and the
volume of material dispersion, with larger numbers of injections and larger injection volumes
having the greatest effects on myocardial fiber stress.
simulated injections

31,32

32

Despite these findings, the models used

or three-dimensional echocardiographic data from large animal studies.

33

In contrast, MRI myocardial tagging enables a highly detailed assessment of myocardial motion
as a measure of myocardial strain.

34

FE models using MRI tagging strains as input parameters

have been examined in large animals

33,35-37

and humans

34,38

post-MI, but none have done so in

the context of assessing the ability of injectable biomaterials to decrease myocardial stress.
The goal of this chapter was to better understand the role that injectable hydrogels have
on positive structural and functional outcomes post-MI using cardiac MRI and FE modeling. As
discussed in Section 4.1, hydrogels were formed by crosslinking HA, a linear polysaccharide
found in native cardiac extracellular matrix (ECM) that plays a role in cardiac embryogenesis,
scar reduction, cell migration and angiogenesis.

39-42

In vivo function was assessed in a well-

established porcine infarct model at 1, 4, 8, and 12 weeks post-MI to determine the temporal
effect of HA hydrogels on global LV remodeling, infarct expansion, myocardial wall motion, and
myocardial stiffness. This study was the first to examine the efficacy of hydrogel therapies for MI
repair using MRI-derived measures of regional myocardial systolic strain and FE-model derived
measures of passive myocardial stiffness based on in vivo inputs. Ultimately, these results can
broaden our understanding of hydrogel therapies to prevent progression to heart failure.
7.2. Materials and methods
7.2.1. Synthesis of HeMA-HA Macromer
As discussed previously in Section 4.2.1, HA was modified to include a hydrolytically
degradable group, hydroxyethyl methacrylate (HeMA). Briefly, HeMA-HA was made by coupling
190

HA-tetrabutyl-ammonium salt (HA-TBA) to 2-hydroxyethyl-methacryl-succinate (HeMA-COOH)
using 4-dimethylaminopyridine (DMAP, Sigma) and the coupling agent di-tert-butyl dicarbonate
(BOC2O, Sigma) for 20 hours at 45°C.

19

The macromer was purified by dialyzing against

deionized (DI) water at 4°C, acetone precipitating, and dialyzing again. The macromer was then
1

frozen and lyophilized. The extent of HA modification with HeMA was assessed with H-NMR
(Bruker, 360 MHz) and found to be ~25% of the HA repeat units, as in Section 4.2.1.
7.2.2. Hydrogel Formation and Characterization
Hydrogels were formed by crosslinking the methacrylate groups of HeMA-HA using a
redox initiator system of ammonium persulfate (APS, 5 mM, Sigma) and N,N,N,N’,N’tetramethylenediamine (TEMED, 5 mM, Sigma),

43

as discussed in Section 4.2.3. Gel onset was

quantified using an AR2000ex Rheometer (TA Instruments) by monitoring the storage (G’) and
loss (G”) moduli over time at 37°C under 1% strain and 1 Hz frequency in a cone-plate geometry
(1°, 20 mm diameter). For in vitro characterization of mechanics and degradation, hydrogels were
formed between two glass slides in a Teflon mold sealed with vacuum grease. Compression
testing was performed on gels using a Dynamic Mechanical Analyzer (DMA) (Q800 TA
Instruments) at a strain rate of 10%/min and compressive moduli were calculated from 10 to 20%
44

strain.

Degradation was monitored in PBS at 37°C and mass loss quantified using an uronic

acid assay.

45,46

Mechanics and degradation were assessed immediately after gelation (day 0) and

at desired time points throughout degradation (i.e., days 1, 7, 14, 28, 56 and 84 after gelation).
7.2.3. In Vivo Evaluation in Porcine Infarct Model
Fourteen male Yorkshire swine weighing 40-50 kg were enrolled in this study (n=8
hydrogel treatment, n=6 saline control). All animals received care in compliance with protocols
approved by the University of Pennsylvania’s Institutional Animal Care and Use Committee in
accordance with the National Institutes of Health’s “Guide for the Care and Use of Laboratory
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Animals” (NIH Publication 85-23, revised 1996). All animals received a baseline MRI scan to
evaluate LV volumes and regional strains 5-7 days prior to MI.

Figure 7.1. MRI analysis of in vivo porcine infarct model. In vivo function (n=3-6/group) was
assessed in a porcine MI model (A). Inserts in panel A show a 3D MRI reconstruction of a
hydrogel in a myocardial explant (top) and visibility of a MRI marker (white, dashed circle) placed
post-MI for tracking infarct expansion (bottom). Thirty minutes post-MI, animals underwent an
array of twenty 0.3 mL injections of either prepolymer solution or saline in the infarct (B). MRI
compatible markers (white, dashed circles) are visible. MRI scans were performed at baseline
(i.e., prior to infarction) and at 1, 4, 8 and 12 weeks post-MI. MRI data was analyzed to assess
global LV structure and function from segmentation of the blood volume (red shape) in cine MRI
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(C), infarct (red arrow) expansion from LGE MRI (D), and myocardial wall function from tracking
grid displacement (red circles highlight select tags) in SPAMM tagged MRI (E). Scale bar = 2 cm.
For infarct induction, pigs were anesthetized and the LV free wall exposed through a left
thoracotomy. Throughout the procedure, pigs were monitored with electrocardiography and
aseptic technique was maintained. Animals were first sedated with intramuscular ketamine
injection (25-30 mg/kg), intubated, and mechanically ventilated. General anesthesia was
maintained on mixed isoflurane (1.5-3.0%) and oxygen, which was delivered by volumecontrolled ventilation (tidal volume 10-15 mg/kg).
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A posterolateral infarction was induced by

ligation with nonabsorbable polypropylene suture of the left circumflex artery (LCX) and select
obtuse marginal (OM) branches. In nearly all cases, this pattern of coronary ligations produced an
infarct comprising 20-25% of the left ventricle.

48

Akinesis of the infarcted myocardium was

confirmed using intraoperative echocardiography. Following infarct induction, thin MRI
compatible, platinum wire markers were sutured to the epicardium to outline the infarct. These
47

markers were tracked for quantitative assessment of infarct expansion over time (Figure 7.1A).

Thirty minutes after infarction, animals received twenty evenly distributed 0.3 mL
injections of either 0.9% normal saline (control) or HeMA-HA pre-hydrogel solution (treatment) in
the infarct (Figure 7.1B). Real time 3D echocardiographs and hemodynamic data were obtained
at baseline, immediately prior to MI, 30 minutes after MI, and 30 minutes post injection. After
ensuring hemodynamic and electrophysiologic stability, all animals were recovered. MRI scans
were performed at 1, 4, 8, and 12 weeks after injection. Animals were sacrificed at 12 weeks and
histological evaluation of Masson’s Trichrome and H&E staining was performed. Morphometric
analysis was performed to assess infarct wall thickness using planimetry.

47

7.2.4. MRI Acquisition
Serial cardiac MRI was used to noninvasively assess global and regional cardiac
structure and function in each animal through a series of three scans: 1) cine imaging to assess
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global LV morphology and function (Figure 7.1C), 2) late-gadolinium enhancement (LGE)
imaging to assess infarct area thinning and expansion (Figure 7.1D), and 3) SPAMM (SPAtial
Modulation of Magnetization) tagging to assess regional wall motion and function (Figure 7.1E).
MR images were acquired using a 3T Tim Magnetom Trio Scanner (Seimens, Inc.; Malvern, PA).
General anesthesia was maintained throughout all imaging procedures, as described above. For
each MRI scan, a high-fidelity pressure transducer (Millar Instruments; Houston, TX) was guided
into the LV for cardiac gating; the measured pressure was later used as an input for a finite
element (FE) model to assess in vivo myocardial stress-strain relationships.
LV volume imaging was performed using prospectively-gated 3D steady-state free
precession (SSFP) cine MRI with the following imaging parameters: field of view = 300 x 244
2

mm , matrix size = 192 x 156, repetition time = 3.11 ms, echo time = 1.53 ms, bandwidth = 1184
Hz/pixel, slice thickness = 4 mm, averages = 2.
thickness

occurred

fifteen

minutes

following

47

Assessment of infarct location and wall

intravenous

injection

of

0.1

mmol/kg

gadobenatedimeglumine (MultiHance; Bracco Diagnostics, Princeton, NJ) using a 3D LGE
2

spoiled gradient echo sequence with the following parameters: field of view = 350 x 350 mm ,
matrix size = 256 x 256, repetition time = 591.28 ms, echo time = 2.96 ms, inversion time = 200300 ms, flip angle = 25˚, averages = 2.
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Finally, regional LV strain was assessed using a 3D
2

SPAMM tagged sequence with the following parameters: field of view = 260 x 260 mm , matrix
size = 256 x 128, repetition time = 34.4 ms, tag spacing = 6 mm, bandwidth = 330 Hz/pixel, slice
thickness = 2 mm, averages = 4.

47

Separate scans were performed for systolic and diastolic

strain assessment. Images were archived and stored off-line for post-processing.
7.2.5. MR Image Post-Processing
7.2.5.1. LV Volume Measurement
Global LV structure and function was assessed from prospective SSFP cine MRI (Figure
7.1C). Raw short-axis images were automatically sorted, cropped, and contrast-normalized in a
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custom MATLAB (Natick, MA) program to ensure homogenous LV coverage and image quality,
respectively. Segmentation was subsequently performed throughout all cardiac phases using a
semi-automated 3D active contour segmentation program (ITK-SNAP, open access/source)

49

using edge-based snakes to identify the LV blood volume. LV end-diastolic volume (EDV), endsystolic volume (ESV), and ejection fraction (EF) were calculated throughout the entire cardiac
cycle from segmented images using inputs of in-plane and through-plane spatial resolution.
7.2.5.2. Infarct Assessment
Myocardial wall thickness was measured over the course of the study from cine MRI
images at end diastole. For infarct thickness assessment, thirty radially-oriented spokes were
randomly positioned throughout each 3D infarct area in fifteen mid-ventricular slices using ImageJ
software (NIH; Bethesda, MD). Platinum markers placed immediately post-MI and LGE images
were used to confirm infarct boundaries. Infarct thickness was computed at each time point from
the average spoke length. Similarly, remote wall thickness was also measured as a comparison.
Infarct surface area and volume were assessed at end diastole from the LGE images at
each imaging time point using MIPAV software (NIH; Bethesda, MD; Figure 7.1D). Both infarct
surface area and volume were normalized to total LV surface area and volume for each data set,
respectively. The epicardium, endocardium, and infarct regions were manually contoured in
fifteen slices from base to apex. The infarct was identified from the enhanced region in the LGE
images and confirmed by comparing to platinum marker locations in the cine and SPAMM
images. Surface area was calculated by multiplying contour perimeters by the slice thickness (4
mm) and number of analyzed slices. Volume was calculated by converting LGE image contours
to binary masks to sum the voxels and computing a volume based on the spatial resolution
3

(1.37x1.37x4.00 mm ). It should be noted that the epicardial, endocardial, and infarct contours
were the same for both the surface area and volume calculations.
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7.2.5.3. Myocardial Strain Analysis
Regional wall function was assessed in terms of contractility and passive properties using
systolic and diastolic strains, respectively. Regional strain measurements were calculated from
50

3D SPAMM acquisitions using an optical flow technique (Figure 7.1E).

Raw short-axis SPAMM

images were first manually cropped to include only the left ventricle from the apex to the mitral
annulus using ImageJ. Epicardial and endocardial contours were manually segmented at the
early systolic or early diastolic reference state for the systolic and diastolic SPAMM data sets,
respectively. Image masks were created from the segmented contours at the reference state to
isolate the LV myocardium. A custom optical flow mapping algorithm integrated into ImageJ was
used to derive high resolution, 3D displacement flow fields and strain tensors from the SPAMM
images tracking from the reference state through end systole or end diastole for the systolic and
diastolic SPAMM data, respectively.

50

In both data sets, the endocardial and epicardial infarct

boundaries were identified using the previously placed platinum markers and confirmed by
comparison with the enhanced region in the LGE images.
A custom MATLAB program was used for subsequent regional systolic strain analysis.
First, a centroid was placed within the LV for each short-axis slice. The borderzone myocardium
was then automatically defined to be the region extending 20 degrees beyond the infarct
boundaries on each side.

7

Remote regions were automatically defined as extending 60 degrees

beyond the borderzone boundaries on each side. The endocardial and epicardial edges were
excluded to reduce noise from blood and lung movement, respectively. Maximum (εmax) principal
strains were then calculated from the strain tensors for each myocardial region (i.e., borderzone,
remote), where εmax represents the maximum systolic thickening as an estimate of myocardial
contractility. Three-dimensional strain maps were generated to pictorially represent transmural
differences in regional systolic strain.
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7.2.6. In Vivo Diastolic Material Property Estimation
The details of the diastolic material property estimation scheme, which employs a
combination of MRI data, finite element (FE) simulations, and numerical optimization, have been
described previously.

37

Briefly, early diastole was taken to be the reference state for the animal-

specific ventricular FE models since it represents a relatively stress-free state due to minimal LV
pressure. LV volume was calculated at early and end diastole using endocardial contours
performed at those respective time points multiplied by the spatial resolution (area x in-plane
resolution x through-plane resolution). Synchronous LV pressure was recorded throughout
diastole and used as a pressure boundary condition in the model.

Figure 7.2. Development of finite element models from MRI-based animal specific data. FE
models were generated by fitting MRI-derived endocardial and epicardial contours with 3D
surfaces to represent the animal-specific geometry (A, B) and filling the myocardial space with
hexahedral brick elements (C). The boundary between the infarct (blue) and remote (red) region
was defined using 3D spline curves created from MRI-derived infarct contours projected onto the
endocardial and epicardial surfaces (C). Myofiber angles were fixed for the remote region and
assigned via optimization for the infarct region with respect to the circumferential direction (D).
As previously described,

37

FE models were generated by fitting the MRI-derived

endocardial and epicardial contours at early diastole with 3D surfaces (Rapidform; INUS
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Technology, Inc., Sunnyvale, CA; Figure 7.2A,B) and filling the myocardial space with
hexahedral trilinear elements (TrueGrid; XYZ Scientific, Inc., Livermore, CA, USA; Figure 7.2C).
The boundary between the infarct and remote region was defined using 3D spline curves created
from MRI-derived infarct contours projected onto the endocardial and epicardial surfaces (Figure
7.2C). Myofiber angles were assigned for each hexahedral element using a custom MATLAB
code. Remote angles were fixed to be 83° at the endocardial surface and -37° at the epicardial
surface, with respect to the circumferential direction

51-53

whereas the infarct angles were assigned

via an optimization algorithm (Figure 7.2D), which will be discussed later. For both the remote
and infarct regions, the fiber angles were assumed to vary linearly in the transmural direction.
The diastolic material properties of both the control myocardial data and hydrogelinjected myocardial data were described by a nearly incompressible, transversely isotropic
hyperelastic constitutive model given by:

(7.1)

where
(7.2)

The parameters C,

,

,

, are constants that describe diastolic myocardial material properties

and Eii are the components of the Green–Lagrange strain tensor relative to the myofiber
coordinate system (E11 = fiber direction, E22 = cross-fiber in-plane direction, E33 = transverse-fiber
direction) and the remaining Eij parameters are shear strains.

37

After splitting the strain energy

function into dilatational and deviatoric components, near incompressibility was enforced using a
penalty method on the dilatational part. Similar to Kichula et al.,

53

the same constitutive law was

used to describe both the saline- and hydrogel-treated infarcts so that differences in myocardial
stiffness could be attributed to altered material parameters with hydrogel delivery. The strain
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energy function (Equation 7.1) was implemented using LS-DYNA software (Livermore Software
Technology Corporation; Livermore, CA, USA).
Subsequently,

LS-OPT

software

(Livermore

Software

Technology

Corporation;

Livermore, CA, USA) was used to determine the optimal set of material parameters by minimizing
the error between the FE model predicted strain and the in vivo MRI measured strain. The
parameters optimized included the diastolic material parameters (Equation 7.1) for the remote
and infarct regions as well as the endocardial and epicardial fiber angles in the infarct. The mean
standard error (MSE)

37

was the objective function minimized during the optimization to enable a

direct comparison of the fit between the FE model- and MRI-derived strains. This was possible
because the LV contours used to generate the model and the MRI-derived diastolic strains were
from the same SPAMM data. In addition to the diastolic strain, constraints on LV cavity volume
were incorporated into the MSE calculation to ensure better agreement, as described earlier. The
parameters obtained from the optimization were then input into an equi-biaxial extension
simulation to obtain representative stress-strain curves of the saline control and hydrogel treated
regions.

37

To do so, it was assumed that the fiber and cross-fiber directions aligned with the two

loading directions and that the simulated sample was a thin, incompressible tissue with uniform
fiber orientation transmurally. Using a custom MATLAB code, stress was calculated for a range
of strain values to facilitate a clearer interpretation of differences in myocardial properties.
7.2.7. Statistical Analysis
Data is presented as mean ± standard deviation (SD) or mean ± standard error of the
mean (SEM), as indicated in each figure legend. Comparisons in LV volumes and function, wall
thickness, infarct surface area, infarct volume, regional systolic strain, and diastolic material
property estimations were performed using a one-way ANOVA with Tukey’s post hoc evaluation.
A p<0.05 was considered statistically significant.
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7.3. Results
7.3.1. In Vitro Characterization of Selected Hydrogel Formulation

Figure 7.3. In vitro characterization of hydrogel selected for use in vivo. Chemical structure of
HeMA-HA, where 25% of the HA repeat units were modified with HeMA (A). Representative
rheological time sweep after mixing HeMA-HA with APS and TEMED, where the intersection of
the storage (G’) and loss (G”) moduli is defined as gel onset (B). Representative temporal
degradation, n=1, (C) and compressive mechanical, n=4, (D) profiles. Degradation and initial
mechanics of selected HeMA-HA formulation, n=4 (E). Data presented as mean ± SD.
Based on previous HeMA-HA hydrogel characterization studies (Section 4.3.2), a single
HeMA-HA formulation was selected for in vivo assessment: 25% modified HeMA-HA (Figure
7.3A) at 8 wt% and gelled using 5 mM APS and 5 mM TEMED. Prior to its application in vivo, the
properties of this selected formulation were characterized in vitro. Gelation onset occurred at 2.1
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± 0.5 min and the crosslinking reaction reached a plateau within 20 minutes (gel completion: 15.9
± 2.9 min) after introducing the dissolved macromer to the initiators (Figure 7.3B). As discussed
in Section 5.2.6, the timing of gelation onset dictated the timing for injection in vivo. The temporal
degradation (Figure 7.3C) and compressive mechanical (Figure 7.3D) profiles demonstrated
hydrogels of this formulation gradually degraded and lost their mechanics over 12 weeks, which
was the intended duration of the in vivo study. In addition, hydrogels were formed with an initial
compressive modulus of 147.7 ± 34.2 kPa and degraded at 11.9 ± 3.6 weeks (Figure 7.3E).

Figure 7.4. Histological assessment of infarcts. Histological evaluation using Masson’s Trichrome
(A, C) and H&E (B, D) stains of saline treated (A, B) and hydrogel treated (C, D) animals at 12
weeks post-MI. Inset indicated by black square. Scale bar = 2 mm; scale bar for inset = 200 μm.
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7.3.2. Histological Evaluation and Ex Vivo Infarct Thickness
Histological assessment of the infarct region at the terminal time point revealed similar
stages of remodeling (i.e., extensive collagen staining, lack of functional myocytes, etc.) in both
the hydrogel treated and saline control animals (Figure 7.4). Hydrogel was not observed at 12
weeks following injection in the treatment animals, which is consistent with the previous in vitro
degradation (Figure 7.3C,E). Regional myocardial wall thickness measured ex vivo at 12 weeks
using planimetry showed greater thicknesses in the infarct, borderzone, and remote regions in the
hydrogel treated animals relative to saline control animals (Figure 7.6A,B). In both the hydrogel
and saline treated animals, the myocardial wall was most thin in the infarct region and became
increasingly thicker moving outward to the borderzone and then the remote regions.

Figure 7.5. Global cardiac structural and functional outcomes. LV volume and function assessed
by segmenting cine MRI images throughout all cardiac phases, n=3-6/group. Hydrogel treatment
led to decreased LV volumes (A, B) and improved cardiac function in terms of ejection fraction
(D). Data presented as mean ± SEM. *p<0.05 vs. saline controls.
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7.3.3. Global LV Structure and Function
Analysis of the cine MRI data revealed that delivery of the injectable HeMA-HA hydrogel
system to an in vivo porcine infarct model led to smaller LV end systolic volumes (ESV) and end
diastolic volumes (EDV) at all time points relative to control animals that received saline injections
(Figure 7.5A,B). Moreover, the LV volumes in the hydrogel treated animals were significantly
smaller than the volumes of the saline control animals at 1 week post-MI (EDV, p=0.005; ESV,
p=0.03). Overall, a trend towards progressively increasing LV volumes over time was observed in
both the saline control and hydrogel treatment animals. Comparison of the saline treated volumes
relative to the baseline (pre-MI) volumes (EDV, 69.4 ± 7.9 mL; ESV, 35.5 ± 5.7 mL) indicated that
the majority of the ventricular expansion occurred within the first week post-MI. For the saline
control group, all volumes were statistically greater (p<0.05) than the baseline volumes. For the
hydrogel treatment group, all ESV were statistically greater than baseline whereas the EDV were
not statistically different (p>0.05) from baseline values aside from at 8 weeks (p=0.04).
Ventricular function measured in terms of ejection fraction (EF) was greater with hydrogel
therapy than saline at all time points (Figure 7.5C). At 8 weeks, the average EF of the hydrogel
animals was significantly different (p<0.05) than controls. Relative to baseline (51.2 ± 3.5%), EF’s
were statistically different in the saline group at all time points and in the hydrogel group at 1 and
4 weeks post-MI. At 8 and 12 weeks post-MI, the EF of the hydrogel animals was not significantly
different (p>0.05) than the baseline.
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Figure 7.6. Myocardial wall thicknesses measured ex vivo and in vivo. Wall thickness was
measured ex vivo at different locations (INF: infarct; BZ: borderzone; REM: remote) at 12 weeks
using planimetry (A, B) and in vivo in the infarct (white arrows) throughout the study by analyzing
cine MRI at end diastole (C, D). Representative MRI at 12 weeks indicating infarct region (arrows)
are given for saline and hydrogel animals (A, C). Quantification both ex vivo, n=5-6/group (B) and
in vivo, n=3-6/group (D) showed increased myocardial wall thickness with hydrogel therapy. Data
presented as mean ± SEM. *p<0.05 vs. saline controls. Scale bars = 1 cm.
7.3.4. In Vivo Infarct Thickness and Expansion over Time
Infarct wall thickness measured in vivo throughout the duration of the study from cine
MRI demonstrated increased thickness with hydrogel therapy as compared to controls that was
statistically significant past one week (Figure 7.6C,D). Progressive infarct wall thinning occurred
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in both groups over time. This trend was confirmed qualitatively in the LGE MRI, where regions of
enhanced signal were localized to the infarct (Figure 7.7). All infarct thicknesses in both groups
were statistically significant from the baseline posterolateral wall thickness (9.6 ± 0.4 mm) aside
from the hydrogel group at 1 week post-MI (8.4 ± 0.5 mm, p=0.07). As a comparison, the remote
wall thickness remained unchanged over the 12 week study for both groups (average over time
points: hydrogel, 9.5 ± 0.1 mm; saline, 9.6 ± 0.1 mm) and there was no statistically significant
difference as compared to the baseline value at each time point (baseline, 9.6 ± 0.2 mm).

Figure 7.7. Infarct area assessment from late-gadolinium

enhancement (LGE) MRI.

Representative images from saline (A) and hydrogel (B) treated animals demonstrate thinning of
the infarct (enhanced region) without therapy and hydrogel presence (dark regions) out to 8
weeks with treatment (arrows).
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Figure 7.8. Contributions of infarct thinning and expansion from in vivo assessment. Infarct
surface area and volume were quantified by contouring the infarct and LV in LGE images in
MIPAV. Infarct surface area was similar between saline and hydrogel animals (A). Infarct volume
was consistent in hydrogel animals due to bulking but decreased with saline due to thinning (B),
n=3-6/group. Data presented as mean ± SEM. *p<0.05 vs. saline.
Changes in infarct expansion were assessed by analyzing the LGE MR images to
measure infarct surface area and infarct volume. Infarct surface areas normalized to the total LV
surface area were maintained throughout the duration of the study in both the hydrogel and saline
groups without significant differences between the two groups (Figure 7.8A). Thus, the infarct
surface area expanded at the same rate as the LV surface area over the course of the study. In
contrast, infarct volumes normalized to the total LV volumes were maintained in the animals with
hydrogel injections but decreased in saline treated animals over the four time points (Figure
7.8B). Beyond 1 week post-MI, the infarct volume in the hydrogel animals was significantly
different (p<0.05) than the control animals.
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Figure 7.9. Regional wall function assessed in terms of contractility using systolic strain. Threedimensional models of regional maximum principal strain (εmax) from a representative baseline
animal (A) and saline (B) and hydrogel (C) treated animals generated from SPAMM images using
an optical flow method to track tag displacement. Strain was calculated for different myocardial
locations (INF: infarct; BZ: borderzone; REM: remote) at 1, 4, 8, and 12 weeks post-MI.
7.3.5. Myocardial Systolic Strain as an Estimate of Contractility
Regional principal strain analysis of the systolic SPAMM data demonstrated increased
maximum principal strain (εmax) magnitude moving from the borderzone to the remote regions at
each time point in both the hydrogel treatment and saline control groups. This trend was reflected
both qualitatively through 3D strain models (Figure 7.9) and quantitatively (Figure 7.10). Beyond
one week, the systolic borderzone strain magnitudes were higher with hydrogel therapy than
saline delivery (Figure 7.10B), whereas remote systolic strain magnitude remained similar
between the two conditions (Figure 7.10C). However, no statistical differences were observed in
systolic strain magnitudes between the hydrogel and saline groups at each time point or between
the different time points within each group for the borderzone and remote regions. In all regions at
all time points and for both conditions, the systolic strain magnitude was significantly reduced
(p<0.05) relative to the baseline systolic strain magnitude (15.5 ± 1.5%).
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Figure 7.10. Quantification of regional systolic strain as an estimate of myocardial contractility.
Regional radial maximum principal strain (εmax) was calculated from systolic SPAMM images for
the borderzone (A) and remote (B) regions. Beyond one week, systolic borderzone strain was
higher with hydrogel therapy than saline, implying preserved contractility (A), whereas remote
systolic strain remained similar between conditions (B), n=3-6/group. In all regions, systolic strain
was significantly decreased (p<0.05) relative to the baseline (pre-MI) systolic strain of 15.5 ±
1.5%. Data presented as mean ± SEM.
7.3.6. Estimation of In Vivo Diastolic Myocardial Properties using FE Modeling
Animal-specific FE models were used to predict diastolic principal strains, for a given
applied pressure, as a measure of passive myocardial properties (Figure 7.11). The constitutive
model parameters (C,

,

,

) and infarct fiber angles were determined via optimization to

represent the diastolic myocardial properties for each treatment and control animal (Tables 7.1,
7.2). The MSE values, which describe the degree of error between the MRI-derived and FEmodel predicted strains, range from 6.1 ± 1.5 to 11.3 ± 9.5. The average MSE values are
consistent with previous studies

36,54

and imply good agreement between the data and models.

Also, the values were comparable over the different time points and similar but slightly less for the
hydrogel data sets as compared to the saline data.
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Table 7.1. FE model optimization results for infarct region.

Saline

Time Point
Pre-MI

1 Week

4 Week

8 Week

12 Week

C (kPa)

0.39 ± 0.10

1.48 ± 1.40

6.08 ± 4.03

9.38 ± 5.10

4.01 ± 2.34

bf

72.03 ± 29.63

171.53 ± 39.78

13.77 ± 12.54

15.28 ± 19.71

19.01 ± 31.15

bt

5.08 ± 4.53

24.22 ± 19.62

6.58 ± 5.96

8.32 ± 4.59

8.07 ± 5.64

bfs

36.69 ± 18.23

22.25 ± 17.55

8.64 ± 2.51

25.27 ± 27.41

17.19 ± 18.13

-14.89 ± 21.30

-23.00 ± 25.01

-18.15 ±21.81

-33.54 ± 25.73

43.56 ± 2.50

35.66 ± 21.41

26.69 ± 14.61

9.18 ± 15.42

7.43 ± 4.02

7.62 ± 2.08

11.31 ± 9.46

8.14 ± 3.63

C (kPa)

4.05 ± 2.86

4.38 ± 5.00

1.47 ± 1.54

5.36 ± 6.28

bf

137.67 ± 102.75

122.59 ± 94.49

139.26 ± 99.94

41.27 ± 67.66

bt

11.38 ± 6.95

9.21 ± 6.31

18.55 ± 23.25

14.46 ± 14.47

bfs

25.63 ± 21.05

30.02 ± 25.12

25.74 ± 20.63

23.54 ± 29.29

-8.88 ± 15.60

-10.07 ± 17.17

-2.16 ± 3.07

-24.28 ± 20.95

56.84 ± 16.75

32.07 ± 18.96

25.63 ± 17.16

28.83 ± 24.93

6.14 ± 1.53

7.08 ± 2.16

9.81 ± 4.25

8.87 ± 3.55

epi-angle
(deg)
endo-angle
(deg)

Hydrogel

MSE

8.64 ± 1.53

epi-angle
(deg)
endo-angle
(deg)
MSE

Table 7.2. FE model optimization results for remote region.

Hydrogel

Saline

Time Point
Pre-MI

1 Week

4 Week

8 Week

12 Week

C (kPa)

0.39 ± 0.10

2.59 ± 2.13

1.85 ± 2.66

0.52 ± 0.18

0.41 ± 0.24

bf

72.03 ± 29.63

29.44 ± 39.21

30.15 ± 39.21

37.67 ± 28.94

29.52 ± 11.15

bt

5.08 ± 4.53

11.04 ± 15.64

9.28 ± 4.21

17.39 ± 15.75

11.14 ± 7.92

bfs

36.69 ± 18.23

19.35 ± 16.46

28.45 ± 18.67

23.12 ± 15.77

30.86 ± 15.45

C (kPa)

0.75 ± 0.62

0.52 ± 0.43

0.69 ± 0.36

1.19 ± 1.37

bf

31.77 ± 26.07

56.01 ± 33.62

40.55 ± 28.70

42.29 ± 34.98

bt

22.11 ± 16.87

25.14 ± 14.68

19.62 ± 15.13

17.39 ± 18.33

bfs

33.84 ± 13.89

45.49 ± 6.55

43.07 ± 11.50

46.02 ± 4.31
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Figure 7.11. Finite element model to assess passive myocardial properties. Representative finite
element models of a baseline animal (A) and saline (B) and hydrogel (C) treated animals at 1, 4
and 8, and 12 weeks. The infarct (red) and remote (blue) regions were assigned different
myocardial tissue properties. Short axis views taken from roughly the same position at midventricle demonstrate thinning of the infarct region over time (arrows).
The optimized infarct fiber angles ranged from -33.5 ± 25.7° to -2.2 ± 3.1° at the
epicardial surface and 9.2 ± 15.4° to 56.8 ± 16.8° at the endocardial surface. In both animal
conditions, the fiber angles were closer to 0° at the epicardial than endocardial surface, where
proximity to 0° dictates the degree of circumferential fiber orientation. Comparison of the fiber
angles between the hydrogel and saline data sets revealed that the epicardial fiber angles were
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closer to 0° in the hydrogel data but the endocardial angles were closer to 0° in the saline data.
Over time, the epicardial angles increased to be further away from 0° whereas the endocardial
angles decreased closer to 0° in both conditions. Using the optimized parameters, FE models
showed small strains in the infarct that increased outward to the surrounding remote regions in
both groups (Figure 7.12). Also, both the remote and infarct strains increased over the study.

Figure 7.12. Short-axis view of the diastolic principal strain generated from FE model simulations.
Representative short-axis strain maps of a baseline animal (A) and saline (B) and hydrogel (C)
treated animals at 1 and 12 weeks. The end-diastolic pressure was set to be a constant 10
mmHg to ensure all data sets experienced the same load.
To better understand differences in passive myocardial properties, simulated equi-biaxial
tests were used to estimate stress over a given range of strain values and generate stress-strain
curves in the fiber and cross-fiber direction. The Green–Lagrange strain ranges were selected
from the FE model predicted diastolic strains (Figure 7.12). Examination of the stress-strain
curves revealed stiffening of the infarct in both the hydrogel and saline animals at 1 week
following infarct induction as compared to baseline (Figure 7.13). With each subsequent time
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point, the infarct became progressively less stiff in both animal groups, yet remained stiffer than
at baseline even out to 12 week post-MI. These trends were consistent between the fiber and
cross-fiber direction but the stiffness in the fiber direction was greater than the cross-fiber
direction at each time point when comparing within each animal condition. Most importantly, at
each time point, the stiffness of the infarct in the hydrogel treated animals was greater than that of
saline injected animals in both the fiber and cross-fiber direction.

Figure 7.13. Simulated equi-biaxial extension tests using FE model optimization parameters.
Stress-strain equations were implemented to calculate stress at the same set of strain points for
each case. Average stress-strain plots for the infarct region of saline (top) and hydrogel (bottom)
animals in the fiber (A, C) and cross-fiber (B, D) direction in saline treated animals over time.
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Figure 7.14. Quantification of moduli in the infarct region from simulated equi-biaxial tests. Moduli
were calculated at different strain ranges for extension in both the fiber (A, C) and cross-fiber (B,
D) direction in saline and hydrogel treated animals over time. Data presented as mean ± SEM.
Quantification of the moduli from the stress-strain plots over different strain ranges (00.05 and 0.05-0.10) further confirmed greater infarct stiffness in the hydrogel animals as
compared to the saline control animals at each time point out to 12 weeks, particularly in the fiber
direction (Figure 7.14). In addition, infarct stiffness was greater with extension simulated in the
fiber direction relative to the cross-fiber direction and this stiffening response progressively
declined as time from infarct induction increased. Despite the trends, there were no statistical
differences between the hydrogel and control moduli. For the 0-0.05 strain range, all moduli were
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statistically greater than baseline aside from the hydrogel group at 12 weeks in the fiber direction
(p=0.01) and the saline group at 8 weeks in the fiber direction (p=0.03) and at 4 and 8 weeks in
the cross-fiber direction (4 weeks, p=0.03; 8 weeks, p=0.04). For the 0.05-0.10 strain range, all
moduli were significantly different than baseline aside from the moduli in the cross-fiber direction
for the hydrogel group at 12 weeks (p=0.03) and the saline group at 8 weeks (p=0.03).
7.4. Discussion
Over the past decade, it has become evident that the regional mechanical changes in the
myocardium must be considered when designing biomaterial approaches for MI repair.

4,17,55

Previous biomaterial studies designed to alter myocardial mechanics post-MI have demonstrated
that delivery of injectable materials leads to thicker, stiffer infarcts with limited infarct expansion
and preserved LV geometry.

18,19,56,57

and/or decreased infarct size

58

Although promising, increased myocardial wall thickness

58-62

alone do not directly correlate with improved cardiac function.

Thus, a better understanding of the correlations between myocardial tissue properties and
improved outcomes is needed to identify optimal biomaterial properties and improve therapy
design. Towards this goal, this work used MRI and FE modeling as tools to examine the impact of
an injectable hydrogel system on myocardial tissue properties in terms of regional thickness and
expansion, contractility, and stiffening.
In this chapter, a HA hydrogel with high initial mechanics was used to investigate the
ability of injectable hydrogels to alter myocardial tissue properties as a means to attenuate LV
remodeling. Previous in vivo studies using HA hydrogels demonstrated that gels that were
present for over eight weeks with initial mechanics greater than that of the normal myocardium
(compressive modulus ~7-10 kPa) were more effective at maintaining LV structure post-MI than
hydrogels with lower mechanics in an ovine infarct model.

18,19

Moreover, FE modeling using

experimentally derived biaxial inputs from HA hydrogel-myocardial composites indicated that a
stiffer hydrogel formulation will further reduce wall stress to attenuate remodeling.

53

Therefore, a

single hydrogel formulation was selected for in vivo application with the following anticipated
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optimal properties: an in vitro degradation profile greater than eight weeks and an initial
compressive modulus greater than ten times that of the normal myocardium. LGE MR images
throughout the 12 week study correlated with the in vitro degradation profile (Figure 7.3C,E) of
this formulation in that the material appeared to be present in the infarct region at the 8 week time
point but was no longer present at 12 weeks (Figure 7.7). This was further confirmed by histology
where gel was not observed at the terminal time point (Figure 7.4). Even though one hydrogel
formulation was applied, the use of in vivo-derived MRI data and FE modeling as tools to better
understand impact of hydrogels on LV remodeling can be applied to any injectable system.
Remodeling post-MI was evaluated using MRI at 1, 4, 8, and 12 weeks following injection
of either hydrogel for the treatment animals or saline for the control animals. Outcomes were
assessed into the chronic remodeling period to contrast with the majority of previous cardiac
63

biomaterial studies which focus on acute remodeling out to 4 or 8 weeks post-MI.

The impact of

hydrogel delivery on LV remodeling was first examined in terms of global ventricular structure and
function. As expected, intramyocardial hydrogel injection resulted in preserved LV geometry and
improved cardiac function as compared to saline delivery at all time points (Figure 7.5). Although
both groups demonstrated signs of adverse remodeling relative to baseline conditions, the ability
of hydrogel therapy to minimize LV dilation was maintained throughout the 12 week study, in
contrast to previous work where structural LV benefits observed at 4 weeks were lost by the 2
month terminal time point.

61

These findings correlated with our previous echocardiographic

studies which demonstrated better maintenance of LV structure with HA hydrogel injection
compared to infarct controls in an ovine anteroapical infarct model.

18,19

To expand upon our

previous work, this chapter used MRI to serially examine the impact of hydrogel delivery on in
vivo infarct thinning and expansion, myocardial contractility, and passive myocardial stiffening to
better understand how hydrogel therapy led to these positive structural and functional outcomes.
Thinning of the myocardium post-MI has been identified to be an important contributor to
increased wall stress, both in the infarct and surrounding borderzone regions. Thus, myocardial
215

thickness was measured to assess the ability of hydrogel therapy to bulk and stabilize the heart
wall to attenuate remodeling. As anticipated, ex vivo assessment at the terminal time point
revealed increased thickness in the infarct, borderzone, and remote myocardium with hydrogel
therapy, and in vivo assessment over the course of the 12 week study demonstrated increased
infarct thickness in the infarct at each time point due to hydrogel bulking (Figure 7.6A,B). Many
studies have demonstrated similar increases in ex vivo infarct thickness with material
18,19,63

delivery

, but few have quantified parameters of infarct thinning noninvasively over time

similar to this study.

47

Moreover, the progressive decrease in infarct wall thickness observed over

time in both groups is consistent with the global LV outcomes and provides insight into the
biological consequence of remodeling. A contributing factor to remodeling is the increase is the
activation of matrix metalloproteinases (MMPs) in the myocardium which leads to extracellular
matrix (ECM) breakdown;

60,64,65

this offers a biological explanation for the global LV dilation and

associated infarct thinning and expansion.
The infarct expansion into the surrounding borderzone regions that occurs as the heart
dilates and myocardial walls thin has been shown to both precipitate and sustain the entire
remodeling process.

6,66-68

Thus, the impact of hydrogel injection on infarct expansion (i.e.,

stretching) was assessed by measuring the infarct surface area and volume and normalizing to
total LV surface area and volume, respectively. Infarct surface area is primarily a measure of
infarct expansion whereas infarct volume accounts for both infarct thinning and expansion. From
the global ventricular assessment of EDV and ESV (Figure 7.5A,B), it was known that the LV
was dilating outward in both groups over the 12 weeks. The minimal change in infarct surface
area over time and between the two groups suggests that the rate of infarct expansion was
similar to the rate of LV dilation in both hydrogel and saline treated animals (Figure 7.8A).
However, since there was less overall LV dilation with hydrogel delivery at each time point
(Figure 7.5A,B), the infarct in the hydrogel treated animals expanded less than in the saline
animals. Furthermore, since the infarct at the time of induction comprised 20-25% of the LV
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surface area by the surgeon’s visual assessment,

48

infarct surface areas on the order of ~30% at

1 week indicate that the majority of the infarct expansion occurred within the first week after MI.
In contrast to infarct surface area, assessment of infarct volume resulted in differences
between the hydrogel and saline groups. Since infarct volume accounts for both infarct thinning
and expansion, the maintained infarct volume relative to the total LV volume over the four time
points with hydrogel therapy (Figure 7.8B) is consistent with the minimal changes in infarct
thickness (Figure 7.6C,D) and infarct surface area as a measure of expansion (Figure 7.8A).
Similarly, the decrease in infarct volume over time with saline delivery correlates with the extreme
thinning observed over time due to matrix degradation in the infarct (Figure 7.6), since minimal
changes were observed in rate of infarct expansion (Figure 7.8B). Thus, assessment of infarct
surface area demonstrated less infarct expansion with hydrogel therapy due to less LV dilation as
compared to controls whereas assessment of infarct volume over time further confirmed the
trends in infarct thickness in that injectable hydrogels function by bulking the myocardial wall.
Abnormal stress distributions in the borderzone myocardium which result from infarct
thinning and expansion may lead to global contractile dysfunction and heart failure.

5,6,8,66,69

Thus,

regional myocardial systolic strain was measured as an estimate of myocardial contractility and
regional wall function. The low principal strain magnitudes at 1 week seen in all regions and in
both groups can be explained by myocardial stunning in the acute post-MI period.

71

Past 1 week,

hydrogel delivery was shown to improve borderzone myocardial contractility throughout the
duration of the study relative to saline injections (Figure 7.10B). By bulking the myocardial wall in
the region of infarction (Figure 7.6), the injectable HA hydrogels facilitated an environment where
normally perfused myocardium could continue to contract. Combined with a limitation in outward
infarct extension (Figure 7.8B), this suggests that hydrogel therapy prevented the expansion of
contractile dysfunction to progressively larger regions of perfused borderzone myocardium, which
in turn led to improved global cardiac outcomes (Figure 7.5). The increased systolic borderzone
strain in the hydrogel treated animals as compared to controls supports the theory that LV
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remodeling is driven by thinning of the myocardial wall in the region of infarction leading to
increased wall compliance. However, systolic myocardial wall strain and global LV function are
indirect measures of in vivo myocardial compliance and wall stress, parameters that are
traditionally assessed using ex vivo biaxial testing. To circumvent the need for ex vivo
assessment, in vivo strain data was subsequently input into a FE model to simulate LV diastolic
filling and measure forces in the myocardial wall.
Due to the role of increased infarct compliance in sustaining adverse remodeling,

70,72

MRI-derived diastolic strains were input into a FE model to directly quantify in vivo passive
mechanical properties in the myocardium and provide an understanding of the impact of hydrogel
delivery on in vivo wall compliance (Figure 7.11). Assessment of regional stress-strain
relationships using simulated equi-biaxial extension tests demonstrated that hydrogel injection led
to increased myocardial stiffness in the infarct region relative to controls, with a larger impact on
mechanics in the fiber direction as compared to the cross-fiber direction (Figures 7.13, 7.14). In
both animal groups, extensive stiffening of the infarct was seen at 1 week post-MI compared to
baseline and the stiffening response progressively decreased over time. This initial stiffening
response can be attributed to the collagen deposition occurs in the infarct region during
remodeling as the infarct attempts unsuccessfully to repair itself

73,74

whereas the gradual

decrease in infarct stiffness could result from a combination of matrix degradation due to MMP
60,64,65

activation

75

and extensive loss of type I collagen post-MI,

leaving the myocardium at a

mechanical disadvantage. Furthermore, the increased stiffening with hydrogel injection indicates
that hydrogel delivery successfully altered the material properties of the infarct at a time point
prior to when the body had compensated for remodeling and highlights the importance of
appropriately timing hydrogel delivery in the remodeling process to maximize benefit. In
combination with the systolic strain assessment of contractility, this suggests that the stiffening of
the infarct with hydrogel injections led to stabilization of the borderzone myocardium, which in
turn preserved the contractile function in this region (Figure 7.10B).
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7.5. Conclusions
An injectable, degradable hydrogel system was successfully applied to an in vivo porcine
infarct model to examine its effect on global LV remodeling, infarct thinning and expansion, and
regional myocardial wall function using MRI and FE modeling. MRI analysis demonstrated that
injectable HA hydrogels can improve LV structure and function, preserve infarct thickness, limit
infarct dilatation, and preserve borderzone contractility. Input of MRI-derived diastolic strain
parameters into a FE model showed hydrogel delivery led to increased myocardial stiffness in the
infarct that was better maintained throughout the 12 week study as compared to saline-treated
controls. Overall, evaluation of myocardial properties using MRI and FE modeling provides
additional insight into the mechanism by which injectable materials improve long-term structural
and functional outcomes post-MI and ultimately, can serve as a tool to determine optimal
biomaterial properties for MI repair.
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CHAPTER 8

Conclusions, Limitations, and Future Directions

8.1. Conclusions
Left ventricular (LV) remodeling initiated by a myocardial infarction (MI) continues to be a
large clinical burden due to the high rate of progression to heart failure. Current treatment
approaches focus on pharmacological and/or surgical therapies which are either insufficient to
limit remodeling or highly invasive to deploy, respectively. Therefore, as described in Chapter 1,
both noninvasive therapies and noninvasive techniques to assess the effects of therapies are
needed to address the clinical burden of MI induced heart failure.
As discussed in Chapter 3, injectable hydrogels offer a noninvasive approach to target LV
remodeling by simultaneously mechanically stabilizing the myocardial wall and modulating
maladaptive biological processes as a delivery vehicle for therapies, such as cells and growth
factors. Even though injectable materials have shown success in locally delivering cells and
molecules to the heart, concerns with retention, engraftment, and dosage motivate the use of
acellular materials as bulking agents to counteract the geometric changes post-MI in this
dissertation. In addition, various natural and synthetic injectable materials have been investigated
to attenuate remodeling, but the mechanism by which these injectable systems lead to positive
structural and functional outcomes post-MI remains unclear. One step towards understanding this
mechanism is the application of noninvasive imaging techniques to evaluate the reciprocal
interaction between the injected material and the surrounding myocardial tissue. Of the imaging
modalities, magnetic resonance imaging (MRI) is particularly well suited for material assessment
and temporal evaluation of myocardial properties due to its high spatial and temporal resolution.
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To assess differences in material properties once delivered to the myocardium, injectable
systems with tunable properties are needed. Thus, Chapter 4 focused on the in vitro
characterization of tunable, injectable hyaluronic acid (HA) hydrogels. Macromers were
synthesized with a range of modifications by coupling either hydroxyethyl methacrylate (HeMA) or
methacrylate (Me) to HA to generate the gel precursors HeMA-HA and MeHA, respectively.
Hydrogels were formed by covalently crosslinking the methacrylate groups using a two
component redox initiator system of APS and TEMED. In HeMA-HA homopolymer hydrogels, the
initiator concentration, macromer modification, and macromer concentration were altered to
investigate their effect on hydrogel gelation, degradation, and mechanics. Increased initiator
concentration, macromer modification, or macromer concentration led to accelerated gelation,
prolonged degradation, and higher initial mechanics that were maintained over longer durations.
Altering a combination of the macromer modification and concentration was used to tailor HeMAHA hydrogel degradation while maintaining similar initial mechanics. For hydrogels with
approximately the same initial mechanics (30 kPa, 60 kPa, or 90 kPa), formulations with a higher
modification but lower macromer concentration maintained their mechanics for longer and
degraded slower (on the order of 6 weeks or more) than formulations with a lower modification
but higher macromer concentration. Another approach to tuning hydrogel degradation was to
form copolymer hydrogels of HeMA-HA and MeHA, where increased incorporation of nonhydrolytically susceptible MeHA led to slower degradation. The tunability of HA hydrogel
properties was then applied to investigate the ability of MRI to detect these differences ex vivo in
myocardial explants (Chapters 5 and 6) and to select a single hydrogel formulation with
anticipated positive outcomes

1,2

for use in an in vivo infarct model (Chapter 7).

Two MRI approaches were then explored to visualize and characterize the properties of
HA hydrogels in myocardial tissue explants. Theoretical models have demonstrated that hydrogel
3

dispersion in tissue directly correlates with their ability to attenuate LV remodeling. Thus, in
Chapter 5, conventional MRI was used to quantify differences in three-dimensional hydrogel
distribution in tissue based on varied gelation properties. Gelation onset was altered in MeHA
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hydrogels such that an increased initiator concentration or macromer modification led to
accelerated gelation, with initiator concentration having a greater impact on the time to gelation.
Differences in the time to gelation led to differences in the distribution of the crosslinked (MRI
detectable) portion of each hydrogel, with higher initiator concentration and higher macromer
modification (at low initiator concentration) leading to a larger crosslinked volume. To investigate
differences in the mechanism of gelation, hydrogel volumes were also assessed for selfassembling guest-host hydrogels. Unlike covalently crosslinked HA hydrogels which distributed
along the myocardial fibers and formed a composite with the surrounding myocardial tissue,
physically crosslinked guest-host HA hydrogels formed distinct plugs with calculated volumes
comparable to the injected volume. Thus, MRI was successfully shown to characterize
differences in hydrogel distribution based on gelation timing and mechanism of formation.
In Chapter 6, CEST MRI was used to visualize injectable HeMA-HA hydrogels either
alone or after injection into tissue based on manipulation of the exchangeable hydroxyl (–OH)
protons on the HA backbone. The CEST effect was shown to track with changes in material
properties such that as hydrogel macromer concentration increased, the CEST contrast
increased linearly. Furthermore, CEST MRI was used to detect HA hydrogels injected once into
cardiac explants with an increase in signal at the hydrogel site relative to the surrounding
myocardial signal. Unlike conventional MRI, CEST was shown to simultaneously visualize and
discriminate between different injectable materials based on their specific chemical composition.
More specifically, the CEST signal was tuned to detect differences in two hydrogel systems
based on their dominant functional groups. The covalent addition of an arginine-based peptide to
HeMA-HA hydrogels led to a two-fold increase in signal when the exchangeable amine (–NH2)
protons in the peptide were targeted. Therefore, CEST MRI was demonstrated to be a valuable
tool for studying injectable hydrogel properties and could enable further optimization of
biomaterial therapies aimed at clinical translation.
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After examining the use of MRI to characterize the properties of injectable hydrogels
once delivered to myocardial tissue, the focus of this dissertation shifted to using MRI to evaluate
the effects of HA hydrogels on myocardial tissue properties as a means to understand their role in
attenuating adverse remodeling following infarction. In Chapter 7, we investigated the long-term
effects of degradable HeMA-HA hydrogels on global LV remodeling, infarct thinning and
expansion, myocardial wall motion, and myocardial stiffness in a porcine infarct model out to 12
weeks post-MI using MRI and finite element (FE) modeling. Hydrogel treatment generally led to
decreased LV volumes, improved ejection fractions, and increased wall thicknesses as compared
to saline injected controls. Beyond 1 week post-MI, systolic borderzone strain was higher with
hydrogel therapy than saline, implying preserved borderzone contractility. Furthermore, FE model
simulations with diastolic strain inputs demonstrated that hydrogel therapy increased infarct
stiffness out to 12 weeks post-MI. Hence, evaluation of myocardial tissue properties through MRI
and FE modeling provided insight into the effect of injectable HA hydrogels therapies on
myocardial structure and function post-MI and more universally, could serve as tools to
investigate the impact of any injectable system on myocardial tissue properties.
8.2. Limitations
Specific Aim 1: Synthesize and characterize degradable HA hydrogels with a range of properties,
particularly gelation, degradation, and mechanics.
8.2.1. Limitations in In Vitro Characterization Studies
A limitation in the in vitro characterization studies performed for Aim 1 was that
degradation and mechanics were coupled in the HA hydrogel systems used (i.e., HeMA-HA and
MeHA). In pure HeMA-HA hydrogels, even though a wide range of degradation profiles (1.7 to
22.5 weeks) and initial mechanics (2.6 to 457.6 kPa) were achieved by altering the macromer
modification and concentration, the system was limited in that the degradation could only be
tuned within a narrow range without altering the mechanics. To achieve similar initial mechanics,
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the time to hydrogel degradation had to be relatively long (i.e., greater than 7 weeks). Similarly, to
achieve large differences in degradation (i.e., 6 weeks or more), the initial mechanics had to be
high relative to normal myocardial mechanics (i.e., 30 kPa or greater). Thus, it was not possible to
form hydrogels with different rates of degradation but similar initial mechanics that matched those
of the native myocardium (compressive modulus ~7-10 kPa). As will be discussed in Section
8.3.2, to achieve HeMA-HA hydrogels with degradation profiles that fit different stages of LV
4

remodeling (i.e., ~2-3 weeks for acute remodeling and ~10-12 weeks for chronic remodeling),

the desire to have similar initial mechanics had to be sacrificed. Moreover, the incorporation of
MeHA to form HeMA-HA/MeHA copolymer hydrogels further prolonged the degradation, where
gels were stable over the span of several months, which was not physiologically relevant for a
degradable system for MI repair. To decouple degradation and mechanics, other HA hydrogel
5,6

systems should be explored with different mechanisms of crosslinking.

Specific Aim 2: Visualize HA hydrogels using MRI as a means to examine hydrogel dispersion
and detect differences in hydrogel chemical composition ex vivo.
8.2.2. Limitations in T2-Weighted Imaging
In Aim 2 of this dissertation, the T 2-weighted imaging of HA hydrogels was limited to ex
vivo studies and did not progress to in vivo studies. An in vivo study at 3 T was attempted where
HeMA-HA hydrogels were injected into the posterolateral wall of a healthy sheep but magnetic
field inhomogeneities, particularly in the free wall at the injection locations, severely limited
material detection. Magnetic field inhomogeneity in the heart is primarily due to differences in
magnetic field susceptibility

7,8

between the myocardium, blood, lung parenchyma and, in the case

of animals that have undergone a recent thoracotomy, air spaces in the chest wall. Delivery of
injectable materials via catheter may decrease magnetic field susceptibility differences to improve
homogeneity by eliminating air in the chest cavity. However, since the magnetic susceptibility of
cardiac tissue is spatially varying and unique to each animal (i.e., dependent on the animal’s size
and organ distribution), it is not possible to eliminate these effects completely. Shimming, or
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mapping the magnetic field inhomogeneity to compensate for it, does help improve magnetic field
homogeneity but is particularly challenging in the posterolateral heart wall due to the proximity to
9

the lung parenchyma, which leads to a significant magnetic field gradient. Moreover, maintaining
field homogeneity is more difficult at higher field strengths because, from an engineering
perspective, it is more challenging to induce a strong homogeneous magnetic field than a weak
7

one. This not only impacts the main B0 field but also the homogeneity of the RF (B1) field, which
scales linearly with the main field. Thus, moving to lower but still clinically relevant magnetic field
strength, such as 1.5 T, would decrease the inhomogeneity effects. Finally, certain pulse
sequences are more susceptible to field inhomogeneity. As opposed to cardiac sequences such
as those used for cine, perfusion, or SPAMM-tagging MRI, T2 sequences are especially sensitive
to field inhomogeneity because the RF refocusing pulses depend on precise B 1 homogeneity and
the signal readout depends on excellent B0 homogeneity.

9

Another limitation of the T 2-weighted MRI of HA hydrogels in myocardial explants was
that hydrogel visualization and quantification was only possible using normal, non-infarcted
myocardial tissue. Whereas hydrogel distribution was easily quantified in explants following in
vivo injection then sacrifice in a normal animal (Section 5.3.3), it was barely detectable in
infarcted myocardial tissue where HA hydrogels were injected into mini-pigs immediately
following MI and sacrificed at various time points out to two weeks post-MI. The adverse
physiologic state of the infarcted myocardium, consisting of disordered collagen and myofiber
architecture, fibrosis, and inflammation leading to iron deposition,

10-13

prevented quantification of

hydrogel volumes in infarcted explants, potentially due to similarities in T2 relaxation properties
between the injected hydrogel and the surrounding damaged myocardial tissue.
8.2.3. Limitations in CEST Imaging
There were also several limitations and challenges encountered for the second noncontrast MRI technique explored in Aim 2. CEST imaging of HeMA-HA hydrogels phantoms at
both 7 T and 3 T demonstrated that the CEST effect was not uniform within the hydrogels,
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perhaps due to inhomogeneous crosslinking. Furthermore, ex vivo studies showed that the CEST
effect from HeMA-HA hydrogels was fairly small (i.e., less than 3%) and also variable within the
injection site, as may be expected due to crosslinking variations as the material dispersed
between the myocardial fibers. This made translation to in vivo studies challenging. Moving to
high field strength (i.e., 7 T) may help due to the improved signal-to-noise ratio (SNR) and spatial
resolution, as demonstrated in Section 6.3.2. However, as discussed previously, magnetic field
inhomogeneities scale with increased field strength, so increased inhomogeneity would make in
vivo material detection more challenging. In addition, the large increase in power deposition at 7
T limits its clinical use,

14

as opposed to 3 T MR scanners which are utilized clinically.

Moreover, despite the higher concentration of hydroxyl (–OH) protons on the HA
backbone, hydroxyl CEST is generally challenging due to the proximity of the –OH proton
resonance to that of bulk water protons, leading to a higher potential for direct water saturation.
Partial direct water saturation leads to a decrease in the water signal due to the RF pulse
application and not from proton exchange, misconstruing the true CEST effect and thus
decreasing CEST sensitivity.

15,16

As seen in the non-water suppressed spectroscopy studies

(Section 6.3.3), where direct saturation effects should be smaller than at 3 T due to the higher
magnetic field strength of the spectrometer (9.4 T), the –OH proton peak could not be resolved
from the bulk water proton peak. Furthermore, it is possible that partial direct saturation could
explain the positive CEST contrast seen in the phantom and explant studies.
Finally, similar to the T2-weighted hydrogel imaging, CEST MRI was also limited to
myocardial explants. Whereas ex vivo 3 T studies targeting the –OH protons on HA were
promising, an in vivo study of HeMA-HA hydrogel injections attempted at 3 T in a normal sheep
was unsuccessful. The injection site of the material in the posterolateral free wall made detection
challenging due to substantial motion, particularly at higher saturation frequencies further from
the bulk water resonance, despite both respiratory and cardiac gating. This motion led to large
magnetic field inhomogeneities that were not able to be perfectly corrected for using the standard
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WASSR techniques,

17,18

and thus prevented accurate z-spectral fitting of the CEST effect as a

function of chemical shift to extract a reliable CEST contrast. To address the motion concerns of
cardiac CEST in vivo, our collaborators in the Reddy lab developed a more accurate z-spectral
fitting technique based on a probabilistic combination of Lorentzian functions to account for the
direct saturation, magnetization transfer and CEST effects impacting the myocardial tissue.

19,20

When applied to the–OH CEST data from the in vivo injection study, there was substantial
overlap in the proton resonance peaks between the bulk water protons and nearby –OH protons
preventing resolution of the separate peaks for accurate fitting.
The partial direct saturation effect concerns with manipulating the –OH protons on HA
motivated the switch to targeting amine (–NH) protons in an arginine-dominate peptide coupled to
HA since they resonate further downfield from the bulk water protons.

20-23

Even though phantom

studies demonstrated the ability to generate a CEST effect specific to the exchangeable proton
group of interest (Section 6.3.3), this was unsuccessful in attempted explant studies. This
limitation was most likely due to the high background myocardial CEST effect from endogenous
amines that prevented detection of the arginine-based amines in the HA coupled peptide. More
specifically, the labile amines in endogenous myocardial creatine, which is involved in energy
production to power contraction, are known to resonate ~1.8 ppm downfield of bulk water,

20,23

which is identical to the resonance of the amines in the peptide as identified from spectroscopy.
Future work should focus on the coupling of peptides with exchangeable protons whose
resonance differs from that of endogenous myocardial metabolites. HeMA-HA-peptide hydrogels
were also delivered in vivo to a healthy sheep and in vivo CEST imaging attempted. However,
despite the decrease in direct water saturation, the same motion and inhomogeneity concerns as
previously described with the HeMA-HA injections were encountered.
Specific Aim 3: Assess the temporal effects of degradable HA hydrogel therapy on long-term
myocardial tissue remodeling post-MI using cardiac MRI and FE modeling in an in vivo porcine
infarct model.
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8.2.4. Limitations in In Vivo Study
A limitation of the in vivo work performed in Aim 3 was that only a single hydrogel
formulation was assessed. Even though it was selected based on previous studies from our
1,2

group

to have optimal properties (i.e., an in vitro degradation profile greater than eight weeks

and an initial compressive modulus greater than ten times that of the normal myocardium),
delivery of only one formulation prevented assessment of the correlation between material
properties and positive in vivo outcomes. Based on the study design, it could not investigate the
optimal degree and duration of mechanical stabilization needed to attenuate remodeling, and
thus, the specific hydrogel properties for optimal in vivo outcomes remains unclear.
The animal model also involved injecting the hydrogel therapy into the infarct at thirty
minutes following infarction. Even though this timing for delivery has been used by our group
and others

25-27

1,2,24

to evaluate the efficacy of injectable materials in animal MI studies, it is not

clinically relevant

28,29

as MI patients would not receive therapy for at least several hours after the

onset of MI. In addition, patients may be unstable during the initial period following MI trauma due
to the upregulation of MMPs, which may cause the ventricle to be vulnerable to rupture.

30-34

Delivery at one week post-MI would be more clinically practical as it would give patients a period
to recover and stabilize before undergoing an injection procedure.
The mode of material delivery directly into the myocardium through the epicardial surface
with the need for a thoracotomy was also not clinically translatable. As discussed in Chapter 1,
the primary advantage of injectable biomaterials over other tissue engineering strategies for
cardiac repair, such as LV restraints or cardiac patches, is the potential for minimally invasive
delivery, which decreases damage to the target tissue and other surrounding tissues and enables
more rapid translation. Catheter-based approaches are ideal for a clinical setting to decrease
procedure and recovery times for patients. Recent studies have shown the ability for injectable
biomaterials to be delivered to large animal MI models using catheters.
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However, the hydrogel

system utilized in this dissertation was unable to be delivered in vivo via catheter due to its rapid
gelation time over the course of a few minutes.
Furthermore, the in vivo work in Aim 3 focused on the mechanical benefits of injectable
HA hydrogels and their impact on myocardial tissue mechanics. However, biological processes,
such as the activation of MMPs, play an important contributing factor in the progression to global
LV remodeling and thus should be evaluated. In this work, temporal assessment with MRI
prevented examination of the biological aspects of remodeling, aside from at the terminal time
point. In addition, previous studies have demonstrated that HA itself has biological benefits with
the ability to increase angiogenesis and potentially aid in cardiac regeneration in a MI model.

36,37

In the injectable system utilized in Aim 3, the biological benefits of HA delivery could not be
evaluated separately from the mechanical benefits of the hydrogel because degradation and
mechanics were coupled. Comparison to a non-bioactive material with similar hydrogel
degradation and mechanics would demonstrate the biological significance of HA.
8.2.5. Limitations in FE Model
Even though the FE model developed in Aim 3 was novel in that it incorporated in vivoderived parameters to describe the LV geometry and myocardial tissue properties in terms of
regional strains, it was also limited. Myocardial fiber architecture was not incorporated, as the
average myofiber angles were assigned to the myocardium and assumed to vary linearly in the
transmural direction. To generate a more anatomically representative FE model, the spatially
varying myofiber architecture should have been assessed using diffusion tensor MRI as another
input for the model.

38

In addition, the model only examines the LV, which is directly impacted by

the infarct, but does not incorporate pressures and deformations caused by the adjacent RV.
Finally, early diastole was selected to be the reference state on which the FE model was built
since pressure is at a minimum. However, the LV is still partially loaded at this phase and there
may be residual active tension in the myocardial fibers that, if not adequately accounted for,
would alter the mechanical properties of the myocardium. Recent studies have incorporated
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techniques for determining the unloaded LV geometry

39

that should be utilized in the future to

make the model more physiologically relevant.
8.3. Future Directions
8.3.1. In Vivo Hydrogel Imaging
Based on the limitations of the studies performed throughout this dissertation, there are
several avenues for future exploration related to the assessment of injectable HA hydrogels using
MRI. First of all, future studies should involve the translation of the T2-weighted and CEST MRI
techniques investigated in Aim 2 to imaging injectable hydrogels in vivo. As discussed previously
in Section 8.2.2, a major challenge of the in vivo T2-weighted imaging was the presence of
7

magnetic field inhomogeneities at 3 T. If remaining at 3 T, injection via catheter to prevent air
spaces in the chest cavity or injection into a location farther from the lung parenchyma (i.e.,
septum) may decrease the magnetic field susceptibility differences to improve homogeneity, but
an ideal imaging technique would enable material detection regardless of delivery method or
injection site. Preliminary work from the explanted heart following in vivo HeMA-HA injection
suggests that the T2 relaxation times of the material and surrounding myocardium are different
enough to enable in vivo detection of the hydrogel if the magnetic field inhomogeneity is
decreased by moving to a lower field strength of 1.5 T; thus, this is the most promising approach.
Due to the specificity of CEST imaging for the specific functional groups in the hydrogel, it
would be highly beneficial to progress to in vivo work as well. Unlike T2-weighted imaging, CEST
MRI may provide the opportunity to image hydrogels in vivo after infarction if the exchangeable
proton group manipulated is selected appropriately. Recent work from our collaborators
demonstrated that amine protons in creatine can be manipulated by CEST to distinguish between
healthy and infarcted myocardium in large animals.

20

A decrease in creatine-based CEST

contrast was observed in infarcted relative to healthy tissue, suggesting a decrease in creatine
levels in the akinetic, ischemic tissue as contractile function becomes limited.
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20

Due to the known

background myocardial signal from predominately amine protons resonating at about 1.8 ppm
away from bulk water, selection of a functional group or peptide sequence to couple to HA with an
exchangeable proton group that resonates away from the endogenous amines, preferably further
downfield from bulk water protons, would enable detection of HA hydrogels within the infarct. In
addition, the functional group or peptide sequence should have a single, uniform peak for the
exchangeable protons, unlike the peptide sequence chosen for this study which had multiple
exchangeable protons peaks, as demonstrated by high-resolution, non-water suppressed
spectroscopy. A single resolved peak will not only lead to enhanced CEST contrast but also
enable application of the new fitting technique based on a probabilistic model to better
compensate for magnetic field inhomogeneity in vivo, as previously described.

20

The ability to specifically visualize injectable hydrogels in vivo using CEST MRI would
provide the opportunity to track changes in hydrogel properties over time. One material property
of particular interest is the rate of in vivo degradation since previous MI studies in large animals
have demonstrated that the therapeutic impact of hydrogels depends on their duration of
1

mechanical stabilization and thus, degradation. To determine the optimal rate of degradation for
positive in vivo outcomes, different hydrogel formulations could be directly compared and tracked
over the chronic remodeling process. Furthermore, previous studies from our lab have shown that
encapsulated small molecule release tracks with HA hydrogel degradation.

5,40

Thus, the ability to

track hydrogel degradation in vivo would provide an indirect assessment of therapeutic molecule
release, as will be discussed further in Section 8.3.2. Ultimately, the use of a single, clinically
relevant imaging modality (i.e., MRI) to simultaneously track hydrogel properties over time in vivo
and investigate their impact on myocardial tissue properties (as described in Aim 3) would enable
direct correlation between specific material properties and their positive effects on tissue
remodeling post-MI within a single scan period. This would provide insight for the future
development of biomaterial systems with optimal properties to attenuate infarct remodeling.
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Figure 8.1. Tuning HeMA-HA hydrogel properties to alter degradation and small molecule
release. Gel onset and completion, n=3-4/group, for selected formulations (A). Degradation time
and initial compressive moduli, n=3-4/group (B). Degradation (C) of both formulations correlated
with release of r-TIMP-3 (D), n=3-4/group. Degradation and release performed in PBS with 1%
reagent diluent BSA. Data presented as mean ± SEM. All comparisons between polymers were
statistically significant (p<0.05) in panels A and B. Differences between formulations were
statistically significant (p<0.05) in panel C aside from at days 1 and 12 and in panel D past day 2.
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8.3.2. Small Molecule Release from Injectable HA Hydrogels
To further apply the temporal control of HA hydrogel degradation discussed in Aim 1 and
expand the in vivo application investigated in Aim 3 to biological process post-MI, HA hydrogels
could be used to deliver encapsulated small molecules; as the hydrogel degrades, the molecule
is released.

5,40,41

A model small molecule that has recently been explored by our group for MI
5

repair is tissue inhibitor of metalloproteinase-3 (TIMP-3). As previously discussed in Chapter 1,
following MI, there is an increase in the activation of matrix metalloproteinases (MMPs) in the
myocardium, which contributes to breakdown of extracellular matrix (ECM) and consequently
infarct expansion and associated LV dilation.

42-45

endogenous tissue inhibitors (TIMPs) are not.

Whereas MMPs are upregulated post-MI, their

46-48

More specifically, TIMP-3 is a critical regulator

of MMP activity; all four TIMPs inhibit MMPs but TIMP-3 has the broadest inhibition spectrum.

49

In

addition, unlike the other TIMPs, TIMP-3 is tightly bound to the ECM due to interactions with
GAGs,

49-51

5

suggesting there is a native affinity between HA and TIMP-3. Thus, HA hydrogels can

serve as a platform for TIMP-3 release as a model small molecule both in vitro and in vivo.
To demonstrate the feasibility of tuning small molecule release based on differences in
degradation, release of rTIMP-3 was examined from two HeMA-HA hydrogels formulations with
anticipated differences in degradation based on previous studies (Section 4.3.2): 10% modified
HeMA-HA at 5 wt% and 25% modified HeMA-HA at 8 wt%, both gelled using 5 mM APS/TEMED.
As predicted, gel onset and completion times were slightly slower in the 10% than 25% modified
gels (Figure 8.1A) and the initial compressive moduli slightly lower (Figure 8.1B). More
importantly, degradation of the 25% modified gels (11.6 ± 3.8 weeks) was significantly (p<0.05)
slower than the 10% modified gels (3.1 ± 0.4 weeks, Figure 8.1B). Quantification of mass loss
over time further highlighted these degradation differences, with significantly less HA loss from
the 25% modified gels at all time points aside from days 1 and 12 (Figure 8.1C).
Correspondingly, release of rTIMP-3 as a model small molecule was slower in the 25% than 10%
modified gels and significantly so past day 2 (Figure 8.1D). Due to the native affinity between HA
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and TIMP-3,

49-51

as the HA-based hydrogels degraded, TIMP-3 was released through both

diffusion and bound with HA fragments.
For future in vivo applications similar to the study design of Aim 3, the hydrogel
degradation profiles selected for rTIMP-3 release targeted different phases of the LV remodeling
4

process, as discussed in Chapter 3. This is particularly beneficial for TIMP release since the
48,51

activation of MMPs post-MI is time-dependent.

The degradation of the 10% modified hydrogel

at about 3 weeks correlates well with the acute LV remodeling stage, whereas the degradation of
the 25% modified hydrogel at slightly before 12 weeks corresponds well to the chronic remodeling
stage. In addition, previous studies from our group examined the in vivo benefit of rTIMP-3
5

release from HA hydrogels post-MI. However, these studies were performed using a single
hydrogel formulation and outcome assessment primarily occurred during the acute period out to 2
5

weeks post-MI with minor assessment of LV volumes at 4 weeks post-MI. Therefore, comparing
in vivo outcomes between hydrogels with different release profiles (Figure 8.1) would elucidate
the optimal rate of TIMP-3 delivery. Furthermore, future studies assessing the therapeutic benefit
of TIMP-3 delivery out to 12 weeks post-MI with an emphasis on the myocardial tissue properties
(as utilized in Aim 3) would provide insight as to if early MMP inhibition delays the progression of
global LV remodeling or permanently interrupts maladaptive myocardial remodeling. Ultimately,
delivery of small, physiologically relevant molecules using the degradable HA hydrogels explored
in Aim 1 would enable HA hydrogel therapy to address the biological implications of post-MI
remodeling in addition to the mechanical benefits discussed in Aim 3 of this dissertation.
8.3.3. Improved In Vivo Study Design
In Aim 3 of this dissertation, a single hydrogel formulation was delivered in vivo as a
platform to develop tools to assess the impact of hydrogel therapy on myocardial tissue
properties. Future in vivo work should focus on applying the combination of MRI and FE modeling
assessment to evaluate a range of hydrogels with varying properties. To make the material
system more clinically applicable, hydrogel injection should occur farther past the onset of MI
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(i.e., 1 week post-MI). Delivering hydrogels at even later times into the chronic remodeling stages
(i.e., weeks to months following MI) would also lead to a better understanding of the therapeutic
window during which injectable materials need to be delivered to optimize their therapeutic
benefit. Finally, the percutaneous delivery of the hydrogels through catheters would facilitate
clinical translation and allow for therapeutic hydrogel application in a wider population of patients
where a thoracotomy is not part of their standard clinical care.
8.4. Summary
Myocardial tissue remodeling following infarction is considered the main contributing
factor in the progression to heart failure, yet current therapies do little to address these alterations
in tissue properties over time. Injectable materials offer a minimally invasive strategy to attenuate
myocardial remodeling, but noninvasive tools are also needed to assess the effects of these
therapies. The goal of this dissertation was to use MRI to investigate injectable HA hydrogel
properties and their therapeutic effect on myocardial properties for infarct repair. The data
presented in this dissertation demonstrates that differences in hydrogel properties can be
noninvasively assessed after delivery to the myocardium and that injectable hydrogels positively
impact myocardial mechanical properties (e.g., thickness, strain, stiffness) into the chronic
remodeling stages. The findings of this dissertation represent advancements in imaging
technology and provide insight into biomaterial design criteria for better therapies to target
myocardial infarct remodeling and prevent progression to heart failure.
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